
<html lang="en"     class="pb-page"  data-request-id="dbb28bad-12b6-4a0d-ae47-47143585bfb9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-23;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b00829"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure–Activity Relationships" /></meta><meta name="dc.Creator" content="Jordi  Gràcia" /></meta><meta name="dc.Creator" content="Maria Antonia  Buil" /></meta><meta name="dc.Creator" content="Jordi  Castro" /></meta><meta name="dc.Creator" content="Peter  Eichhorn" /></meta><meta name="dc.Creator" content="Manel  Ferrer" /></meta><meta name="dc.Creator" content="Amadeu  Gavaldà" /></meta><meta name="dc.Creator" content="Begoña  Hernández" /></meta><meta name="dc.Creator" content="Victor  Segarra" /></meta><meta name="dc.Creator" content="Martin D.  Lehner" /></meta><meta name="dc.Creator" content="Imma  Moreno" /></meta><meta name="dc.Creator" content="Lluís  Pagès" /></meta><meta name="dc.Creator" content="Richard S.  Roberts" /></meta><meta name="dc.Creator" content="Jordi  Serrat" /></meta><meta name="dc.Creator" content="Sara  Sevilla" /></meta><meta name="dc.Creator" content="Joan  Taltavull" /></meta><meta name="dc.Creator" content="Miriam  Andrés" /></meta><meta name="dc.Creator" content="Judit  Cabedo" /></meta><meta name="dc.Creator" content="Dolors  Vilella" /></meta><meta name="dc.Creator" content="Elena  Calama" /></meta><meta name="dc.Creator" content="Carla  Carcasona" /></meta><meta name="dc.Creator" content="Montserrat  Miralpeix" /></meta><meta name="dc.Description" content="Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are t..." /></meta><meta name="Description" content="Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 17, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00829" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00829" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00829" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00829" /></link>
        
    
    

<title>Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure–Activity Relationships | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00829" /></meta><meta property="og:title" content="Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure–Activity Relationships" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0001.jpeg" /></meta><meta property="og:description" content="Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00829"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00829">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00829&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00829&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00829&amp;href=/doi/10.1021/acs.jmedchem.6b00829" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10479-10497</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00659" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00912" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure–Activity Relationships</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jordi++Gr%C3%A0cia">Jordi Gràcia</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Antonia++Buil">Maria Antonia Buil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jordi++Castro">Jordi Castro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Eichhorn">Peter Eichhorn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Manel++Ferrer">Manel Ferrer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amadeu++Gavald%C3%A0">Amadeu Gavaldà</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bego%C3%B1a++Hern%C3%A1ndez">Begoña Hernández</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor++Segarra">Victor Segarra</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+D.++Lehner">Martin D. Lehner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Imma++Moreno">Imma Moreno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Llu%C3%ADs++Pag%C3%A8s">Lluís Pagès</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+S.++Roberts">Richard S. Roberts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jordi++Serrat">Jordi Serrat</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sara++Sevilla">Sara Sevilla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joan++Taltavull">Joan Taltavull</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Miriam++Andr%C3%A9s">Miriam Andrés</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judit++Cabedo">Judit Cabedo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dolors++Vilella">Dolors Vilella</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Calama">Elena Calama</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carla++Carcasona">Carla Carcasona</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Montserrat++Miralpeix">Montserrat Miralpeix</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1.0"><span class="aff-text"><sup>†</sup>Medicinal Chemistry and Screening, <sup>‡</sup>Pharmacokinetics and Metabolism, <sup>§</sup>Experimental Dermatology, and <sup>∥</sup>Licensing and Corporate Development, Centro de Investigación y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div><div class="corresp-info"><strong>*</strong>Phone: +34 93 291 3543. Fax: +34 93 291 3420. E-mail: <a href="/cdn-cgi/l/email-protection#02686d70666b2c657063616b6342636e6f6b70636e6e2c616d6f"><span class="__cf_email__" data-cfemail="503a3f2234397e37223133393110313c3d3922313c3c7e333f3d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00829&amp;href=/doi/10.1021%2Facs.jmedchem.6b00829" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10479–10497</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 9, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 June 2016</li><li><span class="item_label"><b>Published</b> online</span>17 November 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 December 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00829" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00829</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10479%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJordi%2BGr%25C3%25A0cia%252C%2BMaria%2BAntonia%2BBuil%252C%2BJordi%2BCastro%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D23%26contentID%3Dacs.jmedchem.6b00829%26title%3DBiphenyl%2BPyridazinone%2BDerivatives%2Bas%2BInhaled%2BPDE4%2BInhibitors%253A%2BStructural%2BBiology%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10497%26publicationDate%3DDecember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00829"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2415</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00829" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure–Activity Relationships&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jordi&quot;,&quot;last_name&quot;:&quot;Gràcia&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Antonia Buil&quot;},{&quot;first_name&quot;:&quot;Jordi&quot;,&quot;last_name&quot;:&quot;Castro&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Eichhorn&quot;},{&quot;first_name&quot;:&quot;Manel&quot;,&quot;last_name&quot;:&quot;Ferrer&quot;},{&quot;first_name&quot;:&quot;Amadeu&quot;,&quot;last_name&quot;:&quot;Gavaldà&quot;},{&quot;first_name&quot;:&quot;Begoña&quot;,&quot;last_name&quot;:&quot;Hernández&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;Segarra&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;D. Lehner&quot;},{&quot;first_name&quot;:&quot;Imma&quot;,&quot;last_name&quot;:&quot;Moreno&quot;},{&quot;first_name&quot;:&quot;Lluís&quot;,&quot;last_name&quot;:&quot;Pagès&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;S. Roberts&quot;},{&quot;first_name&quot;:&quot;Jordi&quot;,&quot;last_name&quot;:&quot;Serrat&quot;},{&quot;first_name&quot;:&quot;Sara&quot;,&quot;last_name&quot;:&quot;Sevilla&quot;},{&quot;first_name&quot;:&quot;Joan&quot;,&quot;last_name&quot;:&quot;Taltavull&quot;},{&quot;first_name&quot;:&quot;Miriam&quot;,&quot;last_name&quot;:&quot;Andrés&quot;},{&quot;first_name&quot;:&quot;Judit&quot;,&quot;last_name&quot;:&quot;Cabedo&quot;},{&quot;first_name&quot;:&quot;Dolors&quot;,&quot;last_name&quot;:&quot;Vilella&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Calama&quot;},{&quot;first_name&quot;:&quot;Carla&quot;,&quot;last_name&quot;:&quot;Carcasona&quot;},{&quot;first_name&quot;:&quot;Montserrat&quot;,&quot;last_name&quot;:&quot;Miralpeix&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;10479-10497&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00829&quot;},&quot;abstract&quot;:&quot;Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrat&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00829&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00829" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00829&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00829" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00829&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00829" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00829&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00829&amp;href=/doi/10.1021/acs.jmedchem.6b00829" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00829" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00829" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00829%26sid%3Dliteratum%253Aachs%26pmid%3D27933955%26genre%3Darticle%26aulast%3DGr%25C3%25A0cia%26date%3D2016%26atitle%3DBiphenyl%2BPyridazinone%2BDerivatives%2Bas%2BInhaled%2BPDE4%2BInhibitors%253A%2BStructural%2BBiology%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D23%26spage%3D10479%26epage%3D10497%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291308" title="Nucleic acids">Nucleic acids</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/jmcmar.2016.59.issue-23/20161208/jmcmar.2016.59.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Intracellular levels of the secondary messengers cAMP and cGMP are tightly controlled by the phosphodiesterase (PDE) family of enzymes. PDE4 catalyzes the hydrolysis of cAMP by its four isotypes PDE4A–D.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The cAMP pathway is central in several inflammatory cell types and has a key role in pathologies with an inflammatory component such as asthma and chronic obstructive pulmonary disease (COPD), as well as inflammatory bowel disease (IBD), atopic dermatitis (AD), psoriasis, and rheumatoid arthritis (RA).<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> The presence of PDE4A and PDE4B in eosinophils, neutrophils, and monocytes suggests that they are potential targets for the anti-inflammatory actions of PDE4-selective inhibitors.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> PDE4 inhibitors also have a relevant role in the CNS, including antidepressant and memory-enhancing effects.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a></div><div class="NLM_p">Despite this potential, the clinical development of PDE4 inhibitors has been greatly hampered by cardiac<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and emetic<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> side effects, both attributed to the PDE4D isoform. Few isoform-selective inhibitors with sufficient selectivity to individually determine the roles of PDE4B or PDE4D have been reported.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Isoform selectivity remains a formidable challenge given the apparent similarities of the active sites of the various isoforms.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Nevertheless, roflumilast (<b>1</b>) was the first PDE4 inhibitor to be launched for the oral treatment of COPD (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Recently, apremilast (<b>2</b>) has been approved in the U.S. and Canada for the oral treatment of plaque psoriasis.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The clinical development of PDE4 inhibitors has been reviewed by us and by others.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13-16)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of approved oral drugs roflumilast <b>1</b> and apremilast <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to circumvent the potential side effects of PDE4 inhibitors in respiratory disorders, many companies have turned to inhaled delivery to the lung. For inhaled delivery, as oral absorption is neither necessary nor in fact relevant, other kinds of “druglike” properties are needed: molecules can be especially large with molecular weights of >500, often accompanied by a low solubility. Molecules can incorporate metabolically labile groups, susceptible to either oxidative phase I or conjugative phase II metabolism to reduce systemic exposure. Molecules can also incorporate long, lipophilic-linked basic groups with the aim of increasing lung tissue retention. However, since PDE4 is an intracellular target, molecular properties should still be controlled, as cellular permeability is necessary for efficacy. Whole-cell assays are routinely employed to detect any such deficiencies in permeation and target access. Compounds representative of these strategies which have reached clinical trials are the quinolone GSK256066 <b>3</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> from GSK, the dual PDE3/PDE4 inhibitor RPL554 <b>4</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> from Verona Pharma, and Pfizer’s UK-500,001 <b>5</b><a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The development of compounds <b>3</b> and <b>5</b> has since been discontinued.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of inhaled clinical candidates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Here we describe our efforts to discover novel, highly potent (double-digit picomolar) inhaled inhibitors of PDE4 for the treatment of respiratory diseases.</div><div class="NLM_p">The use of structural X-ray crystallography has contributed greatly to the understanding of the catalytic domains of PDE4A–D and is central to the design of newer PDE4 inhibitors.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20-22)</a> Indeed, the binding modes for several classes of PDE4 inhibitors have been described.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27 ref28">(23-28)</a> Structure-based design (SBD) has allowed the discovery of very potent compounds, often with IC<sub>50</sub> values below 0.1 nM.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">From our own extensive oral PDE4 program we had obtained crystal structure data for a series of pyridazinone compounds such as <b>6</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K1I">5K1I</a>, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Left-hand panel: X-ray crystal structure of <b>6</b> bound to the PDE4D active site overlaid with roflumilast <b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ">1XOQ</a>). Ligand, active site, and resolved waters are colored by atom type for complexed <b>6</b> and in blue for complexed roflumilast. Glutamine-369 is represented by sticks. The two metal ions are colored as follows: green for magnesium and gray for zinc. Right-hand panel: conceptual design and interactions of the pyridazinone (PYR) series. Active site regions are defined as follows with respect to the cartoon view: [1] The π-clamp region is a narrow channel formed between a face-to-face interaction with Phe-372 in front of the ligand and an edge-to-face interaction with Phe-340 behind. [2] The “glutamine switch” glutamine-369 provides PDE4’s selectivity for cAMP over cGMP.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> [3] The small lipophilic pocket. [4] The large lipophilic pocket. [5] The metal binding zone of PDE4 responsible for the catalytic hydrolysis of cAMP, containing the enzyme’s two metals ions, zinc and magnesium. [6] The solvent exposed pocket. In the full PDE4 isoenzyme, the helices of the upstream conserved region (UCR2), a negative regulator of cAMP hydrolysis, partially fill this area.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In truncated protein sequences, coding only for the PDE4 active site, this zone is exposed to the bulk solvent, hence the name.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the X-ray structure of <b>6</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) the pyridazinone nucleus was held as expected in the π-clamp region [1] and formed a hydrogen bond to the glutamine switch [2]. On the basis of earlier SAR around this series, we fixed the pyridazinone 2-substituent as ethyl. This was also backed up by the X-ray structure showing a close fit of the ethyl group in the small lipophilic pocket [3]. The phenyl ring in the 6-position of the pyridazinone filled the large lipophilic pocket [4]. Finally, the benzoate was directed toward the metal-binding zone, interacting with the outer solvation sphere.</div><div class="NLM_p">We could see three areas open to optimization of the binding mode: first, we had originally thought that <b>6</b> would maintain an internal hydrogen bond between the acetyl carbonyl and the 6-amino NH group. X-ray analysis of the bound conformation of <b>6</b> revealed that this was not the case and that the acetyl group was not involved in binding, neither internally in the structure of <b>6</b> nor externally to the PDE4 enzyme. Therefore, we removed this group in all subsequent analogues. Second, we could incorporate the dichloropyridine metal-binding motif of roflumilast with suitable spacing. Simple overlay of the X-ray structures of <b>6</b> and <b>1</b> suggested that a urea link would be optimum as a spacer between the 3,5-dichloropyridine group and the pyridazinone. Third, the meta position of the pyridazinone 6-phenyl ring was orientated toward the solvent filled pocket. Here we planned to freely attach groups to specifically modify the physicochemical properties of the series, without significantly changing the binding potency (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Conceptual design of the PYR series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pyridazinones <b>7</b> were synthesized as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The route started with 3-bromoacetophenone <b>8</b> to provide a suitable handle for functionalization in the last step. Claisen condensation of <b>8</b> with ethyl acetate gave diketone <b>9</b>. This was condensed with ethyl chlorooximidoacetate under basic conditions.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This reaction represents a formal [3 + 2] cycloaddition between the nitrile oxide of the chlorooxime and the enolate of <b>9</b>, followed by elimination of water to give <b>10</b>. Although diketone <b>9</b> is asymmetrical, the selectivity of cyclization was always very good with effectively none of the regioisomer of <b>10</b> detected. Ester <b>10</b> was condensed with hydrazine hydrate to form the pyridazinone nucleus <b>11</b>. N-Alkylation with ethyl iodide proceeded smoothly (<b>11</b> → <b>12</b>) followed by reductive ring-opening of the isoxazolo[3,4-<i>d</i>]pyridazin-7(6<i>H</i>)-one core of <b>12</b> to give aminopyridazinone <b>13</b>. The acetyl group was removed by a retro-Claisen-type reaction to give <b>14</b>. The amine of <b>14</b> was first reacted with triphosgene and then condensed with 4-amino-3,5-dichloropyridine. Despite the apparent steric hindrance and low nucleophilicity of this aminopyridine, the addition proceeded in high yield to give key intermediate <b>15</b>. Suzuki coupling with a wide range of commercial and bespoke boronic acids gave the desired pyridazinones <b>7</b> (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Biaryl-Substituted Pyridazinones <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, EtOAc, THF, 0 °C to reflux, 82% yield; (b) Na, ClC(NOH)OEt, EtOH, 0 °C, 89% yield; (c) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, EtOH, rt, 72% yield; (d) EtBr, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 85% yield; (e) H<sub>2</sub>, Raney nickel, THF, EtOH, 90% yield; (f) HBr 48%, 130 °C, 82% yield; (g) triphosgene, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; then 4-amino-3,5-dichloropyridine, THF, rt, 70% yield; (h) ArB(OH)<sub>2</sub> or ArB(pin), PdCl<sub>2</sub>dppf·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 90 °C, 9–74% yield.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35687" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35687" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our desired compound profile was as follows: a potent PDE4 inhibitor (IC<sub>50</sub> in a cellular assay of <1 nM), suitable for once-daily dosing (measured in the LPS-induced neutrophilia in rats by a small drop-off of in vivo efficacy across 24 h; (ED<sub>50</sub> at 24 h)/(ED<sub>50</sub> at 1 h) of <5) and with an acceptable safety profile.</div><div class="NLM_p">Compounds were initially tested for their binding potency in an in vitro enzymatic assay, using the inhibition of the hydrolysis of radiolabeled [<sup>3</sup>H]cAMP as a readout. Compounds were also tested for their in vitro cellular activity in the blockage of TNFα production. We measured the inhibition of TNFα production in washed polynuclear blood monocytes (PBMCs) to give a translation between the in vitro enzymatic potency and a cell-based assay. Since PDE4 is an intracellular target, any large shifts in potency between the two assays here would indicate a problem of compound permeability. We also measured TNFα production in human whole blood (hWB). Any large shifts in potency between the two TNFα assays would indicate a strong compound affinity for plasma proteins. As we sought to remove systemic activity of our compounds, high protein binding (and concomitant loss of potency) was highly desirable. Gratifyingly, intermediate <b>15</b> was highly potent at 1.7 nM in the enzymatic assay and 3.7 nM in the cellular PBMC assay (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), thus suggesting that the urea linker to the dichloropyridine motif was optimal and that the acetyl group of <b>6</b> could be eliminated without problems.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Phenolic R<sup>1</sup> Substituents<a class="ref internalNav" href="#tbl1fn1" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn2"><div class="footnote" id="t1fn2"><sup>Table a</sup><p class="last">20 min incubation with human liver S9 fraction in the presence of both 3′-phosphoadenosine 5′-phosphosulfate (PAPS) and uridine 5′-diphosphoglucuronic acid (UDPGA). G: % glucuronidation. S: % sulfonation.</p></div><div class="footnote" id="tbl1fn1"><sup>Table b</sup><p class="last">n.d.: not determined.</p></div></div><div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Structure–Activity Relationships of the Pyridazinone 6-Position</h3><div class="NLM_p">Our first approach to inhaled compounds with minimal systemic levels was to incorporate a phenolic handle, suitable for glucuronidation, into the meta position of the 6-phenyl ring. The first biphenyl analogue, <b>16</b>, completely fulfilled our expectations of the in vitro potency profile we were looking for: <b>16</b> displayed subnanomolar potencies in both the enzymatic and PBMC assays, indicating an acceptable cell permeability, and a 100-fold shift in whole blood, indicating a high affinity for plasma proteins. Other analogues followed (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). We varied the position of the phenol, with the para position (<b>17</b>) being the most potent enzymatically. We also varied the acidity of the phenol group, introducing a fluorine atom. Again the para-phenols showed the highest enzymatic potency (<b>22</b>, 60 pM; <b>23</b>, 40 pM), but this was compromised by an apparent lower cell permeability and hence only nanomolar potencies in PBMCs. Hydroxypyridines <b>24</b> and <b>25</b> were in a similar range in the in vivo study. In all cases, there was a significant loss of systemic potency.</div><div class="NLM_p">Surprisingly, when we measured the conjugative phase II metabolism (either glucuronidation or sulfonation) of several of these compounds, the turnover was relatively low (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In the case of hydroxypyridine <b>24</b> we did achieve a high level of glucuronidation. Therefore, we also incorporated benzoic acids with the same view to provoke systemic clearance via a glucuronidation mechanism (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Carboxylic Acid R<sup>1</sup> Substituents<a class="ref internalNav" href="#tbl2-fn1" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn2"><div class="footnote" id="t2fn2"><sup>Table a</sup><p class="last">20 min incubation with human liver S9 fraction in the presence of PAPS and UDPGA. G: % glucuronidation. S: % sulfonation.</p></div><div class="footnote" id="t2fn3"><sup>Table b</sup><p class="last">% glucuronidation after 120 min incubation with human liver microsomes in the presence of UDPGA.</p></div><div class="footnote" id="tbl2-fn1"><sup>Table c</sup><p class="last">n.d.: not determined.</p></div></div><div></div></div><div class="NLM_p">As with the phenols, we first scanned the position of the acid. Ortho (<b>26</b>) was reasonably poor, but both meta (<b>27</b>) and para (<b>28</b>) benzoic acids were highly potent enzymatically. We also increased the acidity of the carboxylic acids through the introduction of fluorines or a pyridine ring (<b>29</b>–<b>31</b>), but here the cellular potency in PBMCs was greatly reduced, so we stopped this approach. Phenylacetic acids <b>32</b> and <b>33</b> both showed excellent in vitro profiles, around 50 pM in the enzymatic assay, subnanomolar in PBMCs, and >100 nM in whole blood.</div><div class="NLM_p">Again, when we measured conjugative turnover, the levels were low (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Even increasing the incubation time to 2 h gave moderate levels of turnover (<b>31</b>–<b>33</b>). It should also be taken into account that these compounds all show a very high plasma protein binding. In vivo, this would lead to very low circulating levels of compound, and so associated metabolic clearance processes would also be slowed down. Hence, we abandoned the idea of conjugation as a principal mechanism for reducing circulating systemic levels.</div><div class="NLM_p">Following on from the acids, we made carboxamides to fill the solvent-exposed pocket (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Meta carboxamide <b>34</b> was highly potent and was our first analogue showing <100 pM in the cellular assay. Para-carboxamide <b>35</b> and meta-cyclopropyl carboxamide <b>36</b> had similar activities. In a change to the physicochemical properties, we also introduced basic groups into the amide. Here, we hoped to increase the amount of tissue binding of these compounds and to increase their lung retention time, leading to a longer duration of action. Dimethylamino analogue <b>37</b> was highly potent, so we extended this idea to a series of amines of decreasing basicity based on piperidine (p<i>K</i><sub>B</sub> = 11.2, <b>38</b>), piperazine (p<i>K</i><sub>B</sub> = 9.8, <b>39</b>), and morpholine (p<i>K</i><sub>B</sub> = 8.3, <b>40</b>). All compounds were again highly active, with morpholino analogue <b>40</b> being the most potent at 14 pM in the enzymatic assay and 70 pM in PBMCs. Whole blood potency was still around 2 orders of magnitude lower, as we hoped. Finally, to really push the physicochemical properties toward membrane binding and lung retention, we introduced long aliphatic basic chains <b>43</b>–<b>45</b>. Here, too, compounds <b>43</b> and <b>45</b> were in the double-digit picomolar range in the enzymatic assay, with an order-of-magnitude drop-off in the cellular assay and two further orders-of-magnitude drop-off in whole blood (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Carboxamide R<sup>1</sup> Substituents</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0014.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p last">Overall, the SAR of the analogues of <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> was fairly flat. Apart from a few exceptions, enzymatic potency was around 100 pM. However, this flat SAR was clearly tolerant of a wide variety of functionalities: phenols, acids, bases, aliphatic chains up to 14 atoms long, or no substitution at all. Cellular potencies reflected some of these changes of physicochemical properties; for example, the highly acidic phenols <b>22</b> and <b>23</b> and the carboxylates <b>29</b> and <b>30</b> lost 100- to 1000-fold potency in PBMCs, but in general compounds were still below 1 nM and in a couple of cases below 100 pM.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vivo Neutrophilia Model and Duration of Action</h3><div class="NLM_p">Several of the more promising compounds were tested in a rat LPS-induced neutrophilia model, measuring the inhibition of increase of neutrophils in the bronchoalveolar lavage (BAL) fluid. Compounds were prepared in aqueous suspension and administered intratracheally by using a Penn-Century MicroSprayer Aerosolizer for Rat−Model IA-1B. Animals were challenged 1 h later with nebulized LPS, with the neutrophilia readout a total of 5 h after test compound administration. Roflumilast <b>1</b> was used as a control, showing a clear dose–response, reaching 80% inhibition at 1000 μg/kg and displaying an ED<sub>50</sub> of 126 μg/kg (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Dose–responses of roflumilast <b>1</b> and compound <b>37</b> in a LPS-induced rat neutrophilia model. Compounds in suspension were administered intratracheally (i.t.) by MicroSprayer Aerosolizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Short-term efficacy measured 5 h postdose was first used to rank compounds. Many of the compounds tested at a single dose of 1000 μg/kg in the neutrophilia assay did not reach 50% inhibition (data not shown), and so these compounds could be discarded straight away. Effective doses causing a 50% reduction in neutrophilia (ED<sub>50</sub>) were obtained where possible from dose–response curves (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). For several compounds, we only tested at a single dose, not sufficient to determine an ED<sub>50</sub> but suitable for an estimated value. In other cases ED<sub>50</sub> could not be calculated, since the dose–response curves flattened out around the 50% inhibition mark.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibition of LPS-Induced Neutrophilia in Rat BAL</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">neutrophilia ED<sub>50</sub> (μg/kg), suspension microspray</th><th class="rowsep1 colsep0" colspan="3" align="center">neutrophilia ED<sub>50</sub> (μg/kg), dry powder insufflation</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup> class</th><th class="colsep0 rowsep0" align="center">5 h postdose<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">22 h postdose<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">estimated duration<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">5 h postdose<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">22 h postdose<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">proinflam</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">roflumilast</td><td class="colsep0 rowsep0" align="left">126</td><td class="colsep0 rowsep0" align="left">24% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">204</td><td class="colsep0 rowsep0" align="left">37% at 6000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">phenol</td><td class="colsep0 rowsep0" align="left">416</td><td class="colsep0 rowsep0" align="left">0% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">551</td><td class="colsep0 rowsep0" align="left">7% at 2000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">phenol</td><td class="colsep0 rowsep0" align="left">101</td><td class="colsep0 rowsep0" align="left">14% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">51% at 1000</td><td class="colsep0 rowsep0" align="left">0% at 1000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">phenol</td><td class="colsep0 rowsep0" align="left">342</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">phenol</td><td class="colsep0 rowsep0" align="left">58% at 1000</td><td class="colsep0 rowsep0" align="left">23% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">acid</td><td class="colsep0 rowsep0" align="left">50% at 100, 59% at 1000</td><td class="colsep0 rowsep0" align="left">25% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">8% at 1000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">acid</td><td class="colsep0 rowsep0" align="left">66% at 1000</td><td class="colsep0 rowsep0" align="left">16% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">acid</td><td class="colsep0 rowsep0" align="left">149</td><td class="colsep0 rowsep0" align="left">10% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">amide</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">20% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">48% at 1000</td><td class="colsep0 rowsep0" align="left">15% at 1000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">amide</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">43% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">55% at 1000</td><td class="colsep0 rowsep0" align="left">42% at 1000</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">38% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">38% at 10, 8% at 1000</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">66% at 100</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">62% at 100</td><td class="colsep0 rowsep0" align="left">40% at 100</td><td class="colsep0 rowsep0" align="left">long</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">52% at 100</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">70% at 100</td><td class="colsep0 rowsep0" align="left">57% at 100</td><td class="colsep0 rowsep0" align="left">long</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">48% at 100, 47% at 300</td><td class="colsep0 rowsep0" align="left">long</td><td class="colsep0 rowsep0" align="left">48% at 10, 42% at 100</td><td class="colsep0 rowsep0" align="left">42% at 10, 39% at 100</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">lipophilic, basic</td><td class="colsep0 rowsep0" align="left">79% at 100</td><td class="colsep0 rowsep0" align="left">27% at 1000</td><td class="colsep0 rowsep0" align="left">short</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">lipophilic, basic</td><td class="colsep0 rowsep0" align="left">69% at 100</td><td class="colsep0 rowsep0" align="left">91 μg/kg</td><td class="colsep0 rowsep0" align="left">long</td><td class="colsep0 rowsep0" align="left">23% at 100</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">1.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">ED<sub>50</sub>s expressed as μg/kg or a percentage inhibition at a dose in μg/kg. ED<sub>50</sub>s were generated from dosing at typically at 1000, 100, 10 μg/kg, and where necessary at 1 and 0.1 μg/kg. Single point inhibitions were also measured at 100 μg/kg. Results are average of at least 8 animals. n.d. not determined.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Estimated from percentage inhibitions at 5 and 22 h. See text.</p></div></div></div><div class="NLM_p">Phenol <b>20</b> showed an in vivo efficacy similar to roflumilast: ED<sub>50</sub> of 101 μg/kg, reaching 64% inhibition at 1000 μg/kg. Of the acids, <b>28</b> displayed a similar potency, achieving 50% inhibition at a single dose of 100 μg/kg but only reaching a maximum inhibition of 59% at 1000 μg/kg. Acid <b>33</b> was comparable: ED<sub>50</sub> of 149 μg/kg but this time reaching 80% inhibition at 1000 μg/kg. The amides showed a real increase in efficacy. <b>36</b> gave an ED<sub>50</sub> of 24 μg/kg (70% inhibition at 100 μg/kg), and basic amide <b>37</b> was highly efficacious with an ED<sub>50</sub> of 3.5 μg/kg (70% inhibition at 100 μg/kg, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The other basic amides were also highly potent, with ED<sub>50</sub> values at or below 100 μg/kg (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_p">With potent compounds in hand, we also assessed their duration of action by applying the compounds intratracheally 18 h before the LPS challenge and hence with a BAL readout at 22 h postdose. As before, many compounds were tested at a single representative dose (based on their 5 h effective dose). To our disappointment, many of the compounds simply did not inhibit neutrophilia at this time point. The phenols, acids, and neutral amides essentially all showed <25% inhibition at 1000 μg/kg. Only <b>36</b> showed the first signs of duration of action with 43% inhibition at 1000 μg/kg. The basic compounds performed better, and several showed around 40–50% inhibition at a more reasonable dose of 100 μg/kg. Only in one case (<b>45</b>) were we able to determine an ED<sub>50</sub> of 91 μg/kg at 22 h postdose. Thus, we were unable to quantify the loss of efficacy over time or to select compounds based on our original target of a drop of ED<sub>50</sub> of <5-fold across a 24 h period. However, despite only one measured ED<sub>50</sub> at 22 h, we could still approximate the duration of action and classify compounds as long or short acting according to their apparent loss of ED<sub>50</sub> over time. Efficacies were compared between the 22 and 5 h time points: compounds that showed lower inhibitions at higher doses 22 h postdose were clearly short acting (e.g., <b>28</b>). Compounds that showed small but measurable losses of inhibition at the same dose at 5 and 22 h were longer-acting contenders (e.g., <b>41</b>). Ultimately, the highest efficacy at 22 h postdose was used to prioritize compounds, and so <b>41</b> and <b>45</b> became our two front-runners (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_p last">Clinical delivery of inhaled compounds is almost always carried out using a dry powder formulation of a micronized active ingredient mixed with a lactose carrier. We therefore measured inhibition of lung neutrophilia after dry powder i.t. administration of several compounds, again with roflumilast <b>1</b> as control (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). As before, roflumilast performed well 5 h after dosing, with the inhibition dropping off considerably 22 h after administration. Dry-powder administration is a more demanding system, since particle size distribution, particle deposition, and kinetic solubility effects also come into play. It is not unreasonable to observe an order-of-magnitude shift in potency when switching from intratracheal (i.t.) administration of a liquid suspension to i.t. administration of a dry powder. Several of our compounds followed this trend, for example, phenol <b>20</b> (ID<sub>50</sub> 101 μg/kg when administered as suspension by MicroSprayer Aerosolizer versus inhibition of 51% at 1000 μg/kg after dry powder delivery). Not only did we observe a drop in activity, we found that many compounds’ dose–response curves flattened off at high dose and that we could not achieve more than around 50% inhibition. In addition, some compounds showed bell-shaped dose responses, where higher doses decreased the maximum efficacy (for example, <b>37</b>: 38% inhibition at 10 μg/kg but only 8% inhibition at 1000 μg/kg). Pathological examination of the lungs of animals tested at these high doses showed signs of irritation (data not shown). It was therefore possible that the inhaled formulation was responsible for provoking the same neutrophilia that the mechanism of action was trying to reduce. We tested several compounds for the production of neutrophilia in the absence of the LPS challenge (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). <b>36</b>, <b>38</b>, and <b>40</b> when administered as a micronized dry powder mixed with lactose did not show any increase in neutrophil count above basal levels at 1000 μg/kg. <b>37</b> was clearly proinflammatory, however, causing a 3.2-fold increase in BAL neutrophils. This may well explain the bell-shaped dose–response curve of this compound, as a physical irritation effect at high doses would overcome the mechanistic reduction of inflammation. <b>45</b> was a borderline case, with a 1.9-fold increase in neutrophils. Proinflammatory effects were not related to obvious structural motifs. We therefore set an upper limit of 2-fold proinflammation to profile compounds further.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Safety Profile: Adenosine Receptor Activity</h3><div class="NLM_p">As we further characterized the most advanced compounds, we uncovered an additional problem of selectivity against the adenosine receptors. Four adenosine receptors have been identified and classified into the following subtypes: A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>. These receptors are widely expressed and have been implicated in several biological functions. These include cardiac effects, lipolysis, renal blood flow changes, immune function, sleep regulation, and angiogenesis, as well as inflammatory diseases, ischemia–reperfusion, and CNS disorders.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Therefore, an additional off-target modulation has the potential to induce unexpected effects.</div><div class="NLM_p">The whole series showed adenosine antagonism to varying degrees but apparently independent of the nature of the R<sup>1</sup> substitution (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). In general, compounds were most potent antagonists against the A<sub>1</sub> receptor, followed by the A<sub>2a</sub> receptor. Potencies could reach single-digit nanomolar in some cases, too close to the cellular potencies against PDE4 to give much of a selectivity window. Adenosine antagonism was ruled out as a cause of proinflammation (see above), since two compounds with similar adenosine potencies, <b>36</b> and <b>37</b>, displayed very different proinflammatory responses.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Adenosine Antagonism of Selected Analogues</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">adenosine receptor IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup> class</th><th class="colsep0 rowsep0" align="center">A<sub>1</sub></th><th class="colsep0 rowsep0" align="center">A<sub>2a</sub></th><th class="colsep0 rowsep0" align="center">A<sub>2b</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">phenol</td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="left">168</td><td class="colsep0 rowsep0" align="left">172</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">phenol</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">333</td><td class="colsep0 rowsep0" align="left">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">acid</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">270</td><td class="colsep0 rowsep0" align="left">222</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">acid</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">acid</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">434</td><td class="colsep0 rowsep0" align="left">263</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">acid</td><td class="colsep0 rowsep0" align="left">184</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">amide</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">169</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">145</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">basic</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">105</td><td class="colsep0 rowsep0" align="left">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">lipophilic, basic</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">206</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">lipophilic, basic</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">459</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">lipophilic, basic</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="left">86</td><td class="colsep0 rowsep0" align="left">94</td></tr></tbody></table></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Double Substitution To Increase Adenosine Selectivity</h3><div class="NLM_p">The high potency against several of the adenosine receptors was a cause for concern, so our last attempt was to increase the selectivity window vs PDE4. One of the analogues of the amide series pointed the way to achieve this: through double substitution of the biphenyl portion of the pyridazinone structure. Hence <b>46</b>, a 5-cyano analogue of <b>36</b>, displayed antagonism of 0.6 μM, >1 μM, and >1 μM against the three adenosine receptors A<sub>1</sub>, A<sub>2a</sub>, and A<sub>2b</sub>, respectively, as compared to potencies of 10 nM, 33 nM, 120 nM, respectively, for <b>36</b>. Therefore, we synthesized a series of meta,meta-disubstituted compounds, also incorporating the basic amide chains we found necessary for long duration. Enzymatic and cellular potencies at PDE4 were all excellent and subnanomolar (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Adenosine A<sub>2a</sub> antagonism was effectively removed, while A<sub>1</sub> and A<sub>2b</sub> were significantly reduced giving at least a margin of 100-fold over cellular PDE4 activity and in general >1000-fold (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Several of the compounds were highly potent in the neutrophilia assay at 5 h postdose. In terms of in vivo efficacy, compounds <b>50</b> and <b>56</b> stood out as the derivatives with the longest duration of action. Both compounds showed around 50% inhibition at 22 h after microspray dosing of 30 μg/kg. Despite only a minor proinflammatory effect (neutrophil increases of 1.6- and 1.3-fold, respectively, at 1000 μg/kg, 5 h postdose), both compounds also showed a subdued dose–response and we were only able to achieve a maximum of 60% inhibition 22 h postdose, at 300 μg/kg.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR of Doubly Substituted Biphenyls</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Ratio of most potent adenosine IC<sub>50</sub>/PDE4 IC<sub>50</sub> in PBMCs.</p></div></div><div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53321" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53321" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through structure based design, we modified the structure of our oral PDE4 inhibitor <b>6</b> to a series of dichloropyridyl-urea-pyridazinones <b>7</b> with double-digit picomolar enzymatic potencies. A variety of functional groups and physichochemical profiles could be incorporated into the new series in a region occupying the solvent-filled pocket of the PDE4 enzyme. In vitro potencies were demonstrated in a rat lung neutrophilia model by suspension microspray administration. While many compounds were potent in the short term, only the presence of a basic group gave compounds that displayed efficacy 22 h postdose. Compounds also demonstrated efficacy in the more demanding dry powder system in the short term, albeit at lower levels, but also uncovered a sporadic problem of proinflammation. Further profiling of the series also uncovered a potential selectivity issue against the adenosine receptors, specifically adenosine A<sub>1</sub>. Adenosine selectivity could be greatly increased by the introduction of a meta,meta-disubstitution pattern in the “solvent-filled pocket”. Compounds <b>50</b> and <b>56</b> fulfilled our criteria of potent, long-acting, and potentially safe inhaled PDE4 inhibitors. The program was terminated at this stage, and so these compounds were not advanced further toward preclinical development.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General</h3><div class="NLM_p">All test compounds have purity of >95%. HPLC analysis was conducted according to the described method, with the retention time expressed in minutes. UV chromatograms were processed at 210 nm with blank subtraction. HPLC was performed on a Symmetry C18 column (100 mm × 2.16 mm, 3.5 μm). The mobile phase, at a flow of 0.4 mL/min, was a 20 min binary gradient of water (containing 0.01 M ammonium formate at pH 3.0) and a mixture of acetonitrile–methanol 50:50 (containing 0.01 M ammonium formate) (0–95%). The total run time was 26 min. Reaction products were purified, when necessary, by flash chromatography on silica gel (40–63 μm) with the solvent system indicated. Purifications in reverse phase were made in a Biotage SP1 automated purification system equipped with a C-18 column and using a standard gradient of water–acetonitrile/MeOH (1:1) (0.1% v/v ammonium formate for both phases) from 0% to 100% acetonitrile/MeOH (1:1) in 80 column volumes. Other conditions are stated explicitly in the text. Preparative HPLC–MS was performed on a Waters instrument equipped with a 2767 injector/collector, a 2525 binary gradient pump, a 2996 PDA detector, a 515 pump as a makeup pump, and a ZQ4000 mass spectrometer detector. <sup>1</sup>H nuclear magnetic resonance spectra were recorded on a Gemini 200 MHz spectrometer, Gemini-2000 300 MHz spectrometer, or a Varian Mercury plus operating at a frequency of 400 MHz. Tetramethylsilane was used as reference. Chemical shifts δ are in ppm, and the following abbreviations are used: singlet (s), doublet (d), triplet (t), quartet (q), double doublet (dd), quintet (quin), multiplet (m), broad signal (br s), apparent signal (app). “Partial” generally refers to spectra where compound peaks are hidden below solvent peaks and are therefore unassignable. Mass spectra (<i>m</i>/<i>z</i>) were recorded on Micromass ZMD or Waters ZQ mass spectrometer using ESI ionization. Isotopic distributions are quoted for the mass ion of the lowest molecular weight isotope (<sup>35</sup>Cl and <sup>79</sup>Br) and the number of isotopes detected. PdCl<sub>2</sub>dppf·CH<sub>2</sub>Cl<sub>2</sub> refers to [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex.</div><div class="NLM_p last">The following general synthetic procedures are exemplified: Suzuki reaction (<b>16</b>), pinacol boronate ester formation (<b>22a</b>), ester hydrolysis (<b>26a</b>), amide coupling (<b>38</b>).</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 1-(3-Bromophenyl)butane-1,3-dione (<b>9</b>)</h3><div class="NLM_p last">Sodium hydride (50 g, 60% dispersion in oil, previously washed with pentane, 1.25 mol) was suspended in 920 mL of dry tetrahydrofuran. Ethyl acetate (123 mL, 1.25 mol) was added followed by 15 drops of absolute ethanol. The mixture was cooled in an ice–water bath. A solution of 1-(3-bromophenyl)ethanone <b>8</b> (125 g, 0.63 mol) dissolved in 330 mL of tetrahydrofuran was added with stirring, maintaining the reaction temperature below 20 °C. Upon completion of addition 18-crown-6 (3.5 g, 0.01 mol) was added. The mixture was stirred at room temperature for 15 min, at 40 °C for 15 min, then at reflux for 5.5 h, and then overnight, cooling to room temperature. The mixture was evaporated and the residue taken up in 1.5 L of water. The aqueous portion was extracted with 5 × 250 mL of ether and was then cooled in an ice-bath and acidified to pH 1–2 with concentrated hydrochloric acid. The aqueous phase was extracted with 3 × 250 mL of ether. The combined organics were washed twice with water and once with brine. The organics were dried over sodium sulfate, filtered, and evaporated to give <b>9</b> (124.9 g, 0.52 mol, 82%) as an oil, contaminated with several small impurities. It was used as such without further purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) enol tautomer: δ ppm 2.22 (s, 3H), 6.15 (s, 1H), 7.33 (t, <i>J</i> = 8.0 Hz, 1H), 7.64 (d, <i>J</i> = 7.7 Hz, 1H), 7.80 (d, <i>J</i> = 7.7 Hz, 1H), 8.01 (s, 1H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Ethyl 4-(3-Bromobenzoyl)-5-methylisoxazole-3-carboxylate (<b>10</b>)</h3><div class="NLM_p last">Sodium metal (13 g, previously washed with pentane, 0.57 mol) was mechanically stirred in 50 mL of absolute ethanol until completely dissolved. The solution was cooled to between 0 and −5 °C with an ice–salt bath, and a solution of <b>9</b> (124 g, 0.51 mol) dissolved in 325 mL of ethanol was added dropwise with stirring, maintaining the reaction temperature below 0 °C. The mixture was stirred for 15 min, and then a solution of ethyl 2-chloro-2-(hydroxyimino)acetate (85 g, 0.56 mol) dissolved in 180 mL of ethanol was added dropwise, maintaining the reaction temperature below 0 °C. The mixture was stirred for 30 min at 0 °C and then overnight, warming to room temperature. The solution (at pH 7) was acidified to pH 5 with 25 mL of acetic acid and was evaporated to dryness. The residue was taken up in 750 mL of ice–water and was extracted with 3 × 300 mL of ether. The combined organics were washed successively with 4% sodium bicarbonate solution, water, and brine. The organics were dried over sodium sulfate, decolorized at reflux with activated carbon, and filtered. Evaporation under high vacuum gave <b>10</b> (155.4 g, 0.46 mol, 89%) as an oil which solidified upon standing. It was used as such without further purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.14 (t, <i>J</i> = 7.0 Hz, 3H), 2.57 (s, 3H), 4.18 (q, <i>J</i> = 7.0 Hz, 2H), 7.36 (t, <i>J</i> = 7.8 Hz, 1H), 7.66 (d, <i>J</i> = 7.4 Hz, 1H), 7.74 (d, <i>J</i> = 7.7 Hz, 1H), 7.90 (s, 1H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 4-(3-Bromophenyl)-3-methylisoxazolo[3,4-<i>d</i>]pyridazin-7(6<i>H</i>)-one (<b>11</b>)</h3><div class="NLM_p last">Pyridazinone <b>10</b> (155.4 g, 0.46 mol) was suspended in 1.15 L of ethanol. Hydrazine hydrate (34.1 mL, 0.70 mol) was slowly added with stirring, dissolving the remaining solid. The mixture was stirred at room temperature overnight, precipitating a solid. The mixture was cooled in an ice–water bath for 15 min and then filtered. The solid was washed with ethanol, then with ether and was dried in a stream of air and then at 50 °C under vacuum to give <b>11</b> (101.5 g, 0.33 mol, 72%) as a solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.35 (s, 3H), 7.53 (t, <i>J</i> = 7.9 Hz, 1H), 7.66 (d, <i>J</i> = 7.6 Hz, 1H), 7.77 (d, <i>J</i> = 7.9 Hz, 1H), 7.83 (s, 1H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 4-(3-Bromophenyl)-6-ethyl-3-methylisoxazolo[3,4-<i>d</i>]pyridazin-7(6<i>H</i>)-one (<b>12</b>)</h3><div class="NLM_p last">Compound <b>11</b> (18.9 g, 61.8 mmol) was dissolved in 200 mL of anhydrous dimethylformamide. Potassium carbonate (25.7 g, 186 mmol) was added and the mixture stirred for 20 min. Bromoethane (13.9 mL, 186 mmol) was added dropwise with stirring, maintaining the reaction temperature below 30 °C, and the mixture was stirred at room temperature overnight. The mixture was evaporated to dryness and the residue taken up in 200 g of ice–water and extracted several times with ethyl acetate. The combined organics were washed successively with water, 4% sodium bicarbonate solution, water, brine–water, and brine. The organics were dried over sodium sulfate, decolorized at reflux with activated carbon, and filtered. Evaporation gave a solid which was broken up in ether and collected by filtration. The solid was washed with ether and was dried in a stream of air and then at 50 °C under vacuum to give <b>12</b> (17.6 g, 51 mmol, 85%) as a solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.42 (t, <i>J</i> = 7.1 Hz, 3H), 2.58 (s, 3H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.50 (d, <i>J</i> = 7.7 Hz, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (s, 1H). HPLC/MS (15 min) retention time 8.83 min. LRMS: <i>m</i>/<i>z</i> 334 (M + H<sup>+</sup>, 1 × Br).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 5-Acetyl-4-amino-6-(3-bromophenyl)-2-ethylpyridazin-3(2<i>H</i>)-one (<b>13</b>)</h3><div class="NLM_p last">Isoxazole <b>12</b> (34.4 g 103 mmol) was dissolved in 500 mL of tetrahydrofuran and 100 mL of ethanol. A heaping spoonful of Raney nickel was added and the mixture agitated under hydrogen atmosphere (14 psi) overnight. The mixture was filtered and the catalyst washed with tetrahydrofuran. The combined filtrate was evaporated, and the solid residue was broken up in 100 mL of hot ethanol. Upon cooling to room temperature, the solid was collected by filtration, was washed with ether, and was dried in a stream of air and then at 50 °C under vacuum to give <b>13</b> (31.2 g, 92.8 mmol, 90%) as a solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.42 (t, <i>J</i> = 7.1 Hz, 3H), 1.83 (s, 3H), 4.25 (q, <i>J</i> = 7.2 Hz, 2H), 7.29–7.40 (m, 2H), 7.60 (d, <i>J</i> = 7.4 Hz, 1H), 7.66 (s, 1H). HPLC/MS (15 min) retention time 7.77 min. LRMS: <i>m</i>/<i>z</i> 336 (M + H<sup>+</sup>, 1 × Br).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4-Amino-6-(3-bromophenyl)-2-ethylpyridazin-3(2<i>H</i>)-one (<b>14</b>)</h3><div class="NLM_p last">Acetylpyridazinone <b>13</b> (29.4 g, 87.5 mmol) was suspended in 215 mL of 48% hydrobromic acid and was heated at 130 °C for 1.25 h. The mixture was allowed to cool and was carefully diluted with ice–water and basified with solid sodium carbonate. Once basic, the aqueous portion was extracted with 2 × 300 mL of ethyl acetate. The combined organics were washed successively with water and brine. The organics were dried over sodium sulfate, decolorized at reflux with activated carbon, and filtered. Evaporation gave a residue which was broken up in 100 mL of hot diisopropyl ether. Upon cooling, the solid was collected by filtration, washed with diisopropyl ether, and dried in a stream of air and then at 50 °C under vacuum to give <b>14</b> (21.1 g, 71.7 mmol, 82%) as a solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.45 (t, <i>J</i> = 7.3 Hz, 3H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 5.02 (br s, 2H), 6.67 (s, 1H), 7.30 (t, <i>J</i> = 7.7 Hz, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.93 (s, 1H). HPLC/MS (15 min) retention time 8.58 min. LRMS: <i>m</i>/<i>z</i> 294 (M + H<sup>+</sup>, 1 × Br).</div></div><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(3-bromophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>15</b>)</h3><div class="NLM_p"><i>Solution 1.</i> Triphosgene (6.0 g, 20.2 mmol) was dissolved in 94 mL of dichloromethane in a 500 mL flask. A filtered solution of <b>14</b> (16.9 g, 57.5 mmol) and triethylamine (8.5 mL, 60.9 mmol) in 165 mL of dichloromethane was added and the mixture placed under argon atmosphere and stirred for 3 h. The mixture was evaporated to dryness and was re-evaporated twice more from tetrahydrofuran. The residue was taken up in 420 mL of tetrahydrofuran and was filtered to remove triethylamine hydrochloride.</div><div class="NLM_p last"><i>Solution 2.</i> Sodium hydride (5.7 g, 60% dispersion in oil, previously washed with pentane, 142 mmol) was suspended in 120 mL of dry tetrahydrofuran in a 1 L flask. A solution of 4-amino-3,5-dichloropyridine (18.8 g, 115 mmol) dissolved in 140 mL of tetrahydrofuran was added with stirring. The mixture was stirred for 2.5 h, forming a white suspension. The filtrate from solution 1 was added and the mixture stirred overnight at room temperature, precipitating a solid. The mixture was filtered, keeping both the solid and the filtrate. The solid was dissolved in water and the solution acidified to pH 6–7 with 2 M hydrochloric acid, precipitating a solid. The solid was collected by filtration, washed with water, then with ether and was dried in a stream of air and then at 50 °C under vacuum to give <b>15</b> (12.2 g). The filtrate was evaporated to dryness. The residue was taken up in 700 mL of water and acidified to pH 6–7 with 2 M hydrochloric acid, precipitating a solid. The solid was collected by filtration, washed with water, then with ether and was dried in a stream of air and then at 50 °C under vacuum. The solid was dissolved in 500 mL of hot methanol–dichloromethane (30:70) and was decolorized with activated carbon. Filtration and concentration to approximately 120 mL precipitated a solid. The solid was collected by filtration, washed with methanol and was dried in a stream of air and then at 50 °C under vacuum to give a further 7.2 g of <b>15</b>. Total yield, 19.4 g (40.2 mmol, 70%). Mp 176–178 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.37 (t, <i>J</i> = 7.2 Hz, 1H), 4.26 (q, <i>J</i> = 7.2 Hz, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.67 (ddd, <i>J</i> = 8.0, 2.0, 1.0 Hz, 1H), 7.77 (dd, <i>J</i> = 6.6, 1.3 Hz, 1H), 7.95 (t, <i>J</i> = 1.8 Hz, 1H), 8.32 (s, 1H), 8.70 (s, 1H), 9.71 (s, 1H), 9.90 (s, 1H). HPLC/MS (15 min) retention time 10.30 min. LRMS: <i>m</i>/<i>z</i> 480 (M – H<sup>+</sup>, 2 × Cl, 1 × Br).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure for Suzuki Coupling. Exemplified for <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(3′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>16</b>)</h3><div class="NLM_p last">In a Schlenk tube, aryl bromide <b>15</b> (3.00 g, 6.21 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (2.05 g, 6.21 mmol) were dissolved in dioxane (100 mL). Cesium carbonate solution (2 M, 9.31 mL, 18.6 mmol) was added, and the mixture was purged (vacuum–argon three times). PdCl<sub>2</sub>dppf·CH<sub>2</sub>Cl<sub>2</sub> (0.30 g, 0.37 mmol) was added and the mixture purged again (vacuum–argon three times). The mixture was stirred at 90 °C for 3 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted three times with ethyl acetate. The combined organics were washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed in vacuum and the residue was purified by the SP1 automated purification system to give <b>16</b> (1.26 g, 2.54 mmol, 41%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 4.28 (q, <i>J</i> = 7.3 Hz, 2H), 6.80 (ddd, <i>J</i> = 8.1, 2.4, 0.9 Hz, 1H), 7.05 (t, <i>J</i> = 2.1 Hz, 1H), 7.09 (ddd, <i>J</i> = 7.7, 1.6, 0.9 Hz, 1H), 7.29 (t, <i>J</i> = 7.9 Hz, 1H), 7.57 (t, <i>J</i> = 7.8 Hz, 1H), 7.68 (dt, <i>J</i> = 7.7, 1.1 Hz, 1H), 7.76 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.93 (t, <i>J</i> = 1.7 Hz, 1H), 8.40 (s, 1H), 8.69 (s, 2H), 9.61 (s, 1H), 9.64 (s, 1H). HPLC/MS (30 min) retention time 15.94 min. LRMS: <i>m</i>/<i>z</i> 496 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(4′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>17</b>)</h3><div class="NLM_p last">Suzuki reaction <b>15</b> (200 mg, 0.41 mmol) with 4-hydroxyphenylboronic acid (85 mg, 0.62 mmol) according to the general method gave <b>17</b> (30 mg, 0.060 mmol, 15%) after crystallization from ethanol. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.47 (t, <i>J</i> = 7.1 Hz, 3H), 4.35 (d, <i>J</i> = 6.7 Hz, 2H), 6.93 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (s, 1H), 7.38–7.61 (m, 4H), 7.71 (d, <i>J</i> = 7.3 Hz, 1H), 7.97 (s, 1H), 8.52 (s, 2H), 8.74 (s, 1H), 9.53 (s, 1H), 9.63 (s, 1H). HPLC/MS (30 min) retention time 17.33 min. LRMS: <i>m</i>/<i>z</i> 496 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(2′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>18</b>)</h3><div class="NLM_p last">Suzuki reaction of <b>15</b> (200 mg, 0.41 mmol) with 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (61 mg, 0.28 mmol) according to the general method gave <b>18</b> (50 mg, 0.10 mmol, 35%) after crystallization from ethanol. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (t, <i>J</i> = 7.1 Hz, 3H), 4.26 (q, <i>J</i> = 7.2 Hz, 2H), 6.90 (t, <i>J</i> = 7.3 Hz, 1H), 6.95 (d, <i>J</i> = 7.7 Hz, 1H), 7.17 (t, <i>J</i> = 7.5 Hz, 1H), 7.28 (d, <i>J</i> = 6.9 Hz, 1H), 7.51 (t, <i>J</i> = 7.2 Hz, 1H), 7.59 (d, <i>J</i> = 7.8 Hz, 1H), 7.73 (d, <i>J</i> = 7.5 Hz, 1H), 7.94 (s, 1H), 8.39 (s, 1H), 8.69 (s, 2H), 9.61 (s, 1H), 9.69 (s, 1H), 9.90 (s, 1H). HPLC/MS (30 min) retention time 18.12 min. LRMS: <i>m</i>/<i>z</i> 496 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(4′-fluoro-2′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>19</b>)</h3><div class="NLM_p last">Suzuki reaction of <b>15</b> (0.20 g, 0.42 mmol) with 4-fluoro-2-hydroxyphenylboronic acid (0.10 g, 0.64 mmol) according to the general method and purification by the SP1 automated purification system gave <b>19</b> (0.06 g, 0.12 mmol, 28%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 4.26 (d, <i>J</i> = 7.0 Hz, 2H), 6.67–6.83 (m, 2H), 7.33 (dd, <i>J</i> = 8.8, 7.2 Hz, 1H), 7.45–7.63 (m, 2H), 7.73 (d, <i>J</i> = 6.7 Hz, 1H), 7.90 (s, 1H), 8.38 (s, 1H), 8.69 (s, 2H), 9.68 (s, 1H), 9.93 (br s, 1H), 10.19 (br s, 1H). HPLC/MS (30 min) retention time 18.45 min. LRMS: <i>m</i>/<i>z</i> 514 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(5′-fluoro-2′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>20</b>)</h3><div class="NLM_p last">Suzuki reaction of <b>15</b> (2.69 g, 5.40 mmol) with 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-4-fluorophenol (3.3 g, 8.10 mmol) according to the general method gave <b>20</b> (1.65 g, 3.21 mmol, 59%) after crystallization from dichloromethane–methanol (6:4). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 4.26 (q, <i>J</i> = 7.2 Hz, 2H), 6.94 (dd, <i>J</i> = 8.8, 5.0 Hz, 1H), 7.03 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.15 (dd, <i>J</i> = 9.5, 3.0 Hz, 1H), 7.53 (t, <i>J</i> = 7.7 Hz, 1H), 7.61 (d, <i>J</i> = 7.7 Hz, 1H), 7.75 (d, <i>J</i> = 7.7 Hz, 1H), 7.97 (s, 1H), 8.38 (s, 1H), 8.68 (s, 2H), 9.61–9.73 (m, 3H). HPLC/MS (30 min) retention time 18.31 min. LRMS: <i>m</i>/<i>z</i> 514 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(2′-fluoro-3′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>21</b>)</h3><div class="NLM_p"><i>Step 1.</i> 2-Fluoro-3-methoxyphenylboronic acid (1.1 g, 6.5 mmol) was dissolved in 30 mL of dichloromethane and cooled to 5 °C under nitrogen. Boron tribromide solution (32 mL, 1 M in dichloromethane, 32 mmol) was added dropwise with stirring. Upon addition, the mixture was stirred for 1 h at room temperature. The mixture was added dropwise to 50 mL of cold ethanol. The mixture was then neutralized with portionwise addition of excess solid sodium bicarbonate with cooling. The mixture was stirred for 15 min, filtered and the filtrate evaporated. The residue was taken up in tetrahydrofuran, refiltered, and re-evaporated to give 2-(fluoro-3-hydroxyphenyl)boronic acid <b>21a</b> (0.96 g, 6.2 mmol, 96%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 6.91 (m, 3H), 8.13 (br s, 2H), 9.53 (s, 1H).</div><div class="NLM_p last"><i>Step 2.</i> Suzuki reaction of <b>15</b> (250 mg, 0.52 mmol) with <b>21a</b> (125 mg, 0.80 mmol) according to the general method and purification by the SP1 automated purification system gave <b>21</b> (25 mg, 0.049 mmol, 9%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.37 (t, <i>J</i> = 7.2 Hz, 3H), 4.26 (q, <i>J</i> = 7.1 Hz, 2H), 6.87–7.04 (m, 2H), 7.09 (t, <i>J</i> = 8.0, 7.4 Hz, 1H), 7.59 (app d, <i>J</i> = 4.5 Hz, 2H), 7.81 (td, <i>J</i> = 4.6, 1.8 Hz, 1H), 7.87 (s, 1H), 8.39 (s, 1H), 8.69 (s, 2H), 9.67 (br s, 1H), 9.90 (br s, 1H), 9.99 (s, 1H). HPLC/MS (30 min) retention time 17.77 min. LRMS: <i>m</i>/<i>z</i> 514 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(3′-fluoro-4′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>22</b>)</h3><div class="NLM_p"><i>Step 1. General Procedure for Synthesis of Pinacol Boronates.</i> In a Schlenk tube, a mixture of 4-bromo-2-fluorophenol (0.50 g, 4.57 mmol), bis(pinacolato)diboron (1.33 g, 5.23 mmol), and potassium acetate (1.37 g, 14 mmol) was dissolved in dimethylsufoxide (25 mL). The mixture was purged (vacuum–argon three times), and PdCl<sub>2</sub>dppf·CH<sub>2</sub>Cl<sub>2</sub> (0.10 g, 0.13 mmol) was added. The mixture was purged again (vacuum–argon three times) and stirred at 80 °C for 4 h. The suspension was filtered and the filtrate diluted with water and extracted three times with ethyl acetate. The combined organic layers were washed with water and brine and dried over anhydrous sodium sulfate. Solvent was removed in vacuo and the residue was partially purified by flash chromatography (ethyl acetate–hexane, 20:80) and then reverse-phase chromatography using the SP1 automated purification system to give 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol <b>22a</b> (0.25 g, 85% pure, 0.89 mmol, 19% yield). <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) δ ppm 1.31 (s, 12H), 6.87 (t, <i>J</i> = 8.3 Hz, 1H), 7.26–7.41 (m, 2H).</div><div class="NLM_p last"><i>Step 2.</i> Suzuki reaction of <b>15</b> (250 mg, 0.52 mmol) with <b>22a</b> (220 mg, 0.78 mmol) according to the general method and purification by chromatography (methanol–dichloromethane, 5:95) gave <b>22</b> (40 mg, 0.078 mmol, 16%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 4.28 (d, <i>J</i> = 7.3 Hz, 2H), 7.06 (t, <i>J</i> = 8.7 Hz, 1H), 7.36 (ddd, <i>J</i> = 8.2, 2.1, 0.9, 1H), 7.51 (dd, <i>J</i> = 12.6, 2.3 Hz, 1H), 7.56 (d, <i>J</i> = 7.3 Hz, 1H), 7.63–7.74 (m, 2H), 7.93 (t, <i>J</i> = 1.3 Hz, 1H), 8.38 (s, 1H), 8.70 (s, 2H), 9.69 (br s, 1H), 9.91 (br s, 1H), 10.06 (br s, 1H). HPLC/MS (30 min) retention time 17.73 min. LRMS: <i>m</i>/<i>z</i> 514 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-[2-ethyl-6-(2′-fluoro-4′-hydroxybiphenyl-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]urea (<b>23</b>)</h3><div class="NLM_p"><i>Step 1.</i> Pinacol boronate synthesis with 4-bromo-3-fluorophenol (1.00 g, 5.24 mmol) and bis(pinacolato)diboron (2.66 g, 10.47 mmol) according to the general method gave 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol <b>23a</b> (0.37 g, 1.55 mmol, 30%) after purification by reverse-phase chromatography. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.26 (s, 12H), 6.55 (m, 1H), 6.62 (m, 1H), 7.61 (m, 1H). HPLC/MS (9 min) retention time 8.85 min. LRMS: <i>m</i>/<i>z</i> 239 (M + H<sup>+</sup>).</div><div class="NLM_p last"><i>Step 2.</i> Suzuki reaction of <b>15</b> (0.30 g, 0.62 mmol) with <b>23a</b> (0.37 g, 1.55 mmol) according to the method gave <b>23</b> (0.075 g, 0.15 mmol, 37%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.37 (t, <i>J</i> = 7.2 Hz, 3H), 4.26 (q, <i>J</i> = 7.2 Hz, 2H), 6.65–6.78 (m, 2H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.55 (app d, <i>J</i> = 5.1 Hz, 2H), 7.71–7.78 (m, 1H), 7.84 (t, <i>J</i> = 1.3 Hz, 1H), 8.37 (s, 1H), 8.70 (s, 2H), 9.70 (br s, 1H), 9.88 (br s, 1H), 10.10 (br s, 1H). HPLC/MS (30 min) retention time 17.81 min. LRMS: <i>m</i>/<i>z</i> 514 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-{2-ethyl-6-[3-(5-hydroxypyridin-3-yl)phenyl]-3-oxo-2,3-dihydropyridazin-4-yl}urea (<b>24</b>)</h3><div class="NLM_p"><i>Step 1.</i> Pinacol boronate synthesis with 3-bromo-5-methoxypyridine (2.0 g, 10.3 mmol) and bis(pinacolato)diboron (2.88 g, 11.4 mmol) according to the general method gave 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine <b>24a</b> (1.38 g) as an oil. It was used as such without further purification. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.36 (br s, 12H), 3.87 (s, 3H), 7.27 (s, 1H), 8.37 (d, <i>J</i> = 2.34 Hz, 1H), 8.55 (s, 1H).</div><div class="NLM_p"><i>Step 2.</i> Suzuki reaction of <b>15</b> (250 mg, 0.50 mmol) with <b>24a</b> (177 mg, 0.75 mmol) according to the general method gave <i>N</i>-(3,5-dichloropyridin-4-yl)-<i>N</i>′-{2-ethyl-6-[3-(5-methoxypyridin-3-yl)phenyl]-3-oxo-2,3-dihydropyridazin-4-yl}urea <b>24b</b> (50 mg, 0.098 mmol, 19%) after purification by flash chromatography (hexane–ethyl acetate, 2:1). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 3.91 (s, 3H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 7.59–7.71 (m, 2H), 7.82 (d, <i>J</i> = 7.8 Hz, 2H), 8.06 (s, 1H), 8.33 (d, <i>J</i> = 2.7 Hz, 1H), 8.40 (s, 1H), 8.50 (s, 1H), 8.69 (s, 2H), 9.69 (s, 1H), 9.90 (s, 1H). HPLC/MS (30 min) retention time 16.92 min. LRMS: <i>m</i>/<i>z</i> 511 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 3.</i><b>24b</b> (150 mg, 0.28 mmol) was added to a solution of boron tribromide–methyl sulfide complex (0.71 g, 2.27 mmol) in 11 mL of 1,2-dichloroethane. The mixture was stirred at reflux for 10 h. Additional boron tribromide–methyl sulfide complex (2.49 g, 7.97 mmol) was added and the reaction followed by HPLC until the starting material had disappeared. The reaction mixture was diluted with water and neutralized with ammonium hydroxide solution to pH 7–8. Dichloromethane was added precipitating a solid, which was collected by filtration and dried in a stream of air. Purification by preparative HPLC gave <b>24</b> (12 mg, 0.024 mmol, 9%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 7.42 (t, <i>J</i> = 2.0 Hz, 1H), 7.61 (t, <i>J</i> = 7.7 Hz, 1H), 7.73 (d, <i>J</i> = 8.2 Hz, 1H), 7.82 (d, <i>J</i> = 7.7 Hz, 1H), 7.98 (t, <i>J</i> = 1.4 Hz, 1H), 8.16 (d, <i>J</i> = 2.0 Hz, 1H), 8.37 (d, <i>J</i> = 1.6 Hz, 1H), 8.40 (s, 1H), 8.69 (s, 2H), 9.70 (s, 1H), 10.10 (br s, 2H). HPLC/MS (30 min) retention time 14.23 min. LRMS: <i>m</i>/<i>z</i> 497 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(3,5-Dichloropyridin-4-yl)-<i>N</i>′-{2-ethyl-6-[3-(6-hydroxypyridin-3-yl)phenyl]-3-oxo-2,3-dihydropyridazin-4-yl}urea (<b>25</b>)</h3><div class="NLM_p"><i>Step 1.</i> Suzuki reaction of <b>15</b> (0.30 g, 0.62 mmol) with 6-methoxypyridin-3-ylboronic acid (0.19 g, 1.24 mmol) according to the general scheme gave <i>N</i>-(3,5-dichloropyridin-4-yl)-<i>N</i>′-{2-ethyl-6-[3-(6-methoxypyridin-3-yl)phenyl]-3-oxo-2,3-dihydropyridazin-4-yl}urea <b>25a</b> (0.23 g, 0.45 mmol, 74%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 3.90 (s, 3H), 4.30 (q, <i>J</i> = 7.3 Hz, 2H), 6.94 (d, <i>J</i> = 8.6 Hz, 1H), 7.61 (t, <i>J</i> = 7.6 Hz, 1H), 7.72–7.82 (m, 2H), 7.98 (t, <i>J</i> = 1.6 Hz, 1H), 8.06 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 8.40 (s, 1H), 8.53 (d, <i>J</i> = 2.3 Hz, 1H), 8.70 (s, 2H), 9.70 (br s, 1H), 9.90 (s, 1H). HPLC/MS (30 min) retention time 18.98 min. LRMS: <i>m</i>/<i>z</i> 511 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 2.</i><b>25a</b> (153 mg, 0.30 mmol) was suspended in acetonitrile (10 mL) in a microwave vial. Sodium iodide (225 mg, 1.50 mmol) was added. The vial was sealed, purged with argon, and then trimethylsilyl chloride (190 μL, 1.50 mmol) was added. The mixture was microwaved at 100 °C for 5 h. The solvent was evaporated under reduced pressure and the residue purified directly by the SP1 automated purification system to give <b>25</b> (60 mg, 0.121 mmol, 40%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (t, <i>J</i> = 7.1 Hz, 3H), 4.27 (q, <i>J</i> = 7.1 Hz, 2H), 6.45 (d, <i>J</i> = 9.5 Hz, 1H), 7.52 (t, <i>J</i> = 7.8 Hz, 1H), 7.64 (d, <i>J</i> = 7.7, 1H), 7.69 (d, <i>J</i> = 7.7, 1H), 7.77 (d, <i>J</i> = 2.0 Hz, 1H), 7.83–7.90 (m, 2H), 8.37 (s, 1H), 8.70 (s, 2H), 9.69 (s, 1H), 9.90 (s, 1H), 11.86 (s, 1H). HPLC/MS (30 min) retention time 14.66 min. LRMS: <i>m</i>/<i>z</i> 497 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-2-carboxylic Acid (<b>26</b>)</h3><div class="NLM_p"><i>Step 1.</i> Suzuki reaction of <b>15</b> (700 mg, 1.41 mmol) with ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (600 mg, 2.11 mmol) according to the general scheme gave ethyl 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-2-carboxylate <b>26a</b> (440 mg, 0.80 mmol, 57%) after triturating with diethyl ether. HPLC/MS (9 min) retention time 7.57 min. LRMS: <i>m</i>/<i>z</i> 552 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 2. General Method for Ester Hydrolysis.</i> A solution of lithium hydroxide monohydrate (150 mg, 3.57 mmol) in 5 mL of water was added dropwise to a stirred solution of <b>26a</b> (440 mg, 0.71 mmol) in 12 mL of methanol–tetrahydrofuran (2:1). The mixture was stirred at room temperature for 24 h, then diluted with water and acidified with 2 N hydrochloric acid precipitating a solid, which was collected by filtration and dried in a stream of air to give <b>26</b> (130 mg, 0.25 mmol, 34%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.37 (t, <i>J</i> = 7.2 Hz, 3H), 4.25 (q, <i>J</i> = 7.2 Hz, 2H), 7.25–7.99 (m, 8H), 8.38 (br s, 1H), 8.69 (br s, 2H), 9.71 (br s, 1H), 9.90 (br s, 1H), 12.81 (br s, 1H). HPLC/MS (30 min) retention time 17.28 min. LRMS: <i>m</i>/<i>z</i> 524 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylic Acid (<b>27</b>)</h3><div class="NLM_p"><i>Step 1.</i> Suzuki reaction of <b>15</b> (250 mg, 0.50 mmol) with [3-(ethoxycarbonyl)phenyl]boronic acid (0.150 g, 0.77 mmol) according to the general method ethyl 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylate <b>27a</b> (0.159 g, 0.29 mmol, 58%) after trituration with methanol. HPLC/MS (9 min) retention time 7.69 min. LRMS: <i>m</i>/<i>z</i> 552 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 2.</i> Ester hydrolysis of <b>27a</b> (0.159 g, 0.29 mmol) according to the general method gave <b>27</b> (0.043 g, 0.082 mmol, 28%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (t, <i>J</i> = 7.20 Hz, 3H), 4.28 (q, <i>J</i> = 7.20 Hz, 2H), 7.56–7.65 (m, 2H), 7.79 (t, <i>J</i> = 8.41 Hz, 2H), 7.90 (d, <i>J</i> = 7.63 Hz, 1H), 7.96 (d, <i>J</i> = 7.63 Hz, 1H), 8.02 (s, 1H), 8.20 (s, 1H), 8.41 (s, 1H), 8.69 (s, 2H), 9.70 (s, 1H). HPLC/MS (30 min) retention time 18.01 min. LRMS: <i>m</i>/<i>z</i> 524 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-4-carboxylic Acid (<b>28</b>)</h3><div class="NLM_p"><i>Step 1.</i> Suzuki reaction of <b>15</b> (350 mg, 0.72 mmol) with 4-(ethoxycarbonyl)phenylboronic acid (211 mg, 1.09 mmol) according to the general method gave ethyl 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-4-carboxylate <b>28a</b> (190 mg, 0.34 mmol, 46%) after triturating with diethyl ether. HPLC/MS (9 min) retention time 7.71 min. LRMS: <i>m</i>/<i>z</i> 552 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 2.</i> Ester hydrolysis of <b>28a</b> (880 mg, 1.12 mmol) according to the general method gave <b>28</b> (440 mg, 0.84 mmol, 75%) after crystallization with dichloromethane–methanol (7:3). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 4.28 (q, <i>J</i> = 7.2 Hz, 2H), 7.54–8.27 (m, 8H), 8.41 (br s, 1H), 8.70 (br s, 2H), 9.71 (br s, 1H), 9.91 (br s, 1H), 12.99 (br s, 1H). HPLC/MS (30 min) retention time 17.61 min. LRMS: <i>m</i>/<i>z</i> 524 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-6-fluorobiphenyl-3-carboxylic Acid (<b>29</b>)</h3><div class="NLM_p"><i>Step 1.</i> Pinacol boronate synthesis from methyl 3-bromo-4-fluorobenzoate (1.05 g, 4.51 mmol) and bis(pinacolato)diboron (1.14 g, 4.49 mmol) according to the general method gave crude methyl 4-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>29a</b> (1.52 g). It was used as such without further purification. HPLC/MS (9 min) retention time 4.47 min. LRMS: 281 (M + H<sup>+</sup>).</div><div class="NLM_p"><i>Step 2.</i> Suzuki reaction of compound <b>15</b> (1.00 g, 2.07 mmol) with crude <b>29a</b> (1.40 g) according to the general method gave methyl 3′-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-6-fluorobiphenyl-3-carboxylate <b>29b</b> (0.55 g, 0.99 mmol, 48%). HPLC/MS (9 min) retention time 7.53 min. LRMS: <i>m</i>/<i>z</i> 556 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 3.</i> Ester hydrolysis of <b>29b</b> (550 mg, 0.99 mmol) according to the general method (1:1) gave <b>29</b> (274 mg, 0.51 mmol, 51%) after crystallization from ethanol–chloroform. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (t, <i>J</i> = 7.0 Hz, 3H), 4.27 (q, <i>J</i> = 6.9 Hz, 2H), 7.38–7.58 (m, 1H), 7.66 (s, 2H), 7.75–8.22 (m, 4H), 8.39 (s, 1H), 8.69 (s, 2H), 9.70 (s, 1H), 9.90 (s, 1H), 13.20 (s, 1H). HPLC/MS (30 min) retention time 17.87 min. LRMS: <i>m</i>/<i>z</i> 542 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-4-fluorobiphenyl-3-carboxylic Acid (<b>30</b>)</h3><div class="NLM_p"><i>Step 1.</i> Pinacol boronate synthesis from methyl 5-bromo-2-fluorobenzoate (0.50 g, 2.15 mmol) and bis(pinacolato)diboron (1.09 g, 4.29 mmol) according to the general gave methyl 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>30a</b> (1.04 g) as an oil which was used as such without further purification. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.26 (s, 12H), 3.92 (s, 3H), 7.04–7.18 (m, 1H), 7.85–8.01 (m, 1H), 8.36 (d, <i>J</i> = 7.8 Hz, 1H).</div><div class="NLM_p"><i>Step 2.</i> Suzuki reaction of <b>15</b> (535 mg, 1.07 mmol) with crude <b>30a</b> (1.0 g) according to the general method gave methyl 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-4-fluorobiphenyl-3-carboxylate <b>30b</b> (420 mg, 0.75 mmol, 47%) after crystallization from dichloromethane–methanol (8:2). HPLC/MS (9 min) retention time 7.54 min. LRMS: <i>m</i>/<i>z</i> 556 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 3.</i> Ester hydrolysis of <b>30b</b> (420 mg, 0.51 mmol) according to the general method gave <b>30</b> (38 mg, 0.072 mmol, 14%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (t, <i>J</i> = 7.0 Hz, 3H), 4.28 (q, <i>J</i> = 6.9 Hz, 2H), 7.19–7.47 (m, 1H), 7.51–7.68 (m, 1H), 7.67–7.90 (m, 3H), 8.00 (d, <i>J</i> = 8.1 Hz, 2H), 8.39 (s, 1H) 8.69 (s, 2H), 9.71 (br s, 1H). HPLC/MS (30 min) retention time 15.39 min. LRMS: <i>m</i>/<i>z</i> 525 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 5-{3-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]phenyl}nicotinic Acid (<b>31</b>)</h3><div class="NLM_p"><i>Step 1.</i> Pinacol boronate synthesis from methyl 5-bromonicotinate (1.0 g, 4.63 mmol) and bis(pinacolato)diboron (1.29 g, 5.08 mmol) according to the general method gave methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate <b>31a</b> (1.12 g) as an oil which was used as such without further purification. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.21–1.31 (m, 12H), 3.95 (s, 3H), 8.67 (br s, 1H), 9.09 (br s, 1H), 9.27 (br s, 1H).</div><div class="NLM_p"><i>Step 2.</i> Suzuki reaction of <b>15</b> (500 mg, 1 mmol) with crude <b>31a</b> (396 mg, 1.51 mmol) according to the general method gave methyl 5-{3-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]phenyl}nicotinate <b>31b</b> (160 mg, 0.30 mmol, 27%) after crystallization from dichloromethane–methanol (8:2). HPLC/MS (9 min) retention time 6.83 min. LRMS: <i>m</i>/<i>z</i> 537 (M – H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 3.</i> Ester hydrolysis of <b>31b</b> (160 mg, 0.27 mmol) according to the general method gave <b>31</b> (52 mg, 0.10 mmol, 36%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 6.6 Hz, 3H), 4.29 (q, <i>J</i> = 6.6, 2H), 7.56–7.78 (m, 1H), 7.87 (m, 2H), 8.10 (br s, 1H), 8.41 (br s, 1H), 8.49 (br s, 1H), 8.69 (s, 2H), 9.09 (br s, 1H), 9.14 (br s, 1H), 9.71 (br s, 1H), 9.91 (br s, 1H). HPLC/MS (30 min) retention time 15.39 min. LRMS: <i>m</i>/<i>z</i> 525 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> {3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-yl}acetic Acid (<b>32</b>)</h3><div class="NLM_p"><i>Step 1.</i> Pinacol boronate synthesis from methyl (3-bromophenyl)acetate (2.05 g, 7.43 mmol) and bis(pinacolato)diboron (4.55 g, 18.0 mmol) according to the general method gave methyl [3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate <b>32a</b> (2.0 g). It was used as such without further purification. HPLC/MS (9 min) retention time 6.59 min. LRMS: <i>m</i>/<i>z</i> 277 (M + H<sup>+</sup>).</div><div class="NLM_p"><i>Step 2.</i> Suzuki reaction of <b>15</b> (1.00 g, 2.07 mmol) with crude <b>32a</b> (0.85 g) according to the general method gave methyl {3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-yl}acetate <b>32b</b> (0.76 g, 1.38 mmol, 67%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.36 (t, <i>J</i> = 7.2 Hz, 3H), 3.59 (s, 3H), 3.75 (s, 2H), 4.25 (q, <i>J</i> = 7.2 Hz, 2H), 7.27 (d, <i>J</i> = 7.8 Hz, 1H), 7.42 (t, <i>J</i> = 8.0 Hz, 1H), 7.51–7.61 (m, 3H), 7.69 (d, <i>J</i> = 8.2 Hz, 1H), 7.74 (d, <i>J</i> = 7.8 Hz, 1H), 7.95 (s, 1H), 8.37 (s, 1H), 8.67 (s, 2H), 9.67 (s, 1H), 9.87 (s, 1H). HPLC/MS (9 min) retention time 7.33 min. LRMS: <i>m</i>/<i>z</i> 550 (M – H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 3.</i> Ester hydrolysis of <b>32b</b> (0.76 g, 1.38 mmol) according to the general method gave <b>32</b> (0.33 g, 0.61 mmol, 44%), after crystallization with dichloromethane–methanol (7:3). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.36 (t, <i>J</i> = 7.1 Hz, 3H), 3.64 (s, 2H), 4.25 (q, <i>J</i> = 7.1 Hz, 2H), 7.26 (d, <i>J</i> = 7.8 Hz, 1H), 7.41 (t, <i>J</i> = 7.6 Hz, 1H), 7.50–7.60 (m, 3H), 7.69 (d, <i>J</i> = 8.2 Hz, 1H), 7.73 (d, <i>J</i> = 7.8.2 Hz, 1H), 7.95 (s, 1H), 8.36 (s, 1H), 8.66 (s, 2H), 9.67 (s, 1H), 9.88 (s, 1H), 12.33 (s, 1H). HPLC/MS (30 min) retention time 17.47 min. LRMS: <i>m</i>/<i>z</i> 538 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> {3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-4-yl}acetic Acid (<b>33</b>)</h3><div class="NLM_p"><i>Step 1.</i> Pinacol boronate synthesis from ethyl (4-bromophenyl)acetate (1.0 g, 4.1 mmol) with bis(pinacolato)diboron (2.1 g, 8.3 mmol) according to the general method gave ethyl [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate <b>33a</b> (0.86 g, 2.97 mmol, 72%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.23 (t, <i>J</i> = 6.8 Hz, 3H), 1.34 (s, 12H), 3.62 (s, 2H), 4.13 (q, <i>J</i> = 7.0 Hz, 2H), 7.22–7.34 (m, 2H), 7.77 (d, <i>J</i> = 7.4 Hz, 2H). HPLC/MS (9 min) retention time 6.86 min. LRMS: <i>m</i>/<i>z</i> 308 (M + NH<sub>4</sub><sup>+</sup>).</div><div class="NLM_p"><i>Step 2.</i> Suzuki reaction of <b>15</b> (1.0 g, 2.07 mmol) with <b>33a</b> (0.86 g, 2.97 mmol) according to the general method ethyl {3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-4-yl}acetate gave <b>33b</b> (0.65 g, 1.15 mmol, 55%). HPLC/MS (9 min) retention time 7.56 min. LRMS: <i>m</i>/<i>z</i> 566 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 3.</i> Ester hydrolysis of <b>33b</b> (0.65 g, 1.15 mmol) according to the general method gave <b>33</b> (0.303 g, 0.56 mmol, 49%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.3 Hz, 3H), 3.62 (s, 2H), 4.28 (q, <i>J</i> = 7.3 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.59 (t, <i>J</i> = 7.7 Hz, 2H), 7.64 (d, <i>J</i> = 8.3 Hz, 2H), 7.70–7.79 (m, 2H), 7.99 (s, 1H), 8.40 (s, 1H), 8.70 (s, 2H), 9.70 (s, 1H), 9.90 (s, 1H), 12.37 (s, 1H). HPLC/MS (15 min) retention time 9.10 min. LRMS: <i>m</i>/<i>z</i> 538 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxamide (<b>34</b>)</h3><div class="NLM_p last">Suzuki reaction of <b>15</b> (0.40 g, 0.83 mmol) with [3-(aminocarbonyl)phenyl]boronic acid (0.204 g, 1.05 mmol) according to the general method gave <b>34</b> (0.055 g, 13%) after crystallization with dichloromethane–methanol. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 4.29 (q, <i>J</i> = 7.2 Hz, 2H), 7.45 (s, 1H), 7.60 (dt, <i>J</i> = 17.8, 7.7 Hz, 2H), 7.75–7.93 (m, 4H), 8.05 (s, 1H), 8.13 (s, 1H), 8.19 (s, 1H), 8.40 (s, 1H), 8.70 (s, 2H), 9.71 (s, 1H), 9.90 (s, 1H). HPLC/MS (30 min) retention time 15.98 min. LRMS: <i>m</i>/<i>z</i> 523 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-4-carboxamide (<b>35</b>)</h3><div class="NLM_p last">Suzuki reaction of <b>15</b> (300 mg, 0.60 mmol) with 4-carbamoylphenylboronic acid (149 mg, 0.90 mmol) according to the general method gave <b>35</b> (130 mg, 0.25 mmol, 14%) after purification by chromatography (neutral alumina, methanol–ethyl acetate gradient, 1:99 rising to 4:96). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 6.8 Hz, 3H) 4.28 (q, <i>J</i> = 7.0, 2H), 7.42 (bs, 1H), 7.54–7.70 (m, 1H), 7.72–7.89 (m, 3H), 7.72–7.89 (m, 3H), 7.97–8.04 (m, 5H), 8.41 (s, 1H), 8.69 (s, 2H), 9.69 (br s, 1H), 9.91 (br s, 1H). HPLC/MS (30 min) retention time 16.11 min. LRMS: <i>m</i>/<i>z</i> 523 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-Cyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxamide (<b>36</b>)</h3><div class="NLM_p last">Suzuki reaction of <b>15</b> (0.20 g, 0.41 mmol) with <i>N</i>-cyclopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.142 g, 0.50 mmol) according to the general method gave <b>36</b> (0.072 g, 0.13 mmol, 31%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.55–0.62 (m, 2H), 0.66–0.75 (m, 2H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H), 2.79–2.99 (m, 1H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 7.53–7.66 (m, 2H), 7.74–7.88 (m, 4H), 8.03 (s, 1H), 8.10 (s, 1H), 8.40 (s, 1H), 8.57 (d, <i>J</i> = 4.3 Hz, 1H), 8.70 (s, 2H), 9.71 (s, 1H), 9.90 (s, 1H). HPLC/MS (30 min) retention time 17.51 min. LRMS: <i>m</i>/<i>z</i> 563 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>-[2-(dimethylamino)ethyl]biphenyl-3-carboxamide (<b>37</b>)</h3><div class="NLM_p"><i>Step 1.</i><i>N</i>,<i>N</i>-Dimethylethane-1,2-diamine (0.71 g, 8.06 mmol) was added to a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.00 g, 4.03 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 0.82 g, 6.07 mmol), and <i>N</i>-ethyl-<i>N</i>′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 1.16 g, 6.05 mmol) in 8 mL of dimethylformamide. The mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the residue dissolved in 4% sodium bicarbonate solution. The aqueous phase was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed in vacuum to give <i>N</i>-[2-(dimethylamino)ethyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide <b>37a</b> (0.81 g, 2.55 mmol, 63%). HPLC/MS (9 min) retention time 4.23 min. LRMS: <i>m</i>/<i>z</i> 319 (M + H<sup>+</sup>) .</div><div class="NLM_p last"><i>Step 2.</i> Suzuki reaction of <b>15</b> (0.50 g, 1.04 mmol) with <b>37a</b> (0.493 g, 1.55 mmol) according to the general method gave <b>37</b> (0.320 g, 0.54 mmol, 51%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 2.25 (s, 6H), 2.49–2.54 (m, 2H), 3.32–3.48 (m, 2H), 4.28 (q, <i>J</i> = 7.2 Hz, 2H), 7.61 (dt, <i>J</i> = 15.7, 7.7 Hz, 2H), 7.80 (dt, <i>J</i> = 7.8, 1.7 Hz, 2H), 7.86 (t, <i>J</i> = 7.1 Hz, 2H), 8.04 (s, 1H), 8.14 (s, 1H), 8.19 (s, 1H), 8.40 (s, 1H), 8.59 (t, <i>J</i> = 5.6 Hz, 1H), 8.69 (s, 2H), 9.71 (s, 1H). HPLC/MS (30 min) retention time 12.32 min. LRMS: <i>m</i>/<i>z</i> 594 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> General Method for Amide Coupling Reaction, Exemplified for 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>-(2-piperidin-1-ylethyl)biphenyl-3-carboxamide (<b>38</b>)</h3><div class="NLM_p last">Compound <b>27</b> (170 mg, 0.29 mmol) and 2-(piperidin-1-yl)ethanamine (75 mg, 0.59 mmol) were added to a solution of 1-hydroxybenzotriazole hydrate (60 mg, 0.44 mmol) and <i>N</i>-ethyl-<i>N</i>′-(3-dimethyl-aminopropyl)carbodiimide hydrochloride (85 mg, 0.44 mmol) in dimethylformamide (3.5 mL). The mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the residue dissolved in 4% sodium bicarbonate solution. The aqueous phase was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed in vacuum and the residue purified by crystallization from dichloromethane–methanol (8:2) to give <b>38</b> (70 mg, 0.11 mmol, 37%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 6.6 Hz, 3H), 1.44–1.60 (m, 6H), 2.32–2.52 (m, 6H), 3.39–3.48 (m, 2H), 4.28 (q, <i>J</i> = 6.7 Hz, 2H), 7.83 (m, 2H), 8.04 (br s, 1H), 8.13 (br s, 1H), 8.41 (s, 1H), 8.53 (br s, 1H), 8.68 (s, 2H), 9.68 (br s, 1H), 9.94 (br s, 1H). HPLC/MS (30 min) retention time 11.85 min. LRMS: <i>m</i>/<i>z</i> 634 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3′-(5-(3-(3,5-Dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-<i>N</i>-(2-(piperazin-1-yl)ethyl)biphenyl-3-carboxamide (<b>39</b>)</h3><div class="NLM_p last">Amide coupling of <b>27</b> (200 mg, 0.35 mmol) with 2-(piperidin-1-yl)ethanamine (69 μL, 0.53 mmol) according to the general method gave <b>39</b> (60 mg, 0.095 mmol, 27%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 6.6 Hz, 3H), 1.44–1.60 (m, 6H), 2.32–2.52 (m, 6H), 3.39–3.48 (m, 2H), 4.28 (q, <i>J</i> = 6.7 Hz, 2H), 7.83 (t, <i>J</i> = 8.4 Hz, 6H), 8.04 (br s, 1H), 8.13 (br s, 1H), 8.41 (s, 1H), 8.53 (br s, 1H), 8.68 (s, 2H), 9.68 (br s, 1H), 9.94 (br s, 1H). HPLC/MS (30 min) retention time 11.85 min. LRMS: <i>m</i>/<i>z</i> 635 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>-(2-morpholin-4-ylethyl)biphenyl-3-carboxamide (<b>40</b>)</h3><div class="NLM_p last">Amide coupling of <b>27</b> (170 mg, 0.29 mmol) and 2-morpholinoethanamine (77 mg, 0.59 mmol) according to the general method gave <b>40</b> (70 mg, 0.11 mmol, 37%) after crystallization from dichloromethane–methanol (8:2). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 6.6 Hz, 3H), 2.35–2.45 (m, 8H), 3.56 (br s, 4H), 4.28 (q, <i>J</i> = 6.7 Hz, 2H), 7.51–7.72 (m, 2H), 7.72–7.94 (m, 5H), 8.08 (d,, <i>J</i> = 19.1 Hz, 3H), 8.40 (s, 1H), 8.58 (br s, 1H), 8.70 (s, 2H), 9.72 (br s, 1H), 9.91 (br s, 1H). HPLC/MS (30 min) retention time 12.54 min. LRMS: <i>m</i>/<i>z</i> 636 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>-(2-(1-methylpyrrolidin-2-yl)ethyl)biphenyl-3-carboxamide (<b>41</b>)</h3><div class="NLM_p last">Amide coupling of <b>27</b> (300 mg, 0.57 mmol) and 2-(1-methylpyrrolidin-2-yl)ethylamine (169 mg, 1.15 mmol) according to the general method gave <b>41</b> (190 mg, 0.30 mmol, 52%) after reverse phase chromatography. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 1.42–1.52 (m, 2H), 1.58–1.72 (m, 2H), 1.84–2.04 (m, 2H), 2.07–2.22 (m, 2H), 2.25 (s, 3H), 2.94–3.04 (m, 1H), 3.32 (q, <i>J</i> = 6.9 Hz, 2H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 7.59 (t, <i>J</i> = 8.1 Hz, 1H), 7.64 (d, <i>J</i> = 7.7 Hz, 1H), 7.80 (d, <i>J</i> = 7.7 Hz, 2H), 7.83–7.88 (m, 2H), 8.03 (s, 1H), 8.13 (s, 1H), 8.31 (s, 2H), 8.41 (s, 1H), 8.67 (t, <i>J</i> = 5.5 Hz, 1H), 8.68 (s, 1H). HPLC/MS (30 min) retention time 12.39 min. LRMS: <i>m</i>/<i>z</i> 634 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 2-(3′-(5-(3-(3,5-Dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)biphenyl-4-yl)-<i>N</i>-(2-(piperidin-1-yl)ethyl)acetamide (<b>42</b>)</h3><div class="NLM_p last">Amide coupling of <b>33</b> (300 mg, 0.56 mmol) with 2-(piperidin-1-yl)ethanamine (160 μL, 1.12 mmol) according to the general method gave <b>42</b> (185 mg, 0.29 mmol, 51%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.27 (t, <i>J</i> = 7.3 Hz, 3H), 1.48–2.06 (m, 8H), 3.09–3.35 (m, 4H), 3.66 (s, 2H), 3.73 (bs, 2H), 4.05 (q, <i>J</i> = 7.3 Hz, 2H), 7.03 (d, <i>J</i> = 8.5 Hz, 1H), 7.38 (d, <i>J</i> = 7.6 Hz, 3H), 7.42–7.53 (m, 1H), 7.53–7.67 (m, 3H), 7.67–7.82 (m, 4H), 7.96 (s, 1H), 8.20 (d, <i>J</i> = 8.2 Hz, 1H), 8.33 (s, 1H), 8.40 (s, 1H), 8.70 (s, 1H), 9.72 (s, 1H), 9.93 (s, 1H). HPLC/MS (30 min) retention time 12.64 min. LRMS: <i>m</i>/<i>z</i> 648 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 3′-(5-(3-(3,5-Dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-<i>N</i>-(7-((2-hydroxyethyl)(methyl)amino)heptyl)biphenyl-3-carboxamide (<b>43</b>)</h3><div class="NLM_p"><i>Step 1.</i> 2-(Methylamino)ethanol (1.90 mL, 23.7 mmol) was dissolved in 90 mL of methyl isobutyl ketone, and potassium carbonate (3.27 g, 23.7 mmol) was added. To this mixture was added a solution of 7-bromoheptanenitrile (3.00 g, 15.8 mmol) in 10 mL of methyl isobutyl ketone. The reaction was stirred overnight at 70 °C. The solvent was evaporated under vacuum and the residue taken up in ethyl acetate. The organics were washed with water and brine, dried over magnesium sulfate, filtered, and evaporated to give 7-[(2-hydroxyethyl)(methyl)amino]heptanenitrile <b>43a</b> (2.81 g, 15.3 mmol, 97%) as a yellow oil. HPLC/MS (9 min) retention time 0.67 min. LRMS: <i>m</i>/<i>z</i> 185 (M + H<sup>+</sup>).</div><div class="NLM_p"><i>Step 2.</i> Lithium aluminum hydride (1.74 g, 45.7 mmol) was suspended in 90 mL of dry tetrahydrofuran under nitrogen atmosphere. A solution of <b>43a</b> (2.81 g, 15.3 mmol) in 10 mL of dry tetrahydrofuran was added. The reaction was stirred for 3 h at room temperature. The reaction was quenched with successive additions of 1.75 mL of water, 1.75 mL of 4 N sodium hydroxide, and 5.25 mL of water. The mixture was filtered through Celite, and the filtrates were evaporated under vacuum. The residue was dissolved in dichloromethane and the organics were dried over magnesium sulfate, filtered, and evaporated to give 2-[(7-aminoheptyl)(methyl)amino]ethanol <b>43b</b> (2.32 g, 12.3 mmol, 81%). HPLC/MS (9 min) retention time 0.64 min. LRMS: <i>m</i>/<i>z</i> 189 (M + H<sup>+</sup>).</div><div class="NLM_p last"><i>Step 3.</i> Amide coupling of <b>27</b> (300 mg, 0.57 mmol) with <b>43b</b> (215 mg, 1.14 mmol) according to the general method gave <b>43</b> (169 mg, 0.24 mmol, 43%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.12–1.48 (m, 8H), 1.49–1.88 (m, 3H), 2.76 (s, 3H), 2.86–3.20 (m, 3H), 3.44 (q, <i>J</i> = 6.4 Hz, 2H), 3.77–4.07 (m, 2H), 4.25 (q, <i>J</i> = 7.3 Hz, 2H), 4.91 (s, 4H), 6.67 (t, <i>J</i> = 5.7 Hz, 1H), 7.48 (t, <i>J</i> = 7.6 Hz, 3H), 7.55–7.89 (m, 3H), 8.02 (d, <i>J</i> = 2.0 Hz, 2H), 8.49 (br s, 1H), 8.57 (s, 2H), 8.66 (s, 1H), 9.59 (br s, 1H). HPLC/MS (30 min) retention time 13.44 min. LRMS: <i>m</i>/<i>z</i> 694 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 2-(3′-(5-(3-(3,5-Dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)biphenyl-3-yl)-<i>N</i>-(7-((2-hydroxyethyl)(methyl)amino)heptyl)acetamide (<b>44</b>)</h3><div class="NLM_p last">Amide coupling of <b>32</b> (300 mg, 0.56 mmol) with <b>43b</b> (209 mg, 1.11 mmol) according to the general method gave <b>44</b> (89 mg, 0.125 mmol, 23%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.13–1.53 (m, 10H), 1.56–1.85 (m, 2H), 2.76 (s, 3H), 2.85–3.00 (m, 2H), 3.02–3.12 (m, 2H), 3.20 (q, <i>J</i> = 6.6 Hz, 2H), 3.64 (s, 2H), 3.86–4.04 (m, 2H), 4.26 (q, <i>J</i> = 7.3 Hz, 2H), 5.65 (s, 2H), 5.81 (t, <i>J</i> = 5.9 Hz, 1H), 7.19–7.31 (m, 2H), 7.32–7.66 (m, 4H), 7.81 (d, <i>J</i> = 7.8 Hz, 1H), 7.93 (br s, 1H), 8.52 (br s, 1H), 8.55 (s, 2H), 8.63 (s, 1H), 9.60 (br s, 1H). HPLC/MS (30 min) retention time 13.21 min. LRMS: <i>m</i>/<i>z</i> 708 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 2-(3′-(5-(3-(3,5-Dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)biphenyl-4-yl)-<i>N</i>-(7-((2-hydroxyethyl)(methyl)amino)heptyl)acetamide (<b>45</b>)</h3><div class="NLM_p last">Amide coupling of <b>33</b> (300 mg, 0.56 mmol) with <b>43b</b> (209 mg, 1.11 mmol) according to the general method gave <b>45</b> (97 mg, 0.137 mmol, 25%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.08–1.79 (m, 11H), 2.38–2.54 (m, 3H), 2.56–2.70 (m, 2H), 2.71–2.85 (m, 2H), 3.02–3.41 (m, 4H), 3.62 (s, 2H), 3.67–3.83 (m, 2H), 4.25 (q, <i>J</i> = 7.3 Hz, 2H), 5.60 (t, <i>J</i> = 5.7 Hz, 1H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 7.41–7.68 (m, 4H), 7.83 (d, <i>J</i> = 7.8 Hz, 2H), 7.93–8.04 (m, 2H), 8.57 (s, 2H), 8.70 (s, 1H), 9.61 (br s, 1H). HPLC/MS (30 min) retention time 13.22 min. LRMS: <i>m</i>/<i>z</i> 708 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 5-Cyano-<i>N</i>-cyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxamide (<b>46</b>)</h3><div class="NLM_p"><i>Step 1.</i> 3-Bromo-5-iodobenzoic acid (2.00 g, 6.12 mmol) was dissolved in 25 mL of ethanol. Sulfuric acid (2.1 mL) was added, and the mixture was heated at 90 °C for 5 h. The mixture was allowed to cool and was evaporated. The residue was taken up in water and basified to pH 9 with 32% sodium hydroxide solution. The aqueous was extracted five times with dichloromethane. The organic phase was dried over magnesium sulfate and evaporated to give crude ethyl 3-bromo-5-iodobenzoate <b>46a</b> (2.18 g, purity 87%). It was used as such without further purification. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.40 (t, <i>J</i> = 7.0 Hz, 3H), 4.38 (q, <i>J</i> = 7.0 Hz, 2H), 8.03 (t, <i>J</i> = 1.8 Hz, 1H), 8.13 (t, <i>J</i> = 1.6 Hz, 1H), 8.29 (t, <i>J</i> = 1.4 Hz, 1H). HPLC/MS (9 min) retention time 3.54 min. LRMS: <i>m</i>/<i>z</i> 355 (M + H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 2.</i> Iodide <b>46a</b> (1.59 g, 4.48 mmol) was dissolved in 10 mL of dimethylformamide under argon atmosphere. Zinc cyanide (0.58 g, 4.9 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.52 g, 0.45 mmol) were added, and the mixture was stirred at 80 °C for 1 h. The mixture was allowed to cool and was diluted with ethyl acetate. The organics were washed three times with water, brine and dried over magnesium sulfate. Filtration and evaporation gave ethyl 3-bromo-5-cyanobenzoate <b>46b</b> (0.66 g, 2.60 mmol, 58%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 4.36 (q, <i>J</i> = 7.2 Hz, 2H), 8.34 (br s, 2H), 8.48 (t, <i>J</i> = 1.9 Hz, 1H). HPLC/MS (9 min) retention time 6.43 min. LRMS: <i>m</i>/<i>z</i> 254 (M + H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 3.</i> Pinacol boronate synthesis with <b>46b</b> (660 mg, 2.60 mmol) and bis(pinacolato)diboron (1.32 g, 5.20 mmol) according to the general method gave ethyl 3-cyano-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>46c</b> (650 mg, 2.17 mmol, 84%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.15–1.57 (m, 15H), 4.37 (q, <i>J</i> = 7.2 Hz, 2H), 8.21 (br s, 1H), 8.44 (m, 2H). HPLC/MS (9 min) retention time 5.32 min. LRMS: <i>m</i>/<i>z</i> 302 (M + H<sup>+</sup>).</div><div class="NLM_p"><i>Step 4.</i> Suzuki reaction of <b>15</b> (850 mg, 1.76 mmol) with <b>46c</b> (635 mg, 2.12 mmol) according to the general method gave ethyl 5-cyano-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylate <b>46d</b> (1.00 g, 1.73 mmol, 98%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H), 4.29 (q, <i>J</i> = 7.2 Hz, 2H), 4.38 (q, <i>J</i> = 6.9 Hz, 2H), 7.66 (t, <i>J</i> = 7.1 Hz, 1H), 7.88 (app d, <i>J</i> = 7.4 Hz, 2H), 8.10 (s, 1H), 8.34 (s, 1H), 8.42 (s, 1H), 8.46 (s, 1H), 8.54 (s, 1H), 8.69 (s, 2H), 9.69 (br s, 1H), 9.89 (br s, 1H). HPLC/MS (15 min) retention time 10.17 min. LRMS: <i>m</i>/<i>z</i> 575 (M – H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p"><i>Step 5.</i> Ester hydrolysis of <b>46d</b> (1.00 g, 1.77 mmol) according to the general method gave 5-cyano-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylic acid <b>46e</b> (0.87 g, purity 91%) after triturating with acetonitrile. It was used as such without further purification. HPLC/MS (30 min) retention time 6.83 min. LRMS: <i>m</i>/<i>z</i> 549 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 6.</i> Amide coupling of <b>46e</b> (200 mg, 0.36 mmol) with cyclopropylamine (50 μg, 0.73 mmol) according to the general method gave <b>46</b> (74 mg, 0.125 mmol, 34%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.52–0.66 (m, 2H), 0.67–0.83 (m, 2H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 2.89 (tt, <i>J</i> = 7.9, 4.0 Hz, 1H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.86 (t, <i>J</i> = 7.4 Hz, 2H), 8.11 (t, <i>J</i> = 1.4 Hz, 1H), 8.23 (t, <i>J</i> = 1.3 Hz, 1H), 8.37–8.40 (m, 2H), 8.41 (s, 1H), 8.68 (s, 2H), 8.75 (d, <i>J</i> = 4.3 Hz, 1H), 9.66 (br s, 1H), 9.91 (br s, 1H). HPLC/MS (30 min) retention time 9.15 min. LRMS: <i>m</i>/<i>z</i> 588 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-Cyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-5-ethoxybiphenyl-3-carboxamide (<b>47</b>)</h3><div class="NLM_p"><i>Step 1.</i> A mixture of 3-nitrobenzoic acid (10 g, 0.06 mol), concentrated sulfuric acid (120 mL), silver sulfate (9.33 g, 0.03 mol), and bromine (3.68 mL, 0.07 mol) was stirred at 100 °C for 6 h. The mixture was poured on ice, forming a precipitate, and the solid was collected by filtration. The solid was dissolved in sodium carbonate solution. Acidification gave a precipitate which was collected by filtration and dried in a stream of air to give 3-bromo-5-nitrobenzoic acid <b>47a</b> (7.11 g, 0.029 mol, 47%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.38 (t, <i>J</i> = 1.8, 1.3 Hz, 1H), 8.52 (t, <i>J</i> = 1.5 Hz, 1H), 8.59 (t, <i>J</i> = 1.9 Hz, 1H). HPLC/MS (9 min) retention time 5.69 min. LRMS: <i>m</i>/<i>z</i> 244 (M – H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 2.</i> Concentrated hydrochloric acid (30 mL) was gradually added to a solution of <b>47a</b> (7.2 g, 28.5 mmol) dissolved in 150 mL of ethanol, and the mixture was stirred at room temperature for 5 min. Tin(II) chloride dehydrate (22.5 g, 100 mmol) was added, and the solution was stirred at 50 °C for 2 h. The solution was allowed to cool and was basified to pH 9 with 8 N sodium hydroxide solution, precipitating a solid. The mixture was filtered and the filtrate was acidified with hydrochloric acid to pH 5, forming a precipitate. The solid was collected by filtration and was dried under vacuum to give 3-amino-5-bromobenzoic acid <b>47b</b> (5.8 g, 26.7 mmol, 94%). HPLC/MS (9 min) retention time 4.67 min. LRMS: <i>m</i>/<i>z</i> 214 (M – H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 3.</i><b>47b</b> (5.8 g, 26.7 mmol) was dissolved in 50 mL of water and 5 mL of sulfuric acid. Sodium nitrite (1.85 g, 26.8 mmol) was added followed by 15 mL of water and 15 mL of sulfuric acid. The mixture was stirred at reflux for 100 min. The solution was allowed to cool, forming a precipitate. The solid was collected by filtration and dried under vacuum to give 3-bromo-5-hydroxybenzoic acid <b>47c</b> (3.83 g, 17.7 mmol, 66%). HPLC/MS (9 min) retention time 5.06 min. LRMS: <i>m</i>/<i>z</i> 215 (M – H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 4.</i><b>47c</b> (1.12 g, 5.16 mmol) and potassium carbonate (3.57 g, 25.8 mmol) were suspended in 100 mL of acetonitrile. Iodoethane (0.91 mL, 11.4 mmol) was added, and the mixture was stirred at reflux overnight. The solvent was evaporated, and the residue was partitioned between chloroform and water. The aqueous phase was extracted twice with chloroform. The combined organics were washed with brine, dried over magnesium sulfate, and filtered. The solvent was evaporated to give ethyl 3-bromo-5-ethoxybenzoate <b>47d</b> (1.15 g, 4.21 mmol, 82%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 1.42 (t, <i>J</i> = 7.1 Hz, 3H), 4.06 (q, <i>J</i> = 7.1 Hz, 2H), 4.37 (q, <i>J</i> = 7.1 Hz, 2H), 7.22 (t, <i>J</i> = 2.0 Hz, 1H), 7.49 (dd, <i>J</i> = 2.1, 1.3 Hz, 1H), 7.74 (t, <i>J</i> = 1.3 Hz, 1H). HPLC/MS (9 min) retention time 7.27 min. LRMS: no ionization.</div><div class="NLM_p"><i>Step 5.</i> Pinacol boronate synthesis from <b>47d</b> (0.95 g, 3.27 mmol) and bis(pinacolato)diboron (1.25 g, 4.92 mmol) according to the general method gave ethyl 3-ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>47e</b> (0.97 g, 3.03 mmol, 52%) after purification by chromatography (ethyl acetate–hexane gradient, 0:100 to 30:70). HPLC/MS (9 min) retention time 7.46 min. LRMS: <i>m</i>/<i>z</i> 321 (M + H<sup>+</sup>).</div><div class="NLM_p"><i>Step 6.</i> Suzuki reaction of <b>15</b> (0.98 g, 2.03 mmol) with <b>47e</b> (0.97 g, 3.03 mmol) according to the general method gave ethyl 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-5-ethoxybiphenyl-3-carboxylate <b>47f</b> (0.94 g, 1.57 mmol, 39%) after purification by chromatography ethyl acetate–hexane gradient, 0:100 to 50:50). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.28 (t, <i>J</i> = 7.2 Hz, 3H), 1.38 (t, <i>J</i> = 7.2 Hz, 3H), 1.46 (t, <i>J</i> = 7.2 Hz, 3H), 4.15 (q, <i>J</i> = 7.0 Hz, 2H), 4.27 (q, <i>J</i> = 7.2 Hz, 2H), 4.40 (q, <i>J</i> = 7.2 Hz, 2H), 7.34 (br s, 1H), 7.45–7.60 (m, 2H), 7.65 (d, <i>J</i> = 7.5 Hz, 1H), 7.77–7.94 (m, 2H), 8.06 (s, 1H), 8.62 (s, 2H), 8.74 (s, 1H), 9.19 (br s, 1H), 9.64 (br s, 1H). HPLC/MS (9 min) retention time 7.86 min. LRMS: <i>m</i>/<i>z</i> 596 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p"><i>Step 7.</i> Ester hydrolysis of <b>47f</b> (0.95 g, 1.45 mmol) according to the general method gave 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-5-ethoxybiphenyl-3-carboxylic acid <b>47g</b> (0.304 g, 0.53 mmol, 69%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (q, <i>J</i> = 7.0 Hz, 6H), 4.17 (q, <i>J</i> = 6.9 Hz, 2H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 7.45 (s, 1H), 7.46 (s, 1H), 7.61 (t, <i>J</i> = 7.8 Hz, 1H), 7.75–7.83 (m, 3H), 8.00 (s, 1H), 8.39 (s, 1H), 8.69 (s, 2H), 9.70 (s, 1H), 9.91 (br s, 1H). HPLC/MS (30 min) retention time 17.38 min. LRMS: <i>m</i>/<i>z</i> 568 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 8.</i> Amide coupling of <b>47g</b> (160 mg, 0.24 mmol) and cyclopropanamine (33 μL, 0.48 mmol) according to the general method gave <b>47</b> (102 mg, 0.168 mmol, 70%) after purification by SP1 automated purification system. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.54–0.63 (m, 2H), 0.66–0.77 (m, 2H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 2.80–2.92 (m, 1H), 4.15 (q, <i>J</i> = 7.1 Hz, 2H), 4.27 (q, <i>J</i> = 7.1 Hz, 2H), 7.34 (s, 1H), 7.38 (s, 1H), 7.63 (t, <i>J</i> = 7.3 Hz, 1H), 7.68 (s, 1H), 7.79 (app d, <i>J</i> = 7.4 Hz, 2H), 8.02 (s, 1H), 8.40 (s, 1H), 8.52 (d, <i>J</i> = 3.9 Hz, 1H), 8.68 (s, 2H), 9.67 (br s, 1H), 9.91 (br s, 1H). HPLC/MS (30 min) retention time 17.17 min. LRMS: <i>m</i>/<i>z</i> 607 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>,<i>N</i>′-Dicyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3,5-dicarboxamide (<b>48</b>)</h3><div class="NLM_p"><i>Step 1.</i> Cyclopropanamine (1.0 mL, 14.5 mmol) was added to a solution of 5-bromoisophthalic acid (710 mg, 2.90 mmol), 1-hydroxybenzotriazole hydrate (1.17 g, 8.69 mmol), and <i>N</i>-ethyl-<i>N</i>′-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.66 g, 8.69 mmol) in 20 mL of dimethylformamide. The mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue suspended in 4% sodium bicarbonate solution precipitating a solid. The solid was collected by filtration and dried under vacuum to give 5-bromo-<i>N</i>,<i>N</i>′-dicyclopropylisophthalamide <b>48a</b> (0.65 g, 2.00 mmol, 70%). HPLC/MS (9 min) retention time 5.03 min. LRMS: <i>m</i>/<i>z</i> 321 (M – H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 2.</i> Pinacol boronate synthesis with <b>48a</b> (0.78 g, 2.41 mmol) and bis(pinacolato)diboron (1.22 g, 4.83 mmol) according to the general method gave <i>N</i>,<i>N</i>′-dicyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isophthalamide <b>48b</b> (0.64 g, 1.73 mmol, 72%). HPLC/MS (9 min) retention time 5.77 min. LRMS: <i>m</i>/<i>z</i> 371 (M + H<sup>+</sup>).</div><div class="NLM_p last"><i>Step 3.</i> Suzuki reaction of <b>15</b> (0.20 g, 0.41 mmol) with <b>48b</b> (0.199 g, 0.54 mmol) according to the general method gave <b>48</b> (0.123 g, 0.19 mmol, 46%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.43–0.67 (m, 4H), 0.71 (td, <i>J</i> = 7.1, 5.0 Hz, 4H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 2.88 (tq, <i>J</i> = 8.0, 4.1 Hz, 2H), 4.29 (q, <i>J</i> = 7.2 Hz, 2H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.82 (d, <i>J</i> = 8.2 Hz, 1H), 7.85 (d, <i>J</i> = 7.7 Hz, 1H), 8.07 (t, <i>J</i> = 1.9 Hz, 1H), 8.21 (d, <i>J</i> = 1.6 Hz, 2H), 8.27 (t, <i>J</i> = 1.5 Hz, 1H), 8.41 (s, 1H), 8.68 (d, <i>J</i> = 3.2 Hz, 2H), 8.69 (s, 2H), 9.71 (br s, 1H), 9.90 (br s, 1H). HPLC/MS (15 min) retention time 8.66 min. LRMS: <i>m</i>/<i>z</i> 646 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Methyl 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-5-({[3-(dimethylamino)propyl]amino}carbonyl)biphenyl-3-carboxylate (<b>49</b>)</h3><div class="NLM_p"><i>Step 1.</i> A solution of potassium hydroxide (0.29 g, 5.13 mmol) in 3.7 mL of water was added to a solution of dimethyl 5-bromoisophthalate (2.80 g, 10.3 mmol) in 19 mL of methanol. The mixture was stirred overnight under reflux. The mixture was partitioned between water and ethyl ether. The aqueous phase was washed twice with ether. The aqueous portion was then acidified to acid pH with 5 N hydrochloric acid and was extracted three times with ethyl ether. The combined organics were washed with brine and dried over sodium sulfate. Purification by chromatography (ethyl acetate–hexane gradient, 0:100 to 100:0) gave 3-bromo-5-(methoxycarbonyl)benzoic acid <b>49a</b> (0.70 g, 2.70 mmol, 26%). HPLC/MS (9 min) retention time 5.79 min. LRMS: <i>m</i>/<i>z</i> 257 (M – H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 2.</i> Amide coupling of <b>49a</b> (3.14 g, 12.1 mmol) with <i>N</i>,<i>N</i>-dimethylpropane-1,3-diamine (2.48 g, 24.2 mmol) according to the general method gave methyl 3-bromo-5-({[3-(dimethylamino)propyl]amino}carbonyl)benzoate <b>49b</b> (3.98 g, 11.4 mmol, 94%). HPLC/MS (9 min) retention time 3.82 min. LRMS: <i>m</i>/<i>z</i> 343 (M + H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 3.</i> Pinacol boronate synthesis with <b>49b</b> (3.98 g, 11.4 mmol) with bis(pinacolato)diboron (5.76 g, 22.7 mmol) according to the general method gave methyl 3-({[3-(dimethylamino)propyl]amino}carbonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>49c</b> (3.00 g, 7.69 mmol, 68%). HPLC/MS (9 min) retention time 3.82 min. LRMS: <i>m</i>/<i>z</i> 391 (M + H<sup>+</sup>).</div><div class="NLM_p last"><i>Step 4.</i> Suzuki reaction of <b>15</b> (3.13 g, 6.45 mmol) with <b>49c</b> (3.00 g, 7.69 mmol) according to the general method gave <b>49</b> (0.93 g, 1.40 mmol, 22%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 1.70 (quin, <i>J</i> = 7.1 Hz, 2H), 2.15 (s, 6H), 2.35 (t, <i>J</i> = 7.1 Hz, 2H), 3.33 (q, <i>J</i> = 6.7 Hz, 2H), 3.92 (s, 3H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 7.66 (t, <i>J</i> = 7.8 Hz, 1H), 7.83 (s, 1H), 7.85 (s, 1H), 8.06 (s, 1H), 8.24 (s, 1H), 8.32 (s, 1H), 8.40 (s, 2H), 8.45 (s, 1H), 8.68 (s, 1H), 8.89 (t, <i>J</i> = 5.5 Hz, 1H), 9.69 (br s, 2H). HPLC/MS (30 min) retention time 13.10 min. LRMS: <i>m</i>/<i>z</i> 666 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-Ethyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>′-(2-dimethylaminopropyl)biphenyl-3,5-dicarboxamide (<b>50</b>)</h3><div class="NLM_p"><i>Step 1.</i> Ester hydrolysis of <b>49</b> (930 mg, 1.40 mmol) according to the general method gave <b>50a</b> (900 mg, 1.38 mmol, 99%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 1.92 (quin, <i>J</i> = 7.1 Hz, 2H), 2.70 (s, 6H), 3.02 (t, <i>J</i> = 7.7 Hz, 2H), 3.38 (q, <i>J</i> = 6.4 Hz, 2H), 4.29 (q, <i>J</i> = 7.2 Hz, 2H), 7.66 (t, <i>J</i> = 7.8 Hz, 1H), 7.84 (d, <i>J</i> = 7.8 Hz, 2H), 7.85 (s, 1H), 8.05 (s, 1H), 8.33 (s, 1H), 8.39 (s, 2H), 8.47 (s, 1H), 8.69 (s, 2H), 8.97 (t, <i>J</i> = 5.6 Hz, 1H), 9.72 (s, 1H), 9.94 (br s, 1H). HPLC/MS (9 min) retention time 5.13 min. LRMS: <i>m</i>/<i>z</i> 652 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 2.</i> Amide coupling of <b>50a</b> (175 mg, 0.27 mmol) with ethylamine (270 μL, 0.54 mmol) according to the general method gave <b>50</b> (73 mg, 0.11 mmol, 40%) after reverse-phase chromatography. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.15 (t, <i>J</i> = 7.2 Hz, 3H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H), 1.69 (quin, <i>J</i> = 7.0 Hz, 2H), 2.16 (s, 6H), 2.31 (t, <i>J</i> = 6.9 Hz, 2H), 3.13 (br s, 2H), 3.33 (quin, <i>J</i> = 6.0 Hz, 2H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.80 (d, <i>J</i> = 6.9 Hz, 1H), 7.82 (d, <i>J</i> = 7.5 Hz, 1H), 8.06 (s, 1H), 8.12–8.24 (m, 3H), 8.29 (s, 1H), 8.38 (s, 1H), 8.47 (br s, 1H), 8.54 (br s, 1H), 8.62 (s, 2H), 9.52 (s, 1H). HPLC/MS (30 min) retention time 12.00 min. LRMS: <i>m</i>/<i>z</i> 679 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>-Cyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>′-{2-[(2<i>R</i>)-1-methylpyrrolidin-2-yl]ethyl}biphenyl-3,5-dicarboxamide (<b>51</b>)</h3><div class="NLM_p"><i>Step 1.</i> Amide coupling of <b>49a</b> (0.60 g, 2.32 mmol) with cyclopropanamine (322 μL, 4.63 mmol) according to the general method gave methyl 3-bromo-5-[(cyclopropylamino)carbonyl]benzoate <b>51a</b> (0.66 g, 2.22 mmol, 96%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 0.59–0.73 (m, 2H), 0.83–1.00 (m, 2H), 2.91 (tq, <i>J</i> = 7.0, 3.5, 3.4 Hz, 1H), 3.94 (s, 3H), 6.46 (br s, 1H), 8.15 (t, <i>J</i> = 1.6 Hz, 1H), 8.22 (t, <i>J</i> = 1.4 Hz, 1H), 8.26 (t, <i>J</i> = 1.6 Hz, 1H). HPLC/MS (9 min) retention time 5.64 min. LRMS: <i>m</i>/<i>z</i> 296 (M – H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 2.</i> Pinacol boronate synthesis from <b>51a</b> (0.66 g, 2.22 mmol) and bis(pinacolato)diboron (1.12 g, 4.43 mmol) according to the general method) gave methyl 3-[(cyclopropylamino)carbonyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>51b</b> (0.572 g, 1.65 mmol, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 0.61–0.69 (m, 2H), 0.89 (td, <i>J</i> = 7.0, 5.6 Hz, 2H), 1.36 (s, 12H), 2.92 (tq, <i>J</i> = 7.0, 3.8 Hz, 1H), 3.93 (s, 3H), 6.40 (br s, 1H), 8.29 (dd, <i>J</i> = 1.7, 1.1 Hz, 1H), 8.51 (t, <i>J</i> = 1.8 Hz, 1H), 8.56 (t, <i>J</i> = 1.7, 1.3 Hz, 1H). HPLC/MS (9 min) retention time 6.31 min. LRMS: <i>m</i>/<i>z</i> 346 (M + H<sup>+</sup>).</div><div class="NLM_p"><i>Step 3.</i> Suzuki reaction of <b>15</b> (0.62 g, 1.28 mmol) with <b>51b</b> (0.572 g, 1.65 mmol) according to the general method gave methyl 5-[(cyclopropylamino)carbonyl]-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylate <b>51c</b> (0.54 g, 0.87 mmol, 68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.58–0.65 (m, 2H), 0.69–0.77 (m, 2H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H), 2.86–2.95 (m, 1H), 3.92 (s, 3H), 4.29 (q, <i>J</i> = 6.9 Hz, 2H), 7.66 (t, <i>J</i> = 7.7 Hz, 1H), 7.84 (d, <i>J</i> = 7.7 Hz, 2H), 8.06 (s, 1H), 8.32 (s, 1H), 8.37 (s, 1H), 8.40 (s, 1H), 8.43 (s, 1H), 8.69 (s, 2H), 8.78 (d, <i>J</i> = 3.5 Hz, 1H), 9.71 (br s, 1H), 9.90 (br s, 1H). HPLC/MS (9 min) retention time 7.08 min. LRMS: <i>m</i>/<i>z</i> 621 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p"><i>Step 4.</i> Ester hydrolysis of <b>51c</b> (540 mg, 0.87 mmol) according to the general method gave 5-[(cyclopropylamino)carbonyl]-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylic acid <b>51d</b> (520 mg, 0.86 mmol, 98%). It was used as such without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.50–0.66 (m, 2H), 0.67–0.83 (m, 2H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H), 2.90 (tq, <i>J</i> = 8.1, 3.9 Hz, 1H), 4.29 (q, <i>J</i> = 7.0 Hz, 2H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.79–7.90 (m, 2H), 8.06 (t, <i>J</i> = 1.6 Hz, 1H), 8.31 (t, <i>J</i> = 1.6 Hz, 1H), 8.35 (t, <i>J</i> = 1.7 Hz, 1H), 8.40 (s, 1H), 8.43 (t, <i>J</i> = 1.5 Hz, 1H), 8.70 (s, 2H), 8.78 (d, <i>J</i> = 4.3 Hz, 1H), 9.73 (s, 1H), 9.94 (s, 1H). HPLC/MS (9 min) retention time 6.60 min. LRMS: <i>m</i>/<i>z</i> 607 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 5.</i> Amide coupling of <b>51d</b> (150 mg, 0.25 mmol) with {2-[(2<i>R</i>)-1-methylpyrrolidin-2-yl]ethyl}amine (97 mg, 0.49 mmol) according to the general method gave <b>51</b> (21.6 mg, 0.030 mmol, 12%) after purification by reverse-phase chromatography. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.57–0.65 (m, 2H), 0.67–0.75 (m, 2H), 1.38 (t, <i>J</i> = 7.0 Hz, 3H), 1.41–1.55 (m, 2H), 1.56–1.70 (m, 2H), 1.82–2.00 (m, 2H), 1.99–2.14 (m, 2H), 2.22 (s, 3H), 2.84–2.98 (m, 2H), 3.33 (q, <i>J</i> = 6.8 Hz, 2H), 4.27 (q, <i>J</i> = 7.2 Hz, 2H), 7.63 (t, <i>J</i> = 7.6 Hz, 1H), 7.78–7.83 (m, 2H), 8.07 (s, 1H), 8.20 (br s, 2H), 8.28 (s, 1H), 8.41 (br s, 1H), 8.45 (s, 1H), 8.56 (d, <i>J</i> = 3.9 Hz, 1H), 8.64 (t, <i>J</i> = 5.3 Hz, 1H). HPLC/MS (30 min) retention time 11.73 min. LRMS: <i>m</i>/<i>z</i> 717 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 5-(Cyclopropylmethoxy)-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>-(2-piperidin-1-ylethyl)biphenyl-3-carboxamide (<b>52</b>)</h3><div class="NLM_p"><i>Step 1.</i> Carboxylic acid <b>47c</b> (2.32 g, 8.74 mmol) was dissolved in 25 mL of ethanol. Sulfuric acid (2.10 mL, 39.4 mmol) was added, and the mixture was heated at 90 °C for 5 h. The mixture was allowed to cool and was evaporated. The residue was taken up in water and basified to pH 9 with 32% sodium hydroxide solution. The aqueous was then extracted five times with dichloromethane. The organic phase was dried over magnesium sulfate. Purification by chromatography (ethyl acetate–hexane gradient, 0:100 to 100:0) gave ethyl 3-bromo-5-hydroxybenzoate <b>52a</b> (2.02 g, 8.24 mmol, 94%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.40 (t, <i>J</i> = 7.1 Hz, 3H), 4.38 (q, <i>J</i> = 7.1 Hz, 2H), 8.03 (t, <i>J</i> = 1.5 Hz, 1H), 8.13 (t, <i>J</i> = 1.3 Hz, 1H), 8.29 (t, <i>J</i> = 1.2 Hz, 1H). HPLC/MS (9 min) retention time 6.08 min. LRMS: <i>m</i>/<i>z</i> 243 (M – H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 2.</i> Phenol <b>52a</b> (1.0 g, 4.08 mmol) was dissolved in 15 mL of dimethylformamide. Potassium carbonate (1.13 g, 8.18 mmol) and bromomethylcyclopropane (0.66 g, 4.89 mmol) were added, and the mixture was stirred at 100 °C overnight. The mixture was allowed to cool and partitioned between water and ethyl ether. The organic phase was washed twice with water, twice with brine, dried over magnesium sulfate, and evaporated to give ethyl 3-bromo-5-(cyclopropylmethoxy)benzoate <b>52b</b> (0.98 g, 39.4 mmol, 75%). HPLC/MS (9 min) retention time 7.46 min. LRMS: <i>m</i>/<i>z</i> no ionization.</div><div class="NLM_p"><i>Step 3.</i> Pinacol boronate synthesis from <b>52b</b> (0.98 g, 3.04 mmol) and bis(pinacolato)diboron (1.16 g, 4.56 mmol) according to the general method gave, after purification by chromatography (ethyl acetate–hexane gradient, 0:100 to 100:0), a 55:45 mixture of ethyl 3-(cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>52c</b> and (3-(cyclopropylmethoxy)-5-(ethoxycarbonyl)phenyl)boronic acid <b>52d</b> (0.92 g). It was used as such without further purification. HPLC/MS (9 min) <b>52c</b> retention time 7.57 min. LRMS: <i>m</i>/<i>z</i> 347 (M + H<sup>+</sup>). <b>52d</b> retention time 6.00 min. LRMS: <i>m</i>/<i>z</i> 263 (M – H<sup>+</sup>).</div><div class="NLM_p"><i>Step 4.</i> Suzuki reaction of <b>15</b> (0.85 g, 1.74 mmol) with the mixture of <b>52c</b> and <b>52d</b> (0.92 g) according to the general method gave ethyl 5-(cyclopropylmethoxy)-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylate <b>52e</b> (0.89 g, 1.43 mmol, 76%). Partial <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 0.36–0.43 (m, 2H), 0.64–0.73 (m, 2H), 1.27 (t, <i>J</i> = 7.4 Hz, 3H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H), 3.88–3.96 (m, 2H), 4.26 (q, <i>J</i> = 7.2 Hz, 2H), 4.40 (q, <i>J</i> = 7.1 Hz, 2H), 7.36 (dd, <i>J</i> = 2.4, 1.7 Hz, 1H), 7.51 (t, <i>J</i> = 7.8 Hz, 1H), 7.55 (dd, <i>J</i> = 2.5, 1.4 Hz, 1H), 7.65 (dt, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.83 (dt, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.88 (t, <i>J</i> = 1.5 Hz, 1H), 8.06 (t, <i>J</i> = 1.6 Hz, 1H), 8.62 (s, 2H), 8.76 (s, 1H), 9.26 (br s, 1H), 9.69 (br s, 1H). HPLC/MS (9 min) retention time 7.90 min. LRMS: <i>m</i>/<i>z</i> 622 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p"><i>Step 5.</i> Ester hydrolysis of <b>52e</b> (0.89g, 1.43 mmol) according to the general method gave 5-(cyclopropylmethoxy)-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3-carboxylic acid <b>52f</b> (0.657 g, 1.11 mmol, 66%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.31–0.42 (m, 2H), 0.52–0.65 (m, 2H), 1.17–1.30 (m, 1H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 3.96 (d, <i>J</i> = 7.0 Hz, 2H), 4.28 (q, <i>J</i> = 7.2 Hz, 2H), 7.41–7.51 (m, 2H), 7.60 (t, <i>J</i> = 7.6 Hz, 1H), 7.75–7.86 (m, 3H), 7.97–8.10 (m, 1H), 8.40 (s, 1H), 8.69 (s, 2H), 9.71 (br s, 1H), 9.91 (br s, 1H), 13.14 (br s, 1H). HPLC/MS (9 min) retention time 7.52 min. LRMS: <i>m</i>/<i>z</i> 592 (M – H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 6.</i> Amide coupling of <b>52f</b> (160 mg, 0.23 mmol) with (2-piperidin-1-ylethyl)amine (67 μL, 0.46 mmol) according to the general method and purification by reverse-phase chromatography gave <b>52</b> (105 mg, 0.15 mmol, 65%). Partial <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.31–0.43 (m, 2H), 0.51–0.67 (m, 2H), 1.13–1.31 (m, 1H), 1.39 (t, <i>J</i> = 6.8 Hz, 3H), 1.34–1.59 (m, 6H), 2.39–2.46 (m, 6H), 3.95 (d, <i>J</i> = 7.0 Hz, 2H), 4.27 (q, <i>J</i> = 7.0 Hz, 2H), 7.37 (s, 1H), 7.40 (s, 1H), 7.61 (t, <i>J</i> = 7.6 Hz, 1H), 7.70 (s, 1H), 7.80 (d, <i>J</i> = 7.6 Hz, 2H), 8.02 (s, 1H), 8.20 (s, 1H), 8.39 (s, 1H), 8.54 (t, <i>J</i> = 4.8 Hz, 1H), 8.69 (s, 2H), 9.70 (br s, 1H). HPLC/MS (30 min) retention time 14.15 min. LRMS: <i>m</i>/<i>z</i> 704 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>N</i>-Cyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>′-(2-piperidin-1-ylethyl)biphenyl-3,5-dicarboxamide (<b>53</b>)</h3><div class="NLM_p last">Amide coupling of <b>51d</b> (150 mg, 0.25 mmol) with (2-piperidin-1-ylethyl)amine (0.1 μL, 0.49 mmol) according to the general method and purification by reverse-phase chromatography gave <b>53</b> (88 mg, 0.123 mmol, 50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.55–0.64 (m, 2H), 0.67–0.78 (m, 2H), 1.34–1.38 (m, 2H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H), 1.48 (quin, <i>J</i> = 5.5 Hz, 4H), 2.31–2.43 (m, 4H), 2.45 (t, <i>J</i> = 7.3 Hz, 2H), 2.89 (tq, <i>J</i> = 7.1, 4.0 Hz, 1H), 3.40 (q, <i>J</i> = 6.5 Hz, 2H), 4.29 (q, <i>J</i> = 7.0 Hz, 2H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.82 (d, <i>J</i> = 7.8 Hz, 1H), 7.85 (d, <i>J</i> = 7.7 Hz, 1H), 8.08 (s, 1H), 8.20–8.25 (m, 1H), 8.26–8.32 (m, 1H), 8.40 (s, 1H), 8.65 (t, <i>J</i> = 5.8 Hz, 1H), 8.67 (s, 1H), 8.69 (d, <i>J</i> = 4.2 Hz, 1H), 9.63 (br s, 1H). HPLC/MS (15 min) retention time 6.65 min. LRMS: <i>m</i>/<i>z</i> 717 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 3′-[5-({[(3,5-Dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>-(2-hydroxyethyl)-<i>N</i>′-(2-piperidin-1-ylethyl)biphenyl-3,5-dicarboxamide (<b>54</b>)</h3><div class="NLM_p"><i>Step 1.</i> Amide coupling of <b>49a</b> (2.0 g, 7.72 mmol) with 2-(piperidin-1-yl)ethylamine (2.2 mL, 15.5 mmol) according to the general method gave methyl 3-bromo-5-(2-(piperidin-1-yl)ethylcarbamoyl)benzoate <b>54a</b> (2.80 g, 7.57 mmol, 96%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ ppm 1.40–1.54 (m, 2H), 1.54–1.70 (m, 4H), 2.39–2.51 (m, 4H), 2.58 (t, <i>J</i> = 6.0 Hz, 2H), 3.54 (q, <i>J</i> = 5.7 Hz, 2H), 3.95 (s, 3H), 7.20 (br s, 1H), 8.18 (t, <i>J</i> = 1.8 Hz, 1H), 8.27 (t, <i>J</i> = 1.6 Hz, 1H), 8.33 (t, <i>J</i> = 1.4 Hz, 1H). HPLC/MS (9 min) retention time 4.08 min. LRMS: <i>m</i>/<i>z</i> 369 (M + H<sup>+</sup>, 1 × Br).</div><div class="NLM_p"><i>Step 2.</i> Pinacol boronate synthesis with <b>54a</b> (2.80 g, 7.57 mmol) and bis(pinacolato)diboron (2.90 g, 11.4 mmol) according to the general method gave methyl 3-(2-(piperidin-1-yl)ethylcarbamoyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate <b>54b</b> (2.0 g, 4.80 mmol, 59%). HPLC/MS (9 min) retention time 4.78 min. LRMS: <i>m</i>/<i>z</i> 417 (M + H<sup>+</sup>).</div><div class="NLM_p"><i>Step 3.</i> Suzuki reaction of <b>15</b> (2.0 g, 4.14 mmol) with <b>54b</b> (2.43 g, 4.96 mmol) according to the general method and purification by chromatography ((methanol–ethyl acetate, 20:80)–hexane gradient, 0:100 to 100:0) gave methyl 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-5-{[(2-piperidin-1-ylethyl)amino]carbonyl}biphenyl-3-carboxylate <b>54c</b> (2.42 g, 3.49 mmol, 70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.34–1.36 (m, 2H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 1.48 (quin, <i>J</i> = 5.7 Hz, 4H), 2.34–2.42 (m, 4H), 2.45 (t, <i>J</i> = 7.4 Hz, 2H), 3.41 (q, <i>J</i> = 6.3 Hz, 2H), 3.92 (s, 3H), 4.29 (q, <i>J</i> = 6.8 Hz, 2H), 7.66 (t, <i>J</i> = 7.6 Hz, 1H), 7.84 (d, <i>J</i> = 8.2 Hz, 2H), 8.06 (s, 1H), 8.32 (s, 1H), 8.39 (s, 1H), 8.40 (s, 1H), 8.44 (s, 1H), 8.67 (s, 2H), 8.77 (t, <i>J</i> = 5.3 Hz, 1H), 9.66 (br s, 1H), 9.92 (br s, 1H). HPLC/MS (30 min) retention time 11.77 min. LRMS: <i>m</i>/<i>z</i> 692 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p"><i>Step 4.</i> Ester hydrolysis of <b>54c</b> (2.30 g, 3.32 mmol) according to the general method gave 3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-5-{[(2-piperidin-1-ylethyl)amino]carbonyl}biphenyl-3-carboxylic acid <b>54d</b> (1.40 g, 2.06 mmol, 61%). Partial <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (t, <i>J</i> = 7.1 Hz, 3H), 1.38–1.45 (m, 2H), 1.57 (quin, <i>J</i> = 5.7 Hz, 4H), 2.63–2.70 (m, 2H), 2.71–2.77 (m, 2H), 3.52 (q, <i>J</i> = 6.3 Hz, 2H), 4.27 (q, <i>J</i> = 7.1 Hz, 2H), 7.60 (t, <i>J</i> = 7.7 Hz, 1H), 7.75 (d, <i>J</i> = 8.0 Hz, 1H), 7.78 (d, <i>J</i> = 8.0 Hz, 1H), 7.99 (s, 1H), 8.22 (s, 1H), 8.26 (s, 1H), 8.37 (s, 1H), 8.44 (s, 1H), 8.68 (s, 1H), 8.99 (s, 1H), 9.69 (s, 1H).7.60 (t, <i>J</i> = 7.9 Hz, 1H), 7.71–7.87 (m, 2H), 7.99 (s, 1H), 8.22 (s, 1H), 8.26 (s, 1H), 8.37 (s, 1H), 8.44 (s, 1H), 8.67 (s, 2H), 8.99 (br s, 1H), 9.69 (s, 1H), 9.92 (br s, 1H). HPLC/MS (30 min) retention time 10.73 min. LRMS: <i>m</i>/<i>z</i> 678 (M + H<sup>+</sup>, 2 × Cl).</div><div class="NLM_p last"><i>Step 5.</i> Amide coupling of <b>54d</b> (150 mg, 0.18 mmol) with 2-aminoethanol (22.4 mg, 0.37 mmol) according to the general method and purification by reverse-phase chromatography gave <b>54</b> (67 mg, 0.093 mmol, 49%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.33–1.38 (m, 2H), 1.39 (t, <i>J</i> = 7.3 Hz, 3H), 1.45–1.53 (quin, <i>J</i> = 5.6 Hz, 4H), 2.39 (br s, 4H), 2.46 (t, <i>J</i> = 7.1 Hz, 2H), 3.38–3.45 (m, 4H), 3.55 (q, <i>J</i> = 5.8 Hz, 2H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 4.76 (t, <i>J</i> = 5.2 Hz, 1H), 7.66 (t, <i>J</i> = 7.7 Hz, 1H), 7.82 (d, <i>J</i> = 7.7 Hz, 1H), 7.87 (d, <i>J</i> = 7.7 Hz, 1H), 8.09 (s, 1H), 8.25 (s, 1H), 8.29 (s, 1H), 8.34 (s, 1H), 8.40 (s, 1H), 8.66 (t, <i>J</i> = 6.0 Hz, 1H), 8.68 (s, 2H), 8.71 (t, <i>J</i> = 5.6 Hz, 1H), 9.68 (br s, 1H), 9.91 (br s, 1H). HPLC/MS (30 min) retention time 10.12 min. LRMS: <i>m</i>/<i>z</i> 721 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="secz" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-Cyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-<i>N</i>′-(2-morpholin-4-ylethyl)biphenyl-3,5-dicarboxamide (<b>55</b>)</h3><div class="NLM_p last">. Amide coupling of 51d (150 mg, 0.25 mmol) with 2-morpholinoethanamine (61 mg, 0.47 mmol) according to the general method and purification by reverse-phase chromatography gave 55 (140 mg, 0.195 mmol, 83%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.56–0.63 (m, 2H), 0.68–0.75 (m, 2H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 2.42 (br s, 2H), 2.44–2.50 (m, 4H), 2.89 (tq, <i>J</i> = 7.2, 3.9 Hz, 1H), 3.42 (q, <i>J</i> = 6.2 Hz, 2H), 3.56 (t, <i>J</i> = 4.2 Hz, 4H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 7.65 (t, <i>J</i> = 7.7 Hz, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (d, <i>J</i> = 7.7 Hz, 1H), 8.08 (s, 1H), 8.22 (s, 1H), 8.24 (s, 1H), 8.30 (s, 2H), 8.41 (s, 1H), 8.67 (s, 1H), 8.68–8.73 (m, 2H). HPLC/MS (30 min) retention time 11.91 min. LRMS: <i>m</i>/<i>z</i> 719 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-(1-Benzylpiperidin-4-yl)-<i>N</i>′-cyclopropyl-3′-[5-({[(3,5-dichloropyridin-4-yl)amino]carbonyl}amino)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]biphenyl-3,5-dicarboxamide (<b>56</b>)</h3><div class="NLM_p last">Amide coupling of <b>51d</b> (150 mg, 0.25 mmol) with 1-benzylpiperidin-4-ylamine (95 mg, 0.50 mmol) according to the general method and purification by reverse-phase chromatography gave <b>56</b> (95 mg, 0.122 mmol, 49%). Partial <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.54–0.63 (m, 2H), 0.65–0.79 (m, 2H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H), 1.62 (t, <i>J</i> = 11.0 Hz, 2H), 1.72–1.90 (m, 2H), 2.04 (t, <i>J</i> = 10.9 Hz, 2H), 2.83 (m, 3H), 4.29 (q, <i>J</i> = 6.8 Hz, 2H), 7.21–7.37 (m, 5H), 7.65 (t, <i>J</i> = 7.6 Hz, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 7.86 (d, <i>J</i> = 7.8 Hz, 1H), 8.08 (s, 1H), 8.22 (br s, 3H), 8.28 (s, 1H), 8.41 (s, 1H), 8.53 (d, <i>J</i> = 7.4 Hz, 1H), 8.63–8.76 (m, 3H), 9.72 (br s, 1H). HPLC/MS (30 min) retention time 12.22 min. LRMS: <i>m</i>/<i>z</i> 779 (M + H<sup>+</sup>, 2 × Cl).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> PDE4 Activity Determination</h3><div class="NLM_p">PDE4 activity from human recombinant PDE4B1 subtype was monitored by measuring the hydrolysis of [<sup>3</sup>H]cAMP to [<sup>3</sup>H]AMP using a PDE-SPA kit from Amersham International as previously described.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Enzyme extracts (∼4 μg of protein) were incubated in “low binding” plates (Costar 3604) for 60 min at room temperature. The assay mixture (80 μL) contained 15 nM [<sup>3</sup>H]cAMP (1 μCi/mL) in the assay buffer (50 mM Tris, pH 7.5, 8.3 mM MgCl<sub>2</sub>, 1.7 mM EGTA) and 10 μL of test compound. These compounds were resuspended in DMSO (the final DMSO concentration 5% (v/v)) at a stock concentration of 1 mM. The compounds were tested at different concentrations varying from 10 μM to 10 pM to calculate an IC<sub>50</sub>. These dilutions were done in 96-well plates. In some cases, plates containing diluted compounds were frozen before being assayed. In these cases, the plates were thawed at room temperature and agitated for 15 min.</div><div class="NLM_p last">Hydrolysis of [<sup>3</sup>H]cAMP was initiated by adding 10 μL of a solution containing PDE4 enzyme, and the plate was then incubated under agitation at room temperature. The reaction was stopped after 60 min (with ∼10–20% substrate conversion) by addition of 50 μL of phosphodiesterase scintillation proximity assay (SPA) beads. All reactions were carried out in duplicate. [<sup>3</sup>H]AMP, captured by the SPA beads, was determined by counting the plates in a Wallac-Microbeta Trilux scintillation counter 1 h after addition of the beads, although the signal was quite stable, and samples may be counted from 1 to 48 h after bead addition.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> LPS Induced TNF-α in Human Whole Blood (HWB-TNF-α)</h3><div class="NLM_p">Human whole blood of healthy donors was collected in 50 mL Falcon tubes with heparin (5000 units/mL, heparin Mayne 5%, MAYNEPHARMA). LPS (lipopolysaccharide from <i>Escherichia coli</i>, Sigma, St. Louis, MO) dissolved in PBS (Dulbecco’s phosphate buffered saline, without calcium and magnesium chloride, Sigma, St. Louis, MO) was added to the tubes to give a final concentration in the assay of 1 μg/mL and preincubated at 37 °C for 10 min with rocking. Increasing concentrations of different inhibitors (2 μL), dissolved in 100% DMSO, were added to the 96-well plates, and an amount of 200 μL of blood containing LPS (except for controls) was then distributed into wells. Plates were shaken for 1–2 min, sealed with aluminum foil lid (Beckman Coulter), and then incubated for 24 h at 37 °C under agitation in Kelvitron T (Heraeus Instruments).</div><div class="NLM_p last">After 24 h, plates were placed on ice, an amount of 50 μL of PBS was added, and the reaction was stopped by centrifugation of plates at 2000 rpm (800<i>g</i>) at 4 °C for 15 min. Serum obtained was then subjected to ELISA or kept at −80 °C until use.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> TNF-α Determination</h3><div class="NLM_p last">The quantification of TNF-α in human serum was performed using commercial ELISA kit (DuoSet) obtained from R&D Systems, Inc., and following the manufacturer’s instructions.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Plate Preparation</h3><div class="NLM_p last">First, R&D DuoSet ELISA 96-well microplates were coated with 4.0 μg/mL mouse anti-human TNF-R diluted in PBS, overnight at room temperature. After washing, plates were then blocked with PBS containing 1% BSA for a minimum of 1 h at room temperature and then washed.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Assay Procedure</h3><div class="NLM_p last">100 μL of samples or standard was added and incubated at 2 h at room temperature. After washing (ELX406 Select, BIO-TEK), biotinylated anti-hTNF-α antibody was added and incubated at room temperature for 2 h, followed by incubation with streptavidin–peroxidase for 20 min. Detection of bound hTNF-α was carried out with 100 μL of substrate solution (H<sub>2</sub>O<sub>2</sub> and tetramethylbenzidine) followed by measurement at 450 nm in a SPECTRA max Plus (Molecular Devices). These experiments were performed 2–3 times using the same experimental design. Duplicates from each series of experiments were averaged and expressed as hTNF-α levels in pg/mL.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Inhibition of LPS-Induced Neutrophilia in Rats. Dry Powder Administration</h3><div class="NLM_p">A solution of LPS (Sigma, ref L-2630, 100 mg/vial) was prepared in 10 mL of PBS (CAMBREX BE17-512F). This was further diluted 1:100 with PBS. Solutions were prepared 24 h before use to ensure dissolution and stored at 4 °C. Test compounds were micronized before use and comixed with lactose to the correct dilution.</div><div class="NLM_p last">Male Sprague-Dawley rats (230–280 g, fasted) were anesthetized with isoflurane. A 5 mg mixture of test compound and lactose was loaded into a Penn-Century Insufflator for Rat−Model DP-4 fitted with metal cannula. The cannula was carefully inserted into the trachea of the rat using a laryngoscope for guidance. Test compound was dispensed with 5 mL of air insufflation via a syringe. The cannula was carefully withdrawn and the animals allowed to regain consciousness.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Inhibition of LPS-Induced Neutrophilia in Rats. Liquid Administration</h3><div class="NLM_p">A solution of LPS (Sigma, ref L-2630, 100 mg/vial) was prepared in 10 mL of PBS (CAMBREX BE17-512F). This was further diluted 1:100 with PBS. Solutions were prepared 24 h before use to ensure dissolution and stored at 4 °C. Test compounds were suspended in PBS containing 0.2% Tween 80 and homogenized in a mortar. Compounds were suspended at their maximum test concentration. Other concentrations were made by 1:10 dilutions with PBS containing 0.2% Tween 80.</div><div class="NLM_p last">Male Sprague-Dawley rats (230–280 g, fasted) were anesthetized with isofluoroane. A suspension of 0.2 mL of the test compound was loaded into a Penn-Century MicroSprayer. The tip of the MicroSprayer was carefully inserted to about 1 cm from the tracheal carina using a laryngoscope for guidance. Test compound was dispensed rapidly to aerosolize the suspension. The cannula was carefully withdrawn, and the animals were allowed to regain consciousness.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Nebulization of LPS</h3><div class="NLM_p">1 or 18 h after test compound administration, animals were introduced into Perspex chambers and 30 mL of LPS solution was aerosolized using the DeVilbiss nebulizer during 40 min. After 4 h, the animals were euthanized with dolethal (2 g/mL, 10 mL/kg ip). 2 mL of PBS was introduced into the lungs via a cannula, and 0.8 mL of BAL solution was withdrawn. A further 2 mL of PBS was introduced and a further 1.8 mL of solution withdrawn. Neutrophils were counted directly by flow cytometry using the FACS.</div><div class="NLM_p last">Control groups were formed by i.t. lactose only, i.t. lactose and LPS aerosol and using fluticasone (10% in lactose) and LPS aerosol as positive control.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Animal Studies</h3><div class="NLM_p last">All in vivo experiments were carried out in compliance with the European Committee Directive 2010/63/EU and the Spanish and Catalan laws. Experimental procedures were reviewed by The Animal-Welfare Body of Almirall and approved by the competent authority.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00829">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00829" class="ext-link">10.1021/acs.jmedchem.6b00829</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00829/suppl_file/jm6b00829_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00829/suppl_file/jm6b00829_si_001.csv">jm6b00829_si_001.csv (18.25 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code of compound <b>6</b>: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K1I">5K1I</a> (see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00829" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jordi Gràcia</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3953564b5d50175e4b585a505879585554504b585555175a5654"><span class="__cf_email__" data-cfemail="d4bebba6b0bdfab3a6b5b7bdb594b5b8b9bda6b5b8b8fab7bbb9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Antonia Buil</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jordi Castro</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Eichhorn</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manel Ferrer</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amadeu Gavaldà</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Begoña Hernández</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor Segarra</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin D. Lehner</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Imma Moreno</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lluís Pagès</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard S. Roberts</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jordi Serrat</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sara Sevilla</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joan Taltavull</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miriam Andrés</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judit Cabedo</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dolors Vilella</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Calama</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carla Carcasona</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Montserrat Miralpeix</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and Screening, ‡Pharmacokinetics and Metabolism, §Experimental Dermatology, and ∥Licensing and
Corporate Development, Centro de Investigación
y Desarrollo, Almirall S.A., Crta. Laureà Miró 408-410, Sant Feliu de Llobregat, 08980 Barcelona, Spain</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d128e6523-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the significant technical support provided by Silvia Petit, Carmen Cabello, Agustina de la Cal, Dolores Marín, and Laura Estrella. We also acknowledge Montse Soler, Irena Bonin, and Joan Aymami for the crystal structure determination. We thank Sonia Espinosa and Josep M. Huerta for their support on physicochemical properties analysis and structural characterization of compounds. This work was funded by Almirall, Spain.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i80" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i80"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i81" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i81"> Abbreviations Used</h2><tr><td class="NLM_term">cGMP</td><td class="NLM_def"><p class="first last">cyclic guanosine monophosphate</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">atopic dermatitis</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">SBD</td><td class="NLM_def"><p class="first last">structure-based design</p></td></tr><tr><td class="NLM_term">PYR</td><td class="NLM_def"><p class="first last">pyridazinone</p></td></tr><tr><td class="NLM_term">UCR2</td><td class="NLM_def"><p class="first last">upstream conserved region 2</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">polynuclear blood monocyte</p></td></tr><tr><td class="NLM_term">hWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">PAPS</td><td class="NLM_def"><p class="first last">3′-phosphoadenosine 5′-phosphosulfate</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">5′-diphosphoglucuronic acid</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">pM</td><td class="NLM_def"><p class="first last">picomolar</p></td></tr><tr><td class="NLM_term">BAL</td><td class="NLM_def"><p class="first last">broncoalveolar lavage</p></td></tr><tr><td class="NLM_term">A<sub>1</sub></td><td class="NLM_def"><p class="first last">adenosine subtype 1</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">SPA</td><td class="NLM_def"><p class="first last">scintillation proximity assay</p></td></tr><tr><td class="NLM_term">DP</td><td class="NLM_def"><p class="first last">dry powder</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence-activated cell sorting</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52860" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52860" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Zhang, H. T.</span><span> </span><span class="NLM_article-title">Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1698</span><span class="refDoi"> DOI: 10.2174/138161209788168092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.2174%2F138161209788168092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19442182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtValt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1688-1698&author=H.+T.+Zhang&title=Cyclic+AMP-specific+phosphodiesterase-4+as+a+target+for+the+development+of+antidepressant+drugs&doi=10.2174%2F138161209788168092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs</span></div><div class="casAuthors">Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1688-1698</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-4 (PDE4), one of eleven PDE enzyme families, specifically catalyzes hydrolysis of cAMP; it has four subtypes (PDE4A-D) with at least 25 splice variants.  PDE4 plays a crit. role in the control of intracellular cAMP concns.  PDE4 inhibitors produce antidepressant actions in both animals and humans via enhancement of cAMP signaling in the brain.  However, their clin. utility has been hampered by side effects, in particular nausea and emesis.  While there is still a long way to go before PDE4 inhibitors with high therapeutic indexes are available for treatment of depressive disorders, important advances have been made in the development of PDE4 inhibitors as antidepressants.  First, limited, but significant studies point to PDE4D as the major PDE4 subtype responsible for antidepressant-like effects of PDE4 inhibitors, although the role of PDE4A cannot be excluded.  Second, PDE4D may contribute to emesis, the major side effect of PDE4 inhibitors.  For this reason, identification of roles of PDE4D splice variants in mediating antidepressant activity is particularly important.  Recent studies using small interfering RNAs (siRNAs) have demonstrated the feasibility to identify cellular functions of individual PDE4 variants.  Third, mixed inhibitors of PDE4 and PDE7 or PDE4 and serotonin reuptake have been developed and may be potential antidepressants with minimized side effects.  Finally, relatively selective inhibitors of one or two PDE4 subtypes have been synthesized using structure- and scaffold-based design.  This review also discusses the relationship between PDE4 and antidepressant activity based on structures, brain distributions, and pharmacol. properties of PDE4 and its isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbw6LZusu3QbVg90H21EOLACvtfcHk0ljnaFVaIra4rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtValt7k%253D&md5=461633876ca8e287de7d0aeaf7d74f6c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F138161209788168092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209788168092%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DCyclic%2520AMP-specific%2520phosphodiesterase-4%2520as%2520a%2520target%2520for%2520the%2520development%2520of%2520antidepressant%2520drugs%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D1688%26epage%3D1698%26doi%3D10.2174%2F138161209788168092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span> </span><span class="NLM_article-title">Keynote review: phosphodiesterase-4 as a therapeutic target</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1503</span><span class="NLM_x">–</span> <span class="NLM_lpage">1519</span><span class="refDoi"> DOI: 10.1016/S1359-6446(05)03622-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2FS1359-6446%2805%2903622-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=16257373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1503-1519&author=M.+D.+Houslayauthor=P.+Schaferauthor=K.+Y.+Zhang&title=Keynote+review%3A+phosphodiesterase-4+as+a+therapeutic+target&doi=10.1016%2FS1359-6446%2805%2903622-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 as a therapeutic target</span></div><div class="casAuthors">Houslay, Miles D.; Schafer, Peter; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1503-1519</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-4 selective inhibitors have therapeutic potential for treating major diseases such as asthma and COPD, as well as depression, Parkinson's disease and Alzheimer's disease.  CAMP is a key second messenger in all cells.  It is compartmentalized within cells and its levels are controlled, as a result of spatially discrete signaling cassettes controlling its generation, detection and degrdn.  Underpinning compartmentalized cAMP signaling are ∼20 members of the phosphodiesterase-4 (PDE4) family.  The selective inhibition of this family generates profound, functional effects and PDE4 inhibitors are currently under development to provide potential, novel therapeutics for the treatment of inflammatory diseases, such as asthma, chronic obstructive pulmonary disease and psoriasis, as well as treating depression and serving as cognitive enhancers.  Here, we delineate the range of PDE4 isoforms, their role in signaling, their structural biol. and related preclin. and clin. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOabrPCOweLVg90H21EOLACvtfcHk0ljnaFVaIra4rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL&md5=7c75a76543b75145a44ae8f4a2f3b2ac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903622-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903622-6%26sid%3Dliteratum%253Aachs%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26atitle%3DKeynote%2520review%253A%2520phosphodiesterase-4%2520as%2520a%2520therapeutic%2520target%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1503%26epage%3D1519%26doi%3D10.1016%2FS1359-6446%2805%2903622-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Press, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banner, K. H.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors - a review of the current field</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span><span class="refDoi"> DOI: 10.1016/S0079-6468(08)00202-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2FS0079-6468%2808%2900202-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19328289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=37-74&author=N.+J.+Pressauthor=K.+H.+Banner&title=PDE4+inhibitors+-+a+review+of+the+current+field&doi=10.1016%2FS0079-6468%2808%2900202-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors - a review of the current field</span></div><div class="casAuthors">Press, Neil J.; Banner, Katharine H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-74</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the phosphodiesterase 4 enzyme inhibitors and their potential therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodvxfZgwsOsbVg90H21EOLACvtfcHk0lhslm9h-WGowQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D&md5=45a006d23fedc76f4f42f2f424bd4395</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2808%2900202-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252808%252900202-6%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DBanner%26aufirst%3DK.%2BH.%26atitle%3DPDE4%2520inhibitors%2520-%2520a%2520review%2520of%2520the%2520current%2520field%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D47%26spage%3D37%26epage%3D74%26doi%3D10.1016%2FS0079-6468%2808%2900202-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Jin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFα responses</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">7628</span><span class="NLM_x">–</span> <span class="NLM_lpage">7633</span><span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0lhslm9h-WGowQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Manning, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cieslinski, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essayan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grous, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torphy, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnette, M. S.</span><span> </span><span class="NLM_article-title">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1398</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0702911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1038%2Fsj.bjp.0702911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10602317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=1393-1398&author=C.+D.+Manningauthor=M.+Burmanauthor=S.+B.+Christensenauthor=L.+B.+Cieslinskiauthor=D.+M.+Essayanauthor=M.+Grousauthor=T.+J.+Torphyauthor=M.+S.+Barnette&title=Suppression+of+human+inflammatory+cell+function+by+subtype-selective+PDE4+inhibitors+correlates+with+inhibition+of+PDE4A+and+PDE4B&doi=10.1038%2Fsj.bjp.0702911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span></div><div class="casAuthors">Manning, Carol D.; Burman, Miriam; Christensen, Siegfried B.; Cieslinski, Lenora B.; Essayan, David M.; Grous, Marilyn; Torphy, Theodore J.; Barnette, Mary S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Of the four major phosphodiesterase 4 (PDE4) subtypes, PDE4A, PDE4B and PDE4D are widely expressed in human inflammatory cells, including monocytes and T lymphocytes.  We explored the functional role of these subtypes using ten subtype-selective PDE4 inhibitors, each belonging to one of two classes: (i) dual PDE4A/PDE4B inhibitors or (ii) PDE4D inhibitors.  These compds. were evaluated for their ability to inhibit antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-stimulated tumor necrosis factor α (TNFα) release from peripheral blood monocytes.  All compds. inhibited T-cell proliferation in a concn.-dependent manner; with IC50 values distributed over an approx. 50 fold range.  These compds. also inhibited TNFα release concn.-dependently, with a wider (∼ 1000 fold) range of IC50 values.  In both sets of expts., mean IC50 values were significantly correlated with compd. potency against the catalytic activity of recombinant human PDE4A or PDE4B when analyzed by either linear regression of log IC50 values or by Spearman's rank-order correlation.  The correlation between inhibition of inflammatory cell function and inhibition of recombinant PDE4D catalytic activity was not significant in either anal.  These results suggest that PDE4A and/or PDE4B may play the major role in regulating these two inflammatory cell functions but do not rule out PDE4D as an important mediator of other activities in mononuclear leukocytes and other immune and inflammatory cells.  Much more work is needed to establish the functional roles of the PDE4 subtypes across a broader range of cellular functions and cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3g1B9QQKejbVg90H21EOLACvtfcHk0lhslm9h-WGowQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D&md5=70490a1a73b83ce887e850e4efd2e738</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702911%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DC.%2BD.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DEssayan%26aufirst%3DD.%2BM.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26atitle%3DSuppression%2520of%2520human%2520inflammatory%2520cell%2520function%2520by%2520subtype-selective%2520PDE4%2520inhibitors%2520correlates%2520with%2520inhibition%2520of%2520PDE4A%2520and%2520PDE4B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D1393%26epage%3D1398%26doi%3D10.1038%2Fsj.bjp.0702911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">O’Donnell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. T.</span><span> </span><span class="NLM_article-title">Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4)</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span><span class="refDoi"> DOI: 10.1016/j.tips.2004.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.tips.2004.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=158-163&author=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Antidepressant+effects+of+inhibitors+of+cyclic+AMP+phosphodiesterase+%28PDE4%29&doi=10.1016%2Fj.tips.2004.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DAntidepressant%2520effects%2520of%2520inhibitors%2520of%2520cyclic%2520AMP%2520phosphodiesterase%2520%2528PDE4%2529%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D158%26epage%3D163%26doi%3D10.1016%2Fj.tips.2004.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Li, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. T.</span><span> </span><span class="NLM_article-title">Phosphodiesterase-4D knockout and RNAi-mediated knockdown enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.5236-10.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1523%2FJNEUROSCI.5236-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=21209202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=172-183&author=Y.+F.+Liauthor=Y.+F.+Chengauthor=Y.+Huangauthor=M.+Contiauthor=S.+P.+Wilsonauthor=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Phosphodiesterase-4D+knockout+and+RNAi-mediated+knockdown+enhance+memory+and+increase+hippocampal+neurogenesis+via+increased+cAMP+signaling&doi=10.1523%2FJNEUROSCI.5236-10.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span></div><div class="casAuthors">Li, Yun-Feng; Cheng, Yu-Fang; Huang, Ying; Conti, Marco; Wilson, Steven P.; O'Donnell, James M.; Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis.  PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants.  Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests.  These effects were mimicked by repeated treatment with rolipram in wild-type mice.  In addn., similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus down-regulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  The present results suggest that PDE4D, in particular long-form PDE4D, plays a crit. role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKG03_qqdl7Vg90H21EOLACvtfcHk0ljhvT68r0-ZFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D&md5=928836c09ff122681fdf11db58885b79</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5236-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5236-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DCheng%26aufirst%3DY.%2BF.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DPhosphodiesterase-4D%2520knockout%2520and%2520RNAi-mediated%2520knockdown%2520enhance%2520memory%2520and%2520increase%2520hippocampal%2520neurogenesis%2520via%2520increased%2520cAMP%2520signaling%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D172%26epage%3D183%26doi%3D10.1523%2FJNEUROSCI.5236-10.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lehnart, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehrens, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belevych, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, A. R.</span><span> </span><span class="NLM_article-title">Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1016/j.cell.2005.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.cell.2005.07.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2005&pages=25-35&author=S.+E.+Lehnartauthor=X.+H.+Wehrensauthor=S.+Reikenauthor=S.+Warrierauthor=A.+E.+Belevychauthor=R.+D.+Harveyauthor=W.+Richterauthor=S.+L.+Jinauthor=M.+Contiauthor=A.+R.+Marks&title=Phosphodiesterase+4D+deficiency+in+the+ryanodine-receptor+complex+promotes+heart+failure+and+arrhythmias&doi=10.1016%2Fj.cell.2005.07.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DLehnart%26aufirst%3DS.%2BE.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26aulast%3DReiken%26aufirst%3DS.%26aulast%3DWarrier%26aufirst%3DS.%26aulast%3DBelevych%26aufirst%3DA.%2BE.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DMarks%26aufirst%3DA.%2BR.%26atitle%3DPhosphodiesterase%25204D%2520deficiency%2520in%2520the%2520ryanodine-receptor%2520complex%2520promotes%2520heart%2520failure%2520and%2520arrhythmias%26jtitle%3DCell%26date%3D2005%26volume%3D123%26spage%3D25%26epage%3D35%26doi%3D10.1016%2Fj.cell.2005.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Robichaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamatiou, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.-L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberté, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C.-C.</span><span> </span><span class="NLM_article-title">Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anaesthesia, a behavioural correlate of emesis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span><span class="refDoi"> DOI: 10.1172/JCI0215506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1172%2FJCI0215506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1045-1052&author=A.+Robichaudauthor=P.+B.+Stamatiouauthor=S.-L.+C.+Jinauthor=N.+Lachanceauthor=D.+MacDonaldauthor=F.+Lalibert%C3%A9author=S.+Liuauthor=Z.+Huangauthor=M.+Contiauthor=C.-C.+Chan&title=Deletion+of+phosphodiesterase+4D+in+mice+shortens+a2-adrenoceptor-mediated+anaesthesia%2C+a+behavioural+correlate+of+emesis&doi=10.1172%2FJCI0215506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1172%2FJCI0215506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215506%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DS.-L.%2BC.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DMacDonald%26aufirst%3DD.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DC.-C.%26atitle%3DDeletion%2520of%2520phosphodiesterase%25204D%2520in%2520mice%2520shortens%2520a2-adrenoceptor-mediated%2520anaesthesia%252C%2520a%2520behavioural%2520correlate%2520of%2520emesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1045%26epage%3D1052%26doi%3D10.1172%2FJCI0215506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Naganuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saitoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagumo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawanishi, M.</span><span> </span><span class="NLM_article-title">Discovery of selective PDE4B inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3174</span><span class="NLM_x">–</span> <span class="NLM_lpage">3176</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2009.04.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19447034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3174-3176&author=K.+Naganumaauthor=A.+Omuraauthor=N.+Maekawaraauthor=M.+Saitohauthor=N.+Ohkawaauthor=T.+Kubotaauthor=H.+Nagumoauthor=T.+Kodamaauthor=M.+Takemuraauthor=Y.+Ohtsukaauthor=J.+Nakamuraauthor=R.+Tsujitaauthor=K.+Kawasakiauthor=H.+Yokoiauthor=M.+Kawanishi&title=Discovery+of+selective+PDE4B+inhibitors&doi=10.1016%2Fj.bmcl.2009.04.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective PDE4B inhibitors</span></div><div class="casAuthors">Naganuma, Kenji; Omura, Akifumi; Maekawara, Naomi; Saitoh, Masahiro; Ohkawa, Naoto; Kubota, Takashi; Nagumo, Hiromitsu; Kodama, Toshiyuki; Takemura, Masayoshi; Ohtsuka, Yuji; Nakamura, Junji; Tsujita, Ryuichi; Kawasaki, Koh; Yokoi, Hirotsugu; Kawanishi, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3174-3176</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study the first PDE4B selective inhibitor is described.  Optimization of lead 2-arylpyrimidine derivs. afforded a series of potent PDE4B inhibitors I (R1 = Me, Et, H2C:CHCH2, CN, CHO, etc.; R2 = Me, Et, n-Pr; R3 = Ph, 4-MeC6H4, 2-thienyl, 2-pyridyl, etc.; R4 = H, F; R5 = CO2H, CH2CO2H) with >100-fold selectivity over the PDE4D isoenzyme.  With a good pharmacokinetic profile, a selected compd. I (R1 = Et; R2 = Me; R3 = 5-chloro-2-thienyl; R4 = H; R5 = CH2CO2H) exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOGQ4ols6Z1rVg90H21EOLACvtfcHk0ljKTvBifxeivQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D&md5=aca08592557e5d34da5b02835b0e49d8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.121%26sid%3Dliteratum%253Aachs%26aulast%3DNaganuma%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DA.%26aulast%3DMaekawara%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DM.%26aulast%3DOhkawa%26aufirst%3DN.%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DNagumo%26aufirst%3DH.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DM.%26aulast%3DOhtsuka%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DTsujita%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DYokoi%26aufirst%3DH.%26aulast%3DKawanishi%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520selective%2520PDE4B%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3174%26epage%3D3176%26doi%3D10.1016%2Fj.bmcl.2009.04.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1042/BJ20070970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1042%2FBJ20070970" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=193-201&author=H.+Wangauthor=M.+S.+Pengauthor=Y.+Chenauthor=J.+Gengauthor=H.+Robinsonauthor=M.+D.+Houslayauthor=I.+Caiauthor=H.+Ke&title=Structures+of+the+four+subfamilies+of+phosphodiesterase-4+provide+insight+into+the+selectivity+of+their+inhibitors&doi=10.1042%2FBJ20070970"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1042%2FBJ20070970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070970%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DM.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DCai%26aufirst%3DI.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DStructures%2520of%2520the%2520four%2520subfamilies%2520of%2520phosphodiesterase-4%2520provide%2520insight%2520into%2520the%2520selectivity%2520of%2520their%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D193%26epage%3D201%26doi%3D10.1042%2FBJ20070970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fox, D.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span> </span><span class="NLM_article-title">Structural basis for the design of selective phosphodiesterase</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span><span class="refDoi"> DOI: 10.1016/j.cellsig.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.cellsig.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=24361374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=657-663&author=D.+Foxauthor=A.+B.+Burginauthor=M.+E.+Gurney&title=Structural+basis+for+the+design+of+selective+phosphodiesterase&doi=10.1016%2Fj.cellsig.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span></div><div class="casAuthors">Fox, David, III; Burgin, Alex B.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor -Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial cells.  As such, it is an important, although under-exploited mol. target for anti-inflammatory drugs.  This is due in part to the difficulty of developing selective PDE4B inhibitors as the amino acid sequence of the PDE4 active site is identical in all PDE4 subtypes (PDE4A-D).  We show that highly selective PDE4B inhibitors can be designed by exploiting sequence differences outside the active site.  Specifically, PDE4B selectivity can be achieved by capture of a C-terminal regulatory helix, now termed CR3 (Control Region 3), across the active site in a conformation that closes access by cAMP.  PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 vs. Gln594 in PDE4D).  The reciprocal mutations in PDE4B and PDE4D cause a 70-80 fold shift in selectivity.  Our structural studies show that CR3 is flexible and can adopt multiple orientations and multiple registries in the closed conformation.  The new co-crystal structure with bound ligand provides a guide map for the design of PDE4B selective anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKu3hgg1Kl7Vg90H21EOLACvtfcHk0ljp4EOY3jIAxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D&md5=ab8e72afbfeadffeae27950206402bd9</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DD.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DStructural%2520basis%2520for%2520the%2520design%2520of%2520selective%2520phosphodiesterase%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D657%26epage%3D663%26doi%3D10.1016%2Fj.cellsig.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span>Celgene press release. <a href="http://ir.celgene.com/releasedetail.cfm?ReleaseID=872240" class="extLink">http://ir.celgene.com/releasedetail.cfm?ReleaseID=872240</a>, September 23,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Celgene+press+release.+http%3A%2F%2Fir.celgene.com%2Freleasedetail.cfm%3FReleaseID%3D872240%2C+September+23%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pagès, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehner, M. D.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2005 - 2009)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1519</span><span class="refDoi"> DOI: 10.1517/13543770903313753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543770903313753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19832118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1501-1519&author=L.+Pag%C3%A8sauthor=A.+Gavald%C3%A0author=M.+D.+Lehner&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282005+-+2009%29&doi=10.1517%2F13543770903313753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors: a review of current developments (2005 - 2009)</span></div><div class="casAuthors">Pages, Lluis; Gavalda, Amadeu; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1501-1519</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Despite the sound preclin. database and some promising data from clin. trials, development of PDE4 inhibitors for the treatment of inflammatory or neurol. diseases has been hampered by dose-limiting class-related side effects.  Objective: In the past years, companies opted for different approaches to improve the therapeutic window of their compds. including topical administration of PDE4 inhibitors with the goal of minimizing systemic exposure.  This change in strategy is reflected by the disclosure of novel and chem. diverse mols. that demonstrate the continued interest of pharmaceutical industry in developing PDE4 inhibitors.  Conclusion: This review summarizes the clin. development of PDE4 inhibitors since 2005 and the assocd. patent literature with a focus on strategies applied to minimize systemic adverse effects.  In sum, although a significant no. of new drugs designed for improved tolerability entered clin. trials, so far none of them fulfilled expectations and best progress has been achieved recently with the oral, non-isoform selective PDE4 inhibitor roflumilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6XZlM2_eQxbVg90H21EOLACvtfcHk0ljp4EOY3jIAxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM&md5=4041bbd045ffa269e1fa406746193c3e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543770903313753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903313753%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282005%2520-%25202009%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1501%26epage%3D1519%26doi%3D10.1517%2F13543770903313753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. S.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2010 - 2012)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1016</span><span class="refDoi"> DOI: 10.1517/13543776.2013.794789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543776.2013.794789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=997-1016&author=A.+Gavald%C3%A0author=R.+S.+Roberts&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282010+-+2012%29&doi=10.1517%2F13543776.2013.794789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012)</span></div><div class="casAuthors">Gavalda, Amadeu; Roberts, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">997-1016</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: At last, after many years of research, roflumilast has become the first oral phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on therapy for chronic obstructive pulmonary disease.  A second compd., apremilast is targeted for submission of new drug application for the treatment of psoriasis in the second half of 2013.  These compds. represent a breakthrough and a reward in the field after the many failures to date in clin. development.  Areas covered: This review summarizes the clin. development of PDE4 inhibitors from 2010 - 2012 and the assocd. patent literature with a focus on strategies to overcome the common pitfalls of oral PDE4 inhibitors.  Expert opinion: In the last few years, influenced by the body of published clin. data, many companies have lost interest in PDE4 as a target.  Many of those that have persevered have opted to realign their research programs either toward compds. specifically designed for inhaled delivery or in search of an increase in clin. efficacy by combining two mechanisms in a single compd.  This change is reflected by the continued disclosure of novel and chem. diverse mols., indicating for some in the pharmaceutical industry that all is not yet lost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe0yV5hhUby7Vg90H21EOLACvtfcHk0ljp4EOY3jIAxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L&md5=9a5961a6f439698b11123ac47c5839aa</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.794789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.794789%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282010%2520-%25202012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D997%26epage%3D1016%26doi%3D10.1517%2F13543776.2013.794789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Martinez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span> </span><span class="NLM_article-title">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1517/13543776.2014.968127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543776.2014.968127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=25284693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1311-1321&author=A.+Martinezauthor=C.+Gil&title=cAMP-specific+phosphodiesterase+inhibitors%3A+promising+drugs+for+inflammatory+and+neurological+diseases&doi=10.1517%2F13543776.2014.968127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span></div><div class="casAuthors">Martinez, Ana; Gil, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1311-1321</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: PDEs are key enzymes in the adenosine and guanosine cyclic nucleotides (cAMP and cGMP) signaling cascade.  Their inhibition increases cyclic nucleotide levels inside the cell.  Thus, pharmacol. modulation of PDE activity can have profound effects on the function of cells and organ systems throughout the body.  Areas covered: Among the large PDE families, only PDE4, PDE7 and PDE8 are cAMP-specific hydrolyzing enzymes. cAMP is an important second messenger not only by its involvement in a vast no. of physiol. processes but also by activation of protein kinase A, exchange protein activated by cAMP (Epac) and cAMP response element-binding (CREB) or cyclic nucleotide-gated channels.  Clearly, such enzymes represent ideal drug targets for the pharmacol. treatment of many pathologies.  The discovery and development of small mols. targeting cAMP-specific PDEs reported in the last 5 years is the focus of the present review.  Expert opinion: The first PDE4 inhibitors recently reached the market, having avoided, by different strategies, their dose-limiting side effects (after more than two decades of drug development).  Meanwhile, new cAMP-specific PDE7 and PDE8 inhibitors emerged as effective and safe drugs for severe unmet diseases.  The therapeutic potential of these inhibitors will be tested in the near future, as many of these drug candidates are ready to start clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPWFQGiKhADrVg90H21EOLACvtfcHk0lgfwLei0F6Pnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN&md5=f9ef95eeccba94736c36de427c1715b0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.968127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.968127%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGil%26aufirst%3DC.%26atitle%3DcAMP-specific%2520phosphodiesterase%2520inhibitors%253A%2520promising%2520drugs%2520for%2520inflammatory%2520and%2520neurological%2520diseases%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1311%26epage%3D1321%26doi%3D10.1517%2F13543776.2014.968127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Mulhall, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Droege, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panos, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafar, M. A.</span><span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1597</span><span class="NLM_x">–</span> <span class="NLM_lpage">1611</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1094054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543784.2015.1094054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=26419847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1597-1611&author=A.+M.+Mulhallauthor=C.+A.+Droegeauthor=N.+E.+Ernstauthor=R.+J.+Panosauthor=M.+A.+Zafar&title=Phosphodiesterase+4+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+review+of+current+and+developing+drugs&doi=10.1517%2F13543784.2015.1094054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span></div><div class="casAuthors">Mulhall, Aaron M.; Droege, Christopher A.; Ernst, Neil E.; Panos, Ralph J.; Zafar, Muhammad A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1597-1611</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells.  Roflumilast is the only approved PDE-4 inhibitor (PDE4I) for use in chronic obstructive pulmonary disease (COPD).  Its beneficial clin. effects occur preferentially in patients with chronic bronchitis and frequent COPD exacerbations.  Use of roflumilast as adjunctive or alternate therapy to other COPD medications reduces exacerbations and modestly improves lung function.  This article reviews the current role of PDE4I in COPD treatment emphasizing roflumilast's clin. efficacy and adverse effects.  This article also reviews developing PDE4Is in early clin. trials and in preclin. studies.  After decades of research in drug development, PDE4Is are a welcomed addn. to the COPD therapeutic armamentarium.  In its current clin. role, the salubrious clin. effects of PDE4I in reducing exacerbations and stabilizing the frequent exacerbator phenotype have to be cautiously balanced with numerous adverse effects.  Developing drugs may provide similar or better clin. benefits while minimizing adverse effects by changing the mode of drug delivery to inhaled formulations, combining dual PDE isoenzyme inhibitors (PDE1/4I and PDE3/4I) and by forming hybrid mols. with other bronchodilators (muscarinic receptor antagonist/PDE4I and β2-agonist/PDE4I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNEyjtRW-erVg90H21EOLACvtfcHk0lgfwLei0F6Pnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ&md5=8d5130af94558b2950f624ae1528c86f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1094054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1094054%26sid%3Dliteratum%253Aachs%26aulast%3DMulhall%26aufirst%3DA.%2BM.%26aulast%3DDroege%26aufirst%3DC.%2BA.%26aulast%3DErnst%26aufirst%3DN.%2BE.%26aulast%3DPanos%26aufirst%3DR.%2BJ.%26aulast%3DZafar%26aufirst%3DM.%2BA.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520review%2520of%2520current%2520and%2520developing%2520drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1597%26epage%3D1611%26doi%3D10.1517%2F13543784.2015.1094054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petavy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, A. J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1186/1465-9921-11-26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1186%2F1465-9921-11-26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=20193079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=26-34&author=D.+Singhauthor=F.+Petavyauthor=A.+J.+Macdonald&title=The+inhaled+phosphodiesterase+4+inhibitor+GSK256066+reduces+allergen+challenge+responses+in+asthma&doi=10.1186%2F1465-9921-11-26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span></div><div class="casAuthors">Singh Dave; Petavy Frank; Macdonald Alex J; Lazaar Aili L; O'Connor Brian J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects.  We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.  METHODS:  In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR) and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7 days, followed by allergen challenge.  Methacholine reactivity was measured 24 h post-allergen.  Plasma pharmacokinetics were measured.  The primary endpoint was the effect on LAR.  RESULTS:  GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.  GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.  There was no effect on pre-allergen FEV1 or methacholine reactivity post allergen.  GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4 hours in the majority of subjects.  CONCLUSIONS:  GSK256066 demonstrated a protective effect on the EAR and LAR.  This is the first inhaled PDE4 inhibitor to show therapeutic potential in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6sWKb5nMe2ROk4JA3soTqfW6udTcc2eZtl4CZ-DzEFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D&md5=88d976c3aa2d963dc83c5fa8e32e4f62</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-26%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DPetavy%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520reduces%2520allergen%2520challenge%2520responses%2520in%2520asthma%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D26%26epage%3D34%26doi%3D10.1186%2F1465-9921-11-26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Boswell-Smith, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeds, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, C. P.</span><span> </span><span class="NLM_article-title">The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1124/jpet.105.099192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1124%2Fjpet.105.099192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=16682455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslOlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=840-848&author=V.+Boswell-Smithauthor=D.+Spinaauthor=A.+W.+Oxfordauthor=M.+B.+Comerauthor=E.+A.+Seedsauthor=C.+P.+Page&title=The+pharmacology+of+two+novel+long-acting+phosphodiesterase+3%2F4+inhibitors%2C+RPL554+%5B9%2C10-dimethoxy-2%282%2C4%2C6-trimethylphenylimino%29-3-%28N-carbamoyl-2-aminoethyl%29-3%2C4%2C6%2C7-tetrahydro-2H-pyrimido%5B6%2C1-a%5Disoquinolin-4-one%5D+and+RPL565+%5B6%2C7-dihydro-2-%282%2C6-diisopropylphenoxy%29-9%2C10-dimethoxy-4H-pyrimido%5B6%2C1-a%5Disoquinolin-4-one%5D&doi=10.1124%2Fjpet.105.099192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido [6,1-a]isoquinolin-4-one]</span></div><div class="casAuthors">Boswell-Smith, Victoria; Spina, Domenico; Oxford, Alec W.; Comer, Mike B.; Seeds, Esther A.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">840-848</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. of two novel, trequinsin-like PDE3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido-[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one], has been investigated in a no. of in vitro and in vivo assays.  Elec. field stimulation-induced contraction of guinea pig superfused isolated tracheal prepns. was significantly inhibited by RPL554 (10 μM) and RPL565 (10 μM) (percentage control; 93 ± 1.2 and 84.4 ± 2.7, resp.).  Contractile responses were suppressed for up to 12 h after termination of superfusion with RPL554 demonstrating a long duration of action.  RPL554 and RPL565 inhibited, in a concn.-dependent manner, lipopolysaccharide-induced tumor necrosis factor α release from human monocytes [IC50; 0.52 μM (0.38-0.69) and 0.25 μM (0.18-0.35), resp.] and proliferation of human mononuclear cells to phytohemagglutinin [IC50; 0.46 μM (0.24-0.9) and 2.90 μM (1.6-5.4), resp.].  The inhibitory effect of these drugs in vitro was translated into anti-inflammatory activity in vivo.  RPL554 (10 mg/kg) and RPL565 (10 mg/kg) administered orally significantly inhibited eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs.  Likewise, inhalation of dry powder contg. RPL554 by conscious guinea pigs (25% in micronized lactose) 1.5 h before antigen exposure significantly inhibited the recruitment of eosinophils to the airways.  Exposure of conscious guinea pigs to inhalation of dry powder contg. RPL554 (2.5%) and RPL565 (25%) in micronized lactose significantly inhibited histamine-induced plasma protein extravasation in the trachea and histamine-induced bronchoconstriction over a 5.5-h period.  Thus, RPL554 and RPL565 are novel, long-acting PDE 3/4 inhibitors exhibiting a broad range of both bronchoprotective and anti-inflammatory activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0xQkYCpZ4r7Vg90H21EOLACvtfcHk0lj_qqhkb8hILw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslOlt7w%253D&md5=6669bf3bbd6e17e4246ff7695d16e5ce</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.099192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.099192%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell-Smith%26aufirst%3DV.%26aulast%3DSpina%26aufirst%3DD.%26aulast%3DOxford%26aufirst%3DA.%2BW.%26aulast%3DComer%26aufirst%3DM.%2BB.%26aulast%3DSeeds%26aufirst%3DE.%2BA.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DThe%2520pharmacology%2520of%2520two%2520novel%2520long-acting%2520phosphodiesterase%25203%252F4%2520inhibitors%252C%2520RPL554%2520%255B9%252C10-dimethoxy-2%25282%252C4%252C6-trimethylphenylimino%2529-3-%2528N-carbamoyl-2-aminoethyl%2529-3%252C4%252C6%252C7-tetrahydro-2H-pyrimido%255B6%252C1-a%255Disoquinolin-4-one%255D%2520and%2520RPL565%2520%255B6%252C7-dihydro-2-%25282%252C6-diisopropylphenoxy%2529-9%252C10-dimethoxy-4H-pyrimido%255B6%252C1-a%255Disoquinolin-4-one%255D%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26spage%3D840%26epage%3D848%26doi%3D10.1124%2Fjpet.105.099192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J.</span><span> </span><span class="NLM_article-title">A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1044</span><span class="refDoi"> DOI: 10.1183/09031936.00068908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1183%2F09031936.00068908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19213793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=1039-1044&author=J.+Vestboauthor=L.+Tanauthor=G.+Atkinsonauthor=J.+Ward&title=A+controlled+trial+of+6-weeks%E2%80%99+treatment+with+a+novel+inhaled+phosphodiesterase+type-4+inhibitor+in+COPD&doi=10.1183%2F09031936.00068908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span></div><div class="casAuthors">Vestbo, J.; Tan, L.; Atkinson, G.; Ward, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1039-1044</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an interesting class of drugs to treat inflammation in COPD.  The present authors report the findings of a phase II trial of a novel inhaled PDE4 inhibitor.  Three doses, 0.1, 0.4 and 1.0 mg b.i.d., of the compd. UK-500,001 were tested in a double-blind, placebo-controlled, 6-wk trial in 209 patients with moderate-to-severe COPD.  The primary efficacy parameter was trough forced expiratory vol. in one second after 6 wk of treatment, and secondary end-points included other lung function end-points and symptom scores assessed at 2-wk intervals.  The present study was stopped following a planned interim anal. for futility.  No effect on the primary efficacy parameter, other measures of lung function or symptom scores was obsd. at any dose of UK-500,001 after 6 wk of treatment.  However, after the first 2 wk of treatment, an improvement in a no. of outcome measures in the 1.0 mg b.i.d. dose group was obsd. compared with placebo.  The drug was well tolerated, although PDE4 inhibitor-related side-effects were obsd., esp. in the highest dose group.  The findings of the present study question the role of inhaled phosphodiesterase type-4 inhibitors in chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqfiD54uWV9bVg90H21EOLACvtfcHk0lgJGkuv3UheMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D&md5=73ac7894ef11b2cdd9f95fcd95b52286</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1183%2F09031936.00068908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00068908%26sid%3Dliteratum%253Aachs%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DAtkinson%26aufirst%3DG.%26aulast%3DWard%26aufirst%3DJ.%26atitle%3DA%2520controlled%2520trial%2520of%25206-weeks%25E2%2580%2599%2520treatment%2520with%2520a%2520novel%2520inhaled%2520phosphodiesterase%2520type-4%2520inhibitor%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D33%26spage%3D1039%26epage%3D1044%26doi%3D10.1183%2F09031936.00068908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Xu, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocque, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span> </span><span class="NLM_article-title">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">1822</span><span class="NLM_x">–</span> <span class="NLM_lpage">1825</span><span class="refDoi"> DOI: 10.1126/science.288.5472.1822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1126%2Fscience.288.5472.1822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10846163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2000&pages=1822-1825&author=R.+X.+Xuauthor=A.+M.+Hassellauthor=D.+Vanderwallauthor=M.+H.+Lambertauthor=W.+D.+Holmesauthor=M.+A.+Lutherauthor=W.+J.+Rocqueauthor=M.+V.+Milburnauthor=Y.+Zhaoauthor=H.+Keauthor=R.+T.+Nolte&title=Atomic+structure+of+PDE4%3A+insights+into+phosphodiesterase+mechanism+and+specificity&doi=10.1126%2Fscience.288.5472.1822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span></div><div class="casAuthors">Xu, Robert X.; Hassell, Anne M.; Vanderwall, Dana; Lambert, Millard H.; Holmes, William D.; Luther, Michael A.; Rocque, Warren J.; Milburn, Michael V.; Zhao, Yingdong; Ke, Hengming; Nolte, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">5472</span>),
    <span class="NLM_cas:pages">1822-1825</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclic nucleotides are second messengers that are essential in vision, muscle contraction, neurotransmission, exocytosis, cell growth, and differentiation.  These mols. are degraded by a family of enzymes known as phosphodiesterases, which serve a crit. function by regulating the intracellular concn. of cyclic nucleotides.  We have detd. the three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resoln.  The active site has been identified and contains a cluster of two metal atoms.  The structure suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiesterase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjHOVmP5GzU7Vg90H21EOLACvtfcHk0lgJGkuv3UheMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D&md5=4f7e42a9f7a6a0763a9dcc064ad903c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.288.5472.1822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.288.5472.1822%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BX.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DLuther%26aufirst%3DM.%2BA.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DAtomic%2520structure%2520of%2520PDE4%253A%2520insights%2520into%2520phosphodiesterase%2520mechanism%2520and%2520specificity%26jtitle%3DScience%26date%3D2000%26volume%3D288%26spage%3D1822%26epage%3D1825%26doi%3D10.1126%2Fscience.288.5472.1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Huai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colicelli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">13220</span><span class="NLM_x">–</span> <span class="NLM_lpage">13226</span><span class="refDoi"> DOI: 10.1021/bi034653e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi034653e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=13220-13226&author=Q.+Huaiauthor=J.+Colicelliauthor=H.+Ke&title=The+crystal+structure+of+AMP-bound+PDE4+suggests+a+mechanism+for+phosphodiesterase+catalysis&doi=10.1021%2Fbi034653e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fbi034653e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi034653e%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DColicelli%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520crystal%2520structure%2520of%2520AMP-bound%2520PDE4%2520suggests%2520a%2520mechanism%2520for%2520phosphodiesterase%2520catalysis%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D13220%26epage%3D13226%26doi%3D10.1021%2Fbi034653e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span><span class="refDoi"> DOI: 10.1016/j.jmb.2007.05.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.jmb.2007.05.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=17582435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=302-307&author=H.+Wangauthor=H.+Robinsonauthor=H.+Ke&title=The+molecular+basis+for+different+recognition+of+substrates+by+phosphodiesterase+families+4+and+10&doi=10.1016%2Fj.jmb.2007.05.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10</span></div><div class="casAuthors">Wang, Huanchen; Robinson, Howard; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-307</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are key enzymes that control the cellular concns. of the second messengers cAMP and cGMP.  The mechanism for selective recognition of substrates cAMP and cGMP by individual PDE families remains a puzzle.  To understand the mechanism for substrate recognition by PDE enzymes, the crystal structure of the catalytic domain of an inactive D201N mutant of PDE4D2 in complex with substrate cAMP has been detd. at 1.56 Å resoln.  The structure shows that Gln369 forms only one hydrogen bond with the adenine of cAMP.  This finding provides exptl. evidence against the hypothesis of two hydrogen bonds between the invariant glutamine and the substrate cAMP in PDE4, and thus suggests that the widely circulated "glutamine switch" model is unlikely to be the mechanism for substrate recognition by PDEs.  A structure comparison between PDE4D2-cAMP and PDE10A2-cAMP reveals an anti configuration of cAMP in PDE4D2 but syn in PDE10A2, in addn. to different contact patterns of cAMP in these two structures.  These observations imply that individual PDE families have their characteristic mechanisms for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8WN9h4LiP7Vg90H21EOLACvtfcHk0lidIpmTs5AO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D&md5=2f7f20be9aba1cae9a4d90e349581583</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.05.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520molecular%2520basis%2520for%2520different%2520recognition%2520of%2520substrates%2520by%2520phosphodiesterase%2520families%25204%2520and%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D371%26spage%3D302%26epage%3D307%26doi%3D10.1016%2Fj.jmb.2007.05.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Huai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspiotis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Enantiomer discrimination illustrated by the high resolution crystal structure of Type 4 phosphodiesterase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1867</span><span class="NLM_x">–</span> <span class="NLM_lpage">1873</span><span class="refDoi"> DOI: 10.1021/jm051273d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051273d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1867-1873&author=Q.+Huaiauthor=Y.+Sunauthor=H.+Wangauthor=D.+Macdonaldauthor=R.+Aspiotisauthor=H.+Robinsonauthor=Z.+Huangauthor=H.+Ke&title=Enantiomer+discrimination+illustrated+by+the+high+resolution+crystal+structure+of+Type+4+phosphodiesterase&doi=10.1021%2Fjm051273d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm051273d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051273d%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DEnantiomer%2520discrimination%2520illustrated%2520by%2520the%2520high%2520resolution%2520crystal%2520structure%2520of%2520Type%25204%2520phosphodiesterase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1867%26epage%3D1873%26doi%3D10.1021%2Fjm051273d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hamblin, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angell, T. D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantine, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delves, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J. O.</span><span> </span><span class="NLM_article-title">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4237</span><span class="NLM_x">–</span> <span class="NLM_lpage">4241</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2008.05.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=18539455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4237-4241&author=J.+N.+Hamblinauthor=T.+D.+R.+Angellauthor=S.+P.+Ballantineauthor=C.+M.+Cookauthor=A.+W.+J.+Cooperauthor=J.+Dawsonauthor=C.+J.+Delvesauthor=P.+S.+Jonesauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=C.+J.+Mitchellauthor=M.+Y.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=J.+O.+Wiseman&title=Pyrazolopyridines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2008.05.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span></div><div class="casAuthors">Hamblin, J. Nicole; Angell, Tony D. R.; Ballantine, Stuart P.; Cook, Caroline M.; Cooper, Anthony W. J.; Dawson, John; Delves, Christopher J.; Jones, Paul S.; Lindvall, Mika; Lucas, Fiona S.; Mitchell, Charlotte J.; Neu, Margarete Y.; Ranshaw, Lisa E.; Solanke, Yemisi E.; Somers, Don O.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4237-4241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Optimization of a high-throughput screening hit resulted in the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective inhibitors of Phosphodiesterase 4 (PDE4).  Herein, we describe early SAR studies around this novel template highlighting preferred substituents and rationalization of SAR through X-ray crystal structures of analogs bound to the PDE4 active site.  Pyrazolopyridine 20a (I) was found to be a potent and selective PDE4 inhibitor which also inhibits LPS induced TNF-α prodn. from isolated human peripheral blood mononuclear cells and has an encouraging rat PK profile suitable for oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj75z9PAk27Vg90H21EOLACvtfcHk0lio96NWl6eMyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D&md5=3b425c80dc0258bab9f2c68297260903</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.052%26sid%3Dliteratum%253Aachs%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DAngell%26aufirst%3DT.%2BD.%2BR.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DCook%26aufirst%3DC.%2BM.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DNeu%26aufirst%3DM.%2BY.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DPyrazolopyridines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4237%26epage%3D4241%26doi%3D10.1016%2Fj.bmcl.2008.05.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lunniss, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eldred, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kranz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, A. G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redgrave, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J. O.</span><span> </span><span class="NLM_article-title">Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimization for oral administration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2009.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19195882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1380-1385&author=C.+J.+Lunnissauthor=A.+W.+J.+Cooperauthor=C.+D.+Eldredauthor=M.+Kranzauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=M.+Neuauthor=A.+G.+S.+Prestonauthor=L.+E.+Ranshawauthor=A.+J.+Redgraveauthor=J.+E.+Robinsonauthor=T.+J.+Shipleyauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=J.+O.+Wiseman&title=Quinolines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors.+Optimization+for+oral+administration&doi=10.1016%2Fj.bmcl.2009.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Optimisation for oral administration</span></div><div class="casAuthors">Lunniss, Christopher J.; Cooper, Anthony W. J.; Eldred, Colin D.; Kranz, Michael; Lindvall, Mika; Lucas, Fiona S.; Neu, Margarete; Preston, Alex G. S.; Ranshaw, Lisa E.; Redgrave, Alison J.; Robinson, J. Ed; Shipley, Tracy J.; Solanke, Yemisi E.; Somers, Don O.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1380-1385</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Crystallog.-driven optimization of a lead derived from similarity searching of the GSK compd. collection resulted in the discovery of a series of quinoline derivs. that were highly potent and selective inhibitors of PDE4 with a good pharmacokinetic profile in the rat.  Quinolines 43 and 48 have potential as oral medicines for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6HHpObSkx27Vg90H21EOLACvtfcHk0lio96NWl6eMyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WmsL8%253D&md5=691ca6b69fe02ee29097eac2ee6ff5b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DEldred%26aufirst%3DC.%2BD.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DPreston%26aufirst%3DA.%2BG.%2BS.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DRedgrave%26aufirst%3DA.%2BJ.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DShipley%26aufirst%3DT.%2BJ.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DQuinolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors.%2520Optimization%2520for%2520oral%2520administration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1380%26epage%3D1385%26doi%3D10.1016%2Fj.bmcl.2009.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Woodrow, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantine, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delves, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kranz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvaal, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J. O.</span><span> </span><span class="NLM_article-title">Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimization for inhaled administration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5261</span><span class="NLM_x">–</span> <span class="NLM_lpage">5265</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2009.04.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5261-5265&author=M.+D.+Woodrowauthor=S.+P.+Ballantineauthor=M.+D.+Barkerauthor=B.+J.+Clarkeauthor=J.+Dawsonauthor=T.+W.+Deanauthor=C.+J.+Delvesauthor=B.+Evansauthor=S.+L.+Goughauthor=S.+B.+Guntripauthor=S.+Holmanauthor=D.+S.+Holmesauthor=M.+Kranzauthor=M.+K.+Lindvaalauthor=F.+S.+Lucasauthor=M.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=P.+Wardauthor=J.+O.+Wiseman&title=Quinolines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors.+Optimization+for+inhaled+administration&doi=10.1016%2Fj.bmcl.2009.04.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWoodrow%26aufirst%3DM.%2BD.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DClarke%26aufirst%3DB.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDean%26aufirst%3DT.%2BW.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DEvans%26aufirst%3DB.%26aulast%3DGough%26aufirst%3DS.%2BL.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHolman%26aufirst%3DS.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvaal%26aufirst%3DM.%2BK.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DQuinolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors.%2520Optimization%2520for%2520inhaled%2520administration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5261%26epage%3D5265%26doi%3D10.1016%2Fj.bmcl.2009.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Govek, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzola, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauregard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamache, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellberg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsien, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerch, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malecha, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staszewski, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiau, A. K.</span><span> </span><span class="NLM_article-title">Water-soluble PDE4 inhibitors for the treatment of dry eye</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2928</span><span class="NLM_x">–</span> <span class="NLM_lpage">2932</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2010.03.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2928-2932&author=S.+P.+Govekauthor=G.+Oshiroauthor=J.+V.+Anzolaauthor=C.+Beauregardauthor=J.+Chenauthor=A.+R.+Coyleauthor=D.+A.+Gamacheauthor=M.+R.+Hellbergauthor=J.+N.+Hsienauthor=J.+M.+Lerchauthor=J.+C.+Liaoauthor=J.+W.+Malechaauthor=L.+M.+Staszewskiauthor=D.+J.+Thomasauthor=J.+M.+Yanniauthor=S.+A.+Nobleauthor=A.+K.+Shiau&title=Water-soluble+PDE4+inhibitors+for+the+treatment+of+dry+eye&doi=10.1016%2Fj.bmcl.2010.03.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DOshiro%26aufirst%3DG.%26aulast%3DAnzola%26aufirst%3DJ.%2BV.%26aulast%3DBeauregard%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCoyle%26aufirst%3DA.%2BR.%26aulast%3DGamache%26aufirst%3DD.%2BA.%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DHsien%26aufirst%3DJ.%2BN.%26aulast%3DLerch%26aufirst%3DJ.%2BM.%26aulast%3DLiao%26aufirst%3DJ.%2BC.%26aulast%3DMalecha%26aufirst%3DJ.%2BW.%26aulast%3DStaszewski%26aufirst%3DL.%2BM.%26aulast%3DThomas%26aufirst%3DD.%2BJ.%26aulast%3DYanni%26aufirst%3DJ.%2BM.%26aulast%3DNoble%26aufirst%3DS.%2BA.%26aulast%3DShiau%26aufirst%3DA.%2BK.%26atitle%3DWater-soluble%2520PDE4%2520inhibitors%2520for%2520the%2520treatment%2520of%2520dry%2520eye%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2928%26epage%3D2932%26doi%3D10.1016%2Fj.bmcl.2010.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Nankervis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feil, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holien, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazzetto, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manallack, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M. W.</span><span> </span><span class="NLM_article-title">Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">7089</span><span class="NLM_x">–</span> <span class="NLM_lpage">7093</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2011.09.109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7089-7093&author=J.+L.+Nankervisauthor=S.+C.+Feilauthor=N.+C.+Hancockauthor=Z.+Zhengauthor=H.-L.+Ngauthor=C.+J.+Mortonauthor=J.+K.+Holienauthor=P.+W.+M.+Hoauthor=M.+M.+Frazzettoauthor=I.+G.+Jenningsauthor=D.+T.+Manallackauthor=T.+J.+Martinauthor=P.+E.+Thompsonauthor=M.+W.+Parker&title=Thiophene+inhibitors+of+PDE4%3A+crystal+structures+show+a+second+binding+mode+at+the+catalytic+domain+of+PDE4D2&doi=10.1016%2Fj.bmcl.2011.09.109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.109%26sid%3Dliteratum%253Aachs%26aulast%3DNankervis%26aufirst%3DJ.%2BL.%26aulast%3DFeil%26aufirst%3DS.%2BC.%26aulast%3DHancock%26aufirst%3DN.%2BC.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DNg%26aufirst%3DH.-L.%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DHolien%26aufirst%3DJ.%2BK.%26aulast%3DHo%26aufirst%3DP.%2BW.%2BM.%26aulast%3DFrazzetto%26aufirst%3DM.%2BM.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DManallack%26aufirst%3DD.%2BT.%26aulast%3DMartin%26aufirst%3DT.%2BJ.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DThiophene%2520inhibitors%2520of%2520PDE4%253A%2520crystal%2520structures%2520show%2520a%2520second%2520binding%2520mode%2520at%2520the%2520catalytic%2520domain%2520of%2520PDE4D2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D7089%26epage%3D7093%26doi%3D10.1016%2Fj.bmcl.2011.09.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Dal Piaz, V.; Giovannoni, M. P.; Vergelli, C.; Aguilar Izquierdo, N.</span><span> </span><span class="NLM_article-title">Pyridazin-3(2H)-one derivatives as PDE4 inhibitors</span>. PCT Int. Appl. WO 2003097613, November 27,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=V.+Dal+Piaz&author=M.+P.+Giovannoni&author=C.+Vergelli&author=N.+Aguilar+Izquierdo&title=Pyridazin-3%282H%29-one+derivatives+as+PDE4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDal%2BPiaz%26aufirst%3DV.%26atitle%3DPyridazin-3%25282H%2529-one%2520derivatives%2520as%2520PDE4%2520inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=15260978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=279-286&author=K.+Y.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+glutamine+switch+mechanism+for+nucleotide+selectivity+by+phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span></div><div class="casAuthors">Zhang, Kam Y. J.; Card, Graeme L.; Suzuki, Yoshihisa; Artis, D. Richard; Fong, Daniel; Gillette, Sam; Hsieh, Davin; Neiman, Joshua; West, Brian L.; Zhang, Chao; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-286</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that modulate the immune response, inflammation, and memory, among many other functions.  There are three types of PDEs: cAMP-specific, cGMP-specific, and dual-specific.  Here we describe the mechanism of nucleotide selectivity on the basis of high-resoln. co-crystal structures of the cAMP-specific PDE4B and PDE4D with AMP, the cGMP-specific PDE5A with GMP, and the apo-structure of the dual-specific PDE1B.  These structures show that an invariant glutamine functions as the key specificity determinant by a "glutamine switch" mechanism for recognizing the purine moiety in cAMP or cGMP.  The surrounding residues anchor the glutamine residue in different orientations for cAMP and for cGMP.  The PDE1B structure shows that in dual-specific PDEs a key histidine residue may enable the invariant glutamine to toggle between cAMP and cGMP.  The structural understanding of nucleotide binding enables the design of new PDE inhibitors that may treat diseases in which cyclic nucleotides play a crit. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRXGTDdAa1bVg90H21EOLACvtfcHk0likTjtpNgYJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D&md5=32fab6a75031a67290ec5eda2c3e080b</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520glutamine%2520switch%2520mechanism%2520for%2520nucleotide%2520selectivity%2520by%2520phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30a1"><span>Erratum inMol. Cell<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span>. 10.1016/j.molcel.2004.08.015</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Erratum+inMol.+Cell+2004%2C+15%2C+659.+10.1016%2Fj.molcel.2004.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Burgin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, O. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsteinsdottir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrafnsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-72&author=A.+B.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0likTjtpNgYJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D72%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Renzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Piaz, V.</span><span> </span><span class="NLM_article-title">4,5-Disubstituted 3-carbethoxyisoxazoles I</span> <span class="citation_source-journal">Gazz. Chim. Ital</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1965</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1478</span><span class="NLM_x">–</span> <span class="NLM_lpage">1491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1965&pages=1478-1491&author=G.+Renziauthor=V.+Dal+Piaz&title=4%2C5-Disubstituted+3-carbethoxyisoxazoles+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenzi%26aufirst%3DG.%26aulast%3DDal%2BPiaz%26aufirst%3DV.%26atitle%3D4%252C5-Disubstituted%25203-carbethoxyisoxazoles%2520I%26jtitle%3DGazz.%2520Chim.%2520Ital%26date%3D1965%26volume%3D95%26spage%3D1478%26epage%3D1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Chen, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eltzschig, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">Adenosine receptors as drug targets - what are the challenges?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1038/nrd3955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1038%2Fnrd3955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=23535933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=265-286&author=J.-F.+Chenauthor=H.+K.+Eltzschigauthor=B.+B.+Fredholm&title=Adenosine+receptors+as+drug+targets+-+what+are+the+challenges%3F&doi=10.1038%2Fnrd3955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as drug targets - what are the challenges?</span></div><div class="casAuthors">Chen, Jiang-Fan; Eltzschig, Holger K.; Fredholm, Bertil B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">265-286</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine signalling has long been a target for drug development, with adenosine itself or its derivs. being used clin. since the 1940s.  In addn., methylxanthines such as caffeine have profound biol. effects as antagonists at adenosine receptors.  Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors.  There is strong evidence that adenosine has a functional role in many diseases, and several pharmacol. compds. specifically targeting individual adenosine receptors - either directly or indirectly - have now entered the clinic.  However, only one adenosine receptor-specific agent - the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) - has so far gained approval from the US Food and Drug Administration (FDA).  Here, we focus on the biol. of adenosine signalling to identify hurdles in the development of addnl. pharmacol. compds. targeting adenosine receptors and discuss strategies to overcome these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqhEzWXi1WS7Vg90H21EOLACvtfcHk0lgzSMqbusDjyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D&md5=898fee7a68273ebfbd5a1d3dca307dc5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd3955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3955%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DAdenosine%2520receptors%2520as%2520drug%2520targets%2520-%2520what%2520are%2520the%2520challenges%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D265%26epage%3D286%26doi%3D10.1038%2Fnrd3955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J. P.</span><span> </span><span class="NLM_article-title">Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">241</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1006/bbrc.1997.7542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1006%2Fbbrc.1997.7542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1997&pages=175-180&author=M.+D.+Percivalauthor=B.+Yehauthor=J.+P.+Falgueyret&title=Zinc+dependent+activation+of+cAMP-specific+phosphodiesterase+%28PDE4A%29&doi=10.1006%2Fbbrc.1997.7542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1997.7542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1997.7542%26sid%3Dliteratum%253Aachs%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26atitle%3DZinc%2520dependent%2520activation%2520of%2520cAMP-specific%2520phosphodiesterase%2520%2528PDE4A%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1997%26volume%3D241%26spage%3D175%26epage%3D180%26doi%3D10.1006%2Fbbrc.1997.7542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30a','cit30a1'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ting Peng, Baowen Qi, Jun He, Hengming Ke, <span class="NLM_string-name hlFld-ContribAuthor">Jianyou Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the Development of Phosphodiesterase-4 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10594-10617. <a href="https://doi.org/10.1021/acs.jmedchem.9b02170" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02170%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BPhosphodiesterase-4%252BInhibitors%26aulast%3DPeng%26aufirst%3DTing%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D28122019%26date%3D10062020%26date%3D07042020%26volume%3D63%26issue%3D19%26spage%3D10594%26epage%3D10617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joseph Katigbak, Haotian Li, David Rooklin, <span class="NLM_string-name hlFld-ContribAuthor">Yingkai Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">AlphaSpace 2.0: Representing Concave Biomolecular Surfaces Using β-Clusters. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (3)
                                     , 1494-1508. <a href="https://doi.org/10.1021/acs.jcim.9b00652" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DAlphaSpace%252B2.0%25253A%252BRepresenting%252BConcave%252BBiomolecular%252BSurfaces%252BUsing%252B%2525CE%2525B2-Clusters%26aulast%3DKatigbak%26aufirst%3DJoseph%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D04082019%26date%3D11022020%26date%3D29012020%26volume%3D60%26issue%3D3%26spage%3D1494%26epage%3D1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 5944-5978. <a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BTreatments%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252B%252528COPD%252529%252BUsing%252BLow-Molecular-Weight%252BDrugs%252B%252528LMWDs%252529%26aulast%3DTi%26aufirst%3DHuihui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30092018%26date%3D12022019%26date%3D25012019%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard S. Roberts, Sara Sevilla, Manel Ferrer, Joan Taltavull, Begoña Hernández, Victor Segarra, Jordi Gràcia, Martin D. Lehner, Amadeu Gavaldà, Miriam Andrés, Judit Cabedo, Dolors Vilella, Peter Eichhorn, Elena Calama, Carla Carcasona, <span class="NLM_string-name hlFld-ContribAuthor">Montserrat Miralpeix</span>. </span><span class="cited-content_cbyCitation_article-title">4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2472-2489. <a href="https://doi.org/10.1021/acs.jmedchem.7b01751" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01751</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01751%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Amino-7%25252C8-dihydro-1%25252C6-naphthyridin-5%2525286H%252529-ones%252Bas%252BInhaled%252BPhosphodiesterase%252BType%252B4%252B%252528PDE4%252529%252BInhibitors%25253A%252BStructural%252BBiology%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%26aulast%3DRoberts%26aufirst%3DRichard%2BS.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01122017%26date%3D13032018%26date%3D05032018%26volume%3D61%26issue%3D6%26spage%3D2472%26epage%3D2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oya Unsal  Tan</span>, <span class="hlFld-ContribAuthor ">Keriman  Ozadali Sari</span>. </span><span class="cited-content_cbyCitation_article-title">Azolo[
              d
              ]pyridazinones in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (3)
                                     , 287-311. <a href="https://doi.org/10.4155/fmc-2020-0234" title="DOI URL">https://doi.org/10.4155/fmc-2020-0234</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0234%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAzolo%25255B%252Bd%252B%25255Dpyridazinones%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DTan%26aufirst%3DOya%2BUnsal%26date%3D2021%26volume%3D13%26issue%3D3%26spage%3D287%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan E.  Phillips</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00259" title="DOI URL">https://doi.org/10.3389/fphar.2020.00259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00259%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DInhaled%252BPhosphodiesterase%252B4%252B%252528PDE4%252529%252BInhibitors%252Bfor%252BInflammatory%252BRespiratory%252BDiseases%26aulast%3DPhillips%26aufirst%3DJonathan%2BE.%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Didier F.  Vargas</span>, <span class="hlFld-ContribAuthor ">Enrique L.  Larghi</span>, <span class="hlFld-ContribAuthor ">Teodoro S.  Kaufman</span>. </span><span class="cited-content_cbyCitation_article-title">First total synthesis of ampullosine, a unique isoquinoline alkaloid isolated from
              Sepedonium ampullosporum
              , and of the related permethylampullosine. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (57)
                                     , 33096-33106. <a href="https://doi.org/10.1039/C9RA06839B" title="DOI URL">https://doi.org/10.1039/C9RA06839B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA06839B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA06839B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DFirst%252Btotal%252Bsynthesis%252Bof%252Bampullosine%25252C%252Ba%252Bunique%252Bisoquinoline%252Balkaloid%252Bisolated%252Bfrom%252BSepedonium%252Bampullosporum%252B%25252C%252Band%252Bof%252Bthe%252Brelated%252Bpermethylampullosine%26aulast%3DVargas%26aufirst%3DDidier%2BF.%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D57%26spage%3D33096%26epage%3D33106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chang  Huang</span>, <span class="hlFld-ContribAuthor ">Qiu‐Ping  Zhong</span>, <span class="hlFld-ContribAuthor ">Lv  Tang</span>, <span class="hlFld-ContribAuthor ">Hai‐Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Jiang‐Ping  Xu</span>, <span class="hlFld-ContribAuthor ">Zhong‐Zhen  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2‐(3,4‐dialkoxyphenyl)‐2‐(substituted pyridazin‐3‐yl)acetonitriles as phosphodiesterase 4 inhibitors with anti‐neuroinflammation potential based on three‐dimensional quantitative structure–activity relationship study. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2019,</strong> <em>93 </em>
                                    (4)
                                     , 484-502. <a href="https://doi.org/10.1111/cbdd.13438" title="DOI URL">https://doi.org/10.1111/cbdd.13438</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13438%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDiscovery%252Bof%252B2%2525E2%252580%252590%2525283%25252C4%2525E2%252580%252590dialkoxyphenyl%252529%2525E2%252580%2525902%2525E2%252580%252590%252528substituted%252Bpyridazin%2525E2%252580%2525903%2525E2%252580%252590yl%252529acetonitriles%252Bas%252Bphosphodiesterase%252B4%252Binhibitors%252Bwith%252Banti%2525E2%252580%252590neuroinflammation%252Bpotential%252Bbased%252Bon%252Bthree%2525E2%252580%252590dimensional%252Bquantitative%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudy%26aulast%3DHuang%26aufirst%3DChang%26date%3D2019%26date%3D2018%26volume%3D93%26issue%3D4%26spage%3D484%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient drug discovery by rational lead hybridization based on crystallographic overlay. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (3)
                                     , 805-813. <a href="https://doi.org/10.1016/j.drudis.2018.11.021" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.11.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.11.021%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DEfficient%252Bdrug%252Bdiscovery%252Bby%252Brational%252Blead%252Bhybridization%252Bbased%252Bon%252Bcrystallographic%252Boverlay%26aulast%3DZhang%26aufirst%3DShuo%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D805%26epage%3D813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chantal  Barberot</span>, <span class="hlFld-ContribAuthor ">Aurélie  Moniot</span>, <span class="hlFld-ContribAuthor ">Ingrid  Allart-Simon</span>, <span class="hlFld-ContribAuthor ">Laurette  Malleret</span>, <span class="hlFld-ContribAuthor ">Tatiana  Yegorova</span>, <span class="hlFld-ContribAuthor ">Marie  Laronze-Cochard</span>, <span class="hlFld-ContribAuthor ">Abderrazzaq  Bentaher</span>, <span class="hlFld-ContribAuthor ">Maurice  Médebielle</span>, <span class="hlFld-ContribAuthor ">Jean-Philippe  Bouillon</span>, <span class="hlFld-ContribAuthor ">Eric  Hénon</span>, <span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Frédéric  Velard</span>, <span class="hlFld-ContribAuthor ">Stéphane  Gérard</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>146 </em>, 139-146. <a href="https://doi.org/10.1016/j.ejmech.2018.01.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyridazinone%252Bderivatives%252Bas%252Bpotential%252Banti-inflammatory%252Bagents%26aulast%3DBarberot%26aufirst%3DChantal%26date%3D2018%26volume%3D146%26spage%3D139%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaopeng  Song</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Junhua  Li</span>, <span class="hlFld-ContribAuthor ">Dekun  Hu</span>, <span class="hlFld-ContribAuthor ">Dongsheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Yixian  Liao</span>, <span class="hlFld-ContribAuthor ">Juntong  Lin</span>, <span class="hlFld-ContribAuthor ">Lian-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Zi-Ning  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (20)
                                     , 5709-5717. <a href="https://doi.org/10.1016/j.bmc.2017.08.045" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.08.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.08.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bdesign%252Bof%252Bconformationally%252Bconstrained%252Boxazolidinone-fused%252B1%25252C2%25252C3%25252C4-tetrahydroisoquinoline%252Bderivatives%252Bas%252Bpotential%252BPDE4%252Binhibitors%26aulast%3DSong%26aufirst%3DGaopeng%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5709%26epage%3D5717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Morten  Laursen</span>, <span class="hlFld-ContribAuthor ">Lilliana  Beck</span>, <span class="hlFld-ContribAuthor ">Jan  Kehler</span>, <span class="hlFld-ContribAuthor ">Claus Tornby  Christoffersen</span>, <span class="hlFld-ContribAuthor ">Christoffer  Bundgaard</span>, <span class="hlFld-ContribAuthor ">Susie  Mogensen</span>, <span class="hlFld-ContribAuthor ">Tomas Joachim  Mow</span>, <span class="hlFld-ContribAuthor ">Estéfano  Pinilla</span>, <span class="hlFld-ContribAuthor ">Jakob Schöllhammer  Knudsen</span>, <span class="hlFld-ContribAuthor ">Elise Røge  Hedegaard</span>, <span class="hlFld-ContribAuthor ">Morten  Grunnet</span>, <span class="hlFld-ContribAuthor ">Ulf  Simonsen</span>. </span><span class="cited-content_cbyCitation_article-title">Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2017,</strong> <em>174 </em>
                                    (15)
                                     , 2563-2575. <a href="https://doi.org/10.1111/bph.13868" title="DOI URL">https://doi.org/10.1111/bph.13868</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.13868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.13868%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DNovel%252Bselective%252BPDE%252Btype%252B1%252Binhibitors%252Bcause%252Bvasodilatation%252Band%252Blower%252Bblood%252Bpressure%252Bin%252Brats%26aulast%3DLaursen%26aufirst%3DMorten%26date%3D2017%26date%3D2017%26volume%3D174%26issue%3D15%26spage%3D2563%26epage%3D2575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of approved oral drugs roflumilast <b>1</b> and apremilast <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of inhaled clinical candidates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Left-hand panel: X-ray crystal structure of <b>6</b> bound to the PDE4D active site overlaid with roflumilast <b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ">1XOQ</a>). Ligand, active site, and resolved waters are colored by atom type for complexed <b>6</b> and in blue for complexed roflumilast. Glutamine-369 is represented by sticks. The two metal ions are colored as follows: green for magnesium and gray for zinc. Right-hand panel: conceptual design and interactions of the pyridazinone (PYR) series. Active site regions are defined as follows with respect to the cartoon view: [1] The π-clamp region is a narrow channel formed between a face-to-face interaction with Phe-372 in front of the ligand and an edge-to-face interaction with Phe-340 behind. [2] The “glutamine switch” glutamine-369 provides PDE4’s selectivity for cAMP over cGMP.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> [3] The small lipophilic pocket. [4] The large lipophilic pocket. [5] The metal binding zone of PDE4 responsible for the catalytic hydrolysis of cAMP, containing the enzyme’s two metals ions, zinc and magnesium. [6] The solvent exposed pocket. In the full PDE4 isoenzyme, the helices of the upstream conserved region (UCR2), a negative regulator of cAMP hydrolysis, partially fill this area.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In truncated protein sequences, coding only for the PDE4 active site, this zone is exposed to the bulk solvent, hence the name.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Conceptual design of the PYR series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Biaryl-Substituted Pyridazinones <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, EtOAc, THF, 0 °C to reflux, 82% yield; (b) Na, ClC(NOH)OEt, EtOH, 0 °C, 89% yield; (c) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, EtOH, rt, 72% yield; (d) EtBr, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 85% yield; (e) H<sub>2</sub>, Raney nickel, THF, EtOH, 90% yield; (f) HBr 48%, 130 °C, 82% yield; (g) triphosgene, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; then 4-amino-3,5-dichloropyridine, THF, rt, 70% yield; (h) ArB(OH)<sub>2</sub> or ArB(pin), PdCl<sub>2</sub>dppf·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 90 °C, 9–74% yield.</p></p></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/medium/jm-2016-00829k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Dose–responses of roflumilast <b>1</b> and compound <b>37</b> in a LPS-induced rat neutrophilia model. Compounds in suspension were administered intratracheally (i.t.) by MicroSprayer Aerosolizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b00829/20161202/images/large/jm-2016-00829k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00829&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Zhang, H. T.</span><span> </span><span class="NLM_article-title">Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1698</span><span class="refDoi"> DOI: 10.2174/138161209788168092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.2174%2F138161209788168092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19442182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtValt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1688-1698&author=H.+T.+Zhang&title=Cyclic+AMP-specific+phosphodiesterase-4+as+a+target+for+the+development+of+antidepressant+drugs&doi=10.2174%2F138161209788168092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs</span></div><div class="casAuthors">Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1688-1698</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-4 (PDE4), one of eleven PDE enzyme families, specifically catalyzes hydrolysis of cAMP; it has four subtypes (PDE4A-D) with at least 25 splice variants.  PDE4 plays a crit. role in the control of intracellular cAMP concns.  PDE4 inhibitors produce antidepressant actions in both animals and humans via enhancement of cAMP signaling in the brain.  However, their clin. utility has been hampered by side effects, in particular nausea and emesis.  While there is still a long way to go before PDE4 inhibitors with high therapeutic indexes are available for treatment of depressive disorders, important advances have been made in the development of PDE4 inhibitors as antidepressants.  First, limited, but significant studies point to PDE4D as the major PDE4 subtype responsible for antidepressant-like effects of PDE4 inhibitors, although the role of PDE4A cannot be excluded.  Second, PDE4D may contribute to emesis, the major side effect of PDE4 inhibitors.  For this reason, identification of roles of PDE4D splice variants in mediating antidepressant activity is particularly important.  Recent studies using small interfering RNAs (siRNAs) have demonstrated the feasibility to identify cellular functions of individual PDE4 variants.  Third, mixed inhibitors of PDE4 and PDE7 or PDE4 and serotonin reuptake have been developed and may be potential antidepressants with minimized side effects.  Finally, relatively selective inhibitors of one or two PDE4 subtypes have been synthesized using structure- and scaffold-based design.  This review also discusses the relationship between PDE4 and antidepressant activity based on structures, brain distributions, and pharmacol. properties of PDE4 and its isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbw6LZusu3QbVg90H21EOLACvtfcHk0ljzPGLmSuj3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtValt7k%253D&md5=461633876ca8e287de7d0aeaf7d74f6c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F138161209788168092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209788168092%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DCyclic%2520AMP-specific%2520phosphodiesterase-4%2520as%2520a%2520target%2520for%2520the%2520development%2520of%2520antidepressant%2520drugs%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D1688%26epage%3D1698%26doi%3D10.2174%2F138161209788168092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span> </span><span class="NLM_article-title">Keynote review: phosphodiesterase-4 as a therapeutic target</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1503</span><span class="NLM_x">–</span> <span class="NLM_lpage">1519</span><span class="refDoi"> DOI: 10.1016/S1359-6446(05)03622-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2FS1359-6446%2805%2903622-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=16257373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1503-1519&author=M.+D.+Houslayauthor=P.+Schaferauthor=K.+Y.+Zhang&title=Keynote+review%3A+phosphodiesterase-4+as+a+therapeutic+target&doi=10.1016%2FS1359-6446%2805%2903622-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 as a therapeutic target</span></div><div class="casAuthors">Houslay, Miles D.; Schafer, Peter; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1503-1519</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-4 selective inhibitors have therapeutic potential for treating major diseases such as asthma and COPD, as well as depression, Parkinson's disease and Alzheimer's disease.  CAMP is a key second messenger in all cells.  It is compartmentalized within cells and its levels are controlled, as a result of spatially discrete signaling cassettes controlling its generation, detection and degrdn.  Underpinning compartmentalized cAMP signaling are ∼20 members of the phosphodiesterase-4 (PDE4) family.  The selective inhibition of this family generates profound, functional effects and PDE4 inhibitors are currently under development to provide potential, novel therapeutics for the treatment of inflammatory diseases, such as asthma, chronic obstructive pulmonary disease and psoriasis, as well as treating depression and serving as cognitive enhancers.  Here, we delineate the range of PDE4 isoforms, their role in signaling, their structural biol. and related preclin. and clin. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOabrPCOweLVg90H21EOLACvtfcHk0ljzPGLmSuj3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsrzL&md5=7c75a76543b75145a44ae8f4a2f3b2ac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903622-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903622-6%26sid%3Dliteratum%253Aachs%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26atitle%3DKeynote%2520review%253A%2520phosphodiesterase-4%2520as%2520a%2520therapeutic%2520target%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1503%26epage%3D1519%26doi%3D10.1016%2FS1359-6446%2805%2903622-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Press, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banner, K. H.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors - a review of the current field</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span><span class="refDoi"> DOI: 10.1016/S0079-6468(08)00202-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2FS0079-6468%2808%2900202-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19328289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=37-74&author=N.+J.+Pressauthor=K.+H.+Banner&title=PDE4+inhibitors+-+a+review+of+the+current+field&doi=10.1016%2FS0079-6468%2808%2900202-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors - a review of the current field</span></div><div class="casAuthors">Press, Neil J.; Banner, Katharine H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-74</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the phosphodiesterase 4 enzyme inhibitors and their potential therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodvxfZgwsOsbVg90H21EOLACvtfcHk0lgoXTFRnHzSDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2jtb0%253D&md5=45a006d23fedc76f4f42f2f424bd4395</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2808%2900202-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252808%252900202-6%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DBanner%26aufirst%3DK.%2BH.%26atitle%3DPDE4%2520inhibitors%2520-%2520a%2520review%2520of%2520the%2520current%2520field%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D47%26spage%3D37%26epage%3D74%26doi%3D10.1016%2FS0079-6468%2808%2900202-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Jin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFα responses</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">7628</span><span class="NLM_x">–</span> <span class="NLM_lpage">7633</span><span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0lgoXTFRnHzSDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Manning, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cieslinski, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essayan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grous, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torphy, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnette, M. S.</span><span> </span><span class="NLM_article-title">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1398</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0702911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1038%2Fsj.bjp.0702911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10602317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=1393-1398&author=C.+D.+Manningauthor=M.+Burmanauthor=S.+B.+Christensenauthor=L.+B.+Cieslinskiauthor=D.+M.+Essayanauthor=M.+Grousauthor=T.+J.+Torphyauthor=M.+S.+Barnette&title=Suppression+of+human+inflammatory+cell+function+by+subtype-selective+PDE4+inhibitors+correlates+with+inhibition+of+PDE4A+and+PDE4B&doi=10.1038%2Fsj.bjp.0702911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B</span></div><div class="casAuthors">Manning, Carol D.; Burman, Miriam; Christensen, Siegfried B.; Cieslinski, Lenora B.; Essayan, David M.; Grous, Marilyn; Torphy, Theodore J.; Barnette, Mary S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Of the four major phosphodiesterase 4 (PDE4) subtypes, PDE4A, PDE4B and PDE4D are widely expressed in human inflammatory cells, including monocytes and T lymphocytes.  We explored the functional role of these subtypes using ten subtype-selective PDE4 inhibitors, each belonging to one of two classes: (i) dual PDE4A/PDE4B inhibitors or (ii) PDE4D inhibitors.  These compds. were evaluated for their ability to inhibit antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-stimulated tumor necrosis factor α (TNFα) release from peripheral blood monocytes.  All compds. inhibited T-cell proliferation in a concn.-dependent manner; with IC50 values distributed over an approx. 50 fold range.  These compds. also inhibited TNFα release concn.-dependently, with a wider (∼ 1000 fold) range of IC50 values.  In both sets of expts., mean IC50 values were significantly correlated with compd. potency against the catalytic activity of recombinant human PDE4A or PDE4B when analyzed by either linear regression of log IC50 values or by Spearman's rank-order correlation.  The correlation between inhibition of inflammatory cell function and inhibition of recombinant PDE4D catalytic activity was not significant in either anal.  These results suggest that PDE4A and/or PDE4B may play the major role in regulating these two inflammatory cell functions but do not rule out PDE4D as an important mediator of other activities in mononuclear leukocytes and other immune and inflammatory cells.  Much more work is needed to establish the functional roles of the PDE4 subtypes across a broader range of cellular functions and cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3g1B9QQKejbVg90H21EOLACvtfcHk0lhgKq_6pYCnOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSisb4%253D&md5=70490a1a73b83ce887e850e4efd2e738</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702911%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DC.%2BD.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DEssayan%26aufirst%3DD.%2BM.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26atitle%3DSuppression%2520of%2520human%2520inflammatory%2520cell%2520function%2520by%2520subtype-selective%2520PDE4%2520inhibitors%2520correlates%2520with%2520inhibition%2520of%2520PDE4A%2520and%2520PDE4B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D1393%26epage%3D1398%26doi%3D10.1038%2Fsj.bjp.0702911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">O’Donnell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. T.</span><span> </span><span class="NLM_article-title">Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4)</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span><span class="refDoi"> DOI: 10.1016/j.tips.2004.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.tips.2004.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=158-163&author=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Antidepressant+effects+of+inhibitors+of+cyclic+AMP+phosphodiesterase+%28PDE4%29&doi=10.1016%2Fj.tips.2004.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DAntidepressant%2520effects%2520of%2520inhibitors%2520of%2520cyclic%2520AMP%2520phosphodiesterase%2520%2528PDE4%2529%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D158%26epage%3D163%26doi%3D10.1016%2Fj.tips.2004.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Li, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. T.</span><span> </span><span class="NLM_article-title">Phosphodiesterase-4D knockout and RNAi-mediated knockdown enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.5236-10.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1523%2FJNEUROSCI.5236-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=21209202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=172-183&author=Y.+F.+Liauthor=Y.+F.+Chengauthor=Y.+Huangauthor=M.+Contiauthor=S.+P.+Wilsonauthor=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Phosphodiesterase-4D+knockout+and+RNAi-mediated+knockdown+enhance+memory+and+increase+hippocampal+neurogenesis+via+increased+cAMP+signaling&doi=10.1523%2FJNEUROSCI.5236-10.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span></div><div class="casAuthors">Li, Yun-Feng; Cheng, Yu-Fang; Huang, Ying; Conti, Marco; Wilson, Steven P.; O'Donnell, James M.; Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis.  PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants.  Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests.  These effects were mimicked by repeated treatment with rolipram in wild-type mice.  In addn., similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus down-regulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  The present results suggest that PDE4D, in particular long-form PDE4D, plays a crit. role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKG03_qqdl7Vg90H21EOLACvtfcHk0lhgKq_6pYCnOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D&md5=928836c09ff122681fdf11db58885b79</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5236-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5236-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DCheng%26aufirst%3DY.%2BF.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DPhosphodiesterase-4D%2520knockout%2520and%2520RNAi-mediated%2520knockdown%2520enhance%2520memory%2520and%2520increase%2520hippocampal%2520neurogenesis%2520via%2520increased%2520cAMP%2520signaling%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D172%26epage%3D183%26doi%3D10.1523%2FJNEUROSCI.5236-10.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lehnart, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehrens, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belevych, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, A. R.</span><span> </span><span class="NLM_article-title">Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1016/j.cell.2005.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.cell.2005.07.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2005&pages=25-35&author=S.+E.+Lehnartauthor=X.+H.+Wehrensauthor=S.+Reikenauthor=S.+Warrierauthor=A.+E.+Belevychauthor=R.+D.+Harveyauthor=W.+Richterauthor=S.+L.+Jinauthor=M.+Contiauthor=A.+R.+Marks&title=Phosphodiesterase+4D+deficiency+in+the+ryanodine-receptor+complex+promotes+heart+failure+and+arrhythmias&doi=10.1016%2Fj.cell.2005.07.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DLehnart%26aufirst%3DS.%2BE.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26aulast%3DReiken%26aufirst%3DS.%26aulast%3DWarrier%26aufirst%3DS.%26aulast%3DBelevych%26aufirst%3DA.%2BE.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DMarks%26aufirst%3DA.%2BR.%26atitle%3DPhosphodiesterase%25204D%2520deficiency%2520in%2520the%2520ryanodine-receptor%2520complex%2520promotes%2520heart%2520failure%2520and%2520arrhythmias%26jtitle%3DCell%26date%3D2005%26volume%3D123%26spage%3D25%26epage%3D35%26doi%3D10.1016%2Fj.cell.2005.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Robichaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamatiou, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.-L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberté, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C.-C.</span><span> </span><span class="NLM_article-title">Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anaesthesia, a behavioural correlate of emesis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span><span class="refDoi"> DOI: 10.1172/JCI0215506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1172%2FJCI0215506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1045-1052&author=A.+Robichaudauthor=P.+B.+Stamatiouauthor=S.-L.+C.+Jinauthor=N.+Lachanceauthor=D.+MacDonaldauthor=F.+Lalibert%C3%A9author=S.+Liuauthor=Z.+Huangauthor=M.+Contiauthor=C.-C.+Chan&title=Deletion+of+phosphodiesterase+4D+in+mice+shortens+a2-adrenoceptor-mediated+anaesthesia%2C+a+behavioural+correlate+of+emesis&doi=10.1172%2FJCI0215506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1172%2FJCI0215506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215506%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DS.-L.%2BC.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DMacDonald%26aufirst%3DD.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DC.-C.%26atitle%3DDeletion%2520of%2520phosphodiesterase%25204D%2520in%2520mice%2520shortens%2520a2-adrenoceptor-mediated%2520anaesthesia%252C%2520a%2520behavioural%2520correlate%2520of%2520emesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1045%26epage%3D1052%26doi%3D10.1172%2FJCI0215506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Naganuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saitoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagumo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawanishi, M.</span><span> </span><span class="NLM_article-title">Discovery of selective PDE4B inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3174</span><span class="NLM_x">–</span> <span class="NLM_lpage">3176</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2009.04.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19447034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3174-3176&author=K.+Naganumaauthor=A.+Omuraauthor=N.+Maekawaraauthor=M.+Saitohauthor=N.+Ohkawaauthor=T.+Kubotaauthor=H.+Nagumoauthor=T.+Kodamaauthor=M.+Takemuraauthor=Y.+Ohtsukaauthor=J.+Nakamuraauthor=R.+Tsujitaauthor=K.+Kawasakiauthor=H.+Yokoiauthor=M.+Kawanishi&title=Discovery+of+selective+PDE4B+inhibitors&doi=10.1016%2Fj.bmcl.2009.04.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective PDE4B inhibitors</span></div><div class="casAuthors">Naganuma, Kenji; Omura, Akifumi; Maekawara, Naomi; Saitoh, Masahiro; Ohkawa, Naoto; Kubota, Takashi; Nagumo, Hiromitsu; Kodama, Toshiyuki; Takemura, Masayoshi; Ohtsuka, Yuji; Nakamura, Junji; Tsujita, Ryuichi; Kawasaki, Koh; Yokoi, Hirotsugu; Kawanishi, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3174-3176</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study the first PDE4B selective inhibitor is described.  Optimization of lead 2-arylpyrimidine derivs. afforded a series of potent PDE4B inhibitors I (R1 = Me, Et, H2C:CHCH2, CN, CHO, etc.; R2 = Me, Et, n-Pr; R3 = Ph, 4-MeC6H4, 2-thienyl, 2-pyridyl, etc.; R4 = H, F; R5 = CO2H, CH2CO2H) with >100-fold selectivity over the PDE4D isoenzyme.  With a good pharmacokinetic profile, a selected compd. I (R1 = Et; R2 = Me; R3 = 5-chloro-2-thienyl; R4 = H; R5 = CH2CO2H) exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOGQ4ols6Z1rVg90H21EOLACvtfcHk0ljnRdszHxZBdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eks7w%253D&md5=aca08592557e5d34da5b02835b0e49d8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.121%26sid%3Dliteratum%253Aachs%26aulast%3DNaganuma%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DA.%26aulast%3DMaekawara%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DM.%26aulast%3DOhkawa%26aufirst%3DN.%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DNagumo%26aufirst%3DH.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DM.%26aulast%3DOhtsuka%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DTsujita%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DYokoi%26aufirst%3DH.%26aulast%3DKawanishi%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520selective%2520PDE4B%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3174%26epage%3D3176%26doi%3D10.1016%2Fj.bmcl.2009.04.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1042/BJ20070970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1042%2FBJ20070970" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=193-201&author=H.+Wangauthor=M.+S.+Pengauthor=Y.+Chenauthor=J.+Gengauthor=H.+Robinsonauthor=M.+D.+Houslayauthor=I.+Caiauthor=H.+Ke&title=Structures+of+the+four+subfamilies+of+phosphodiesterase-4+provide+insight+into+the+selectivity+of+their+inhibitors&doi=10.1042%2FBJ20070970"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1042%2FBJ20070970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070970%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DM.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DCai%26aufirst%3DI.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DStructures%2520of%2520the%2520four%2520subfamilies%2520of%2520phosphodiesterase-4%2520provide%2520insight%2520into%2520the%2520selectivity%2520of%2520their%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D193%26epage%3D201%26doi%3D10.1042%2FBJ20070970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fox, D.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span> </span><span class="NLM_article-title">Structural basis for the design of selective phosphodiesterase</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span><span class="refDoi"> DOI: 10.1016/j.cellsig.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.cellsig.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=24361374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=657-663&author=D.+Foxauthor=A.+B.+Burginauthor=M.+E.+Gurney&title=Structural+basis+for+the+design+of+selective+phosphodiesterase&doi=10.1016%2Fj.cellsig.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span></div><div class="casAuthors">Fox, David, III; Burgin, Alex B.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor -Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial cells.  As such, it is an important, although under-exploited mol. target for anti-inflammatory drugs.  This is due in part to the difficulty of developing selective PDE4B inhibitors as the amino acid sequence of the PDE4 active site is identical in all PDE4 subtypes (PDE4A-D).  We show that highly selective PDE4B inhibitors can be designed by exploiting sequence differences outside the active site.  Specifically, PDE4B selectivity can be achieved by capture of a C-terminal regulatory helix, now termed CR3 (Control Region 3), across the active site in a conformation that closes access by cAMP.  PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 vs. Gln594 in PDE4D).  The reciprocal mutations in PDE4B and PDE4D cause a 70-80 fold shift in selectivity.  Our structural studies show that CR3 is flexible and can adopt multiple orientations and multiple registries in the closed conformation.  The new co-crystal structure with bound ligand provides a guide map for the design of PDE4B selective anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKu3hgg1Kl7Vg90H21EOLACvtfcHk0lh2FmvAf67FTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D&md5=ab8e72afbfeadffeae27950206402bd9</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DD.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DStructural%2520basis%2520for%2520the%2520design%2520of%2520selective%2520phosphodiesterase%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D657%26epage%3D663%26doi%3D10.1016%2Fj.cellsig.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span>Celgene press release. <a href="http://ir.celgene.com/releasedetail.cfm?ReleaseID=872240" class="extLink">http://ir.celgene.com/releasedetail.cfm?ReleaseID=872240</a>, September 23,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Celgene+press+release.+http%3A%2F%2Fir.celgene.com%2Freleasedetail.cfm%3FReleaseID%3D872240%2C+September+23%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pagès, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehner, M. D.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2005 - 2009)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1519</span><span class="refDoi"> DOI: 10.1517/13543770903313753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543770903313753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19832118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1501-1519&author=L.+Pag%C3%A8sauthor=A.+Gavald%C3%A0author=M.+D.+Lehner&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282005+-+2009%29&doi=10.1517%2F13543770903313753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors: a review of current developments (2005 - 2009)</span></div><div class="casAuthors">Pages, Lluis; Gavalda, Amadeu; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1501-1519</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Despite the sound preclin. database and some promising data from clin. trials, development of PDE4 inhibitors for the treatment of inflammatory or neurol. diseases has been hampered by dose-limiting class-related side effects.  Objective: In the past years, companies opted for different approaches to improve the therapeutic window of their compds. including topical administration of PDE4 inhibitors with the goal of minimizing systemic exposure.  This change in strategy is reflected by the disclosure of novel and chem. diverse mols. that demonstrate the continued interest of pharmaceutical industry in developing PDE4 inhibitors.  Conclusion: This review summarizes the clin. development of PDE4 inhibitors since 2005 and the assocd. patent literature with a focus on strategies applied to minimize systemic adverse effects.  In sum, although a significant no. of new drugs designed for improved tolerability entered clin. trials, so far none of them fulfilled expectations and best progress has been achieved recently with the oral, non-isoform selective PDE4 inhibitor roflumilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6XZlM2_eQxbVg90H21EOLACvtfcHk0lh2FmvAf67FTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmu7bM&md5=4041bbd045ffa269e1fa406746193c3e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543770903313753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903313753%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282005%2520-%25202009%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1501%26epage%3D1519%26doi%3D10.1517%2F13543770903313753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. S.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2010 - 2012)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1016</span><span class="refDoi"> DOI: 10.1517/13543776.2013.794789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543776.2013.794789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=997-1016&author=A.+Gavald%C3%A0author=R.+S.+Roberts&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282010+-+2012%29&doi=10.1517%2F13543776.2013.794789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012)</span></div><div class="casAuthors">Gavalda, Amadeu; Roberts, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">997-1016</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: At last, after many years of research, roflumilast has become the first oral phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on therapy for chronic obstructive pulmonary disease.  A second compd., apremilast is targeted for submission of new drug application for the treatment of psoriasis in the second half of 2013.  These compds. represent a breakthrough and a reward in the field after the many failures to date in clin. development.  Areas covered: This review summarizes the clin. development of PDE4 inhibitors from 2010 - 2012 and the assocd. patent literature with a focus on strategies to overcome the common pitfalls of oral PDE4 inhibitors.  Expert opinion: In the last few years, influenced by the body of published clin. data, many companies have lost interest in PDE4 as a target.  Many of those that have persevered have opted to realign their research programs either toward compds. specifically designed for inhaled delivery or in search of an increase in clin. efficacy by combining two mechanisms in a single compd.  This change is reflected by the continued disclosure of novel and chem. diverse mols., indicating for some in the pharmaceutical industry that all is not yet lost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe0yV5hhUby7Vg90H21EOLACvtfcHk0liXld46bqPlOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3L&md5=9a5961a6f439698b11123ac47c5839aa</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.794789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.794789%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282010%2520-%25202012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D997%26epage%3D1016%26doi%3D10.1517%2F13543776.2013.794789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Martinez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span> </span><span class="NLM_article-title">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1517/13543776.2014.968127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543776.2014.968127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=25284693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1311-1321&author=A.+Martinezauthor=C.+Gil&title=cAMP-specific+phosphodiesterase+inhibitors%3A+promising+drugs+for+inflammatory+and+neurological+diseases&doi=10.1517%2F13543776.2014.968127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases</span></div><div class="casAuthors">Martinez, Ana; Gil, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1311-1321</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: PDEs are key enzymes in the adenosine and guanosine cyclic nucleotides (cAMP and cGMP) signaling cascade.  Their inhibition increases cyclic nucleotide levels inside the cell.  Thus, pharmacol. modulation of PDE activity can have profound effects on the function of cells and organ systems throughout the body.  Areas covered: Among the large PDE families, only PDE4, PDE7 and PDE8 are cAMP-specific hydrolyzing enzymes. cAMP is an important second messenger not only by its involvement in a vast no. of physiol. processes but also by activation of protein kinase A, exchange protein activated by cAMP (Epac) and cAMP response element-binding (CREB) or cyclic nucleotide-gated channels.  Clearly, such enzymes represent ideal drug targets for the pharmacol. treatment of many pathologies.  The discovery and development of small mols. targeting cAMP-specific PDEs reported in the last 5 years is the focus of the present review.  Expert opinion: The first PDE4 inhibitors recently reached the market, having avoided, by different strategies, their dose-limiting side effects (after more than two decades of drug development).  Meanwhile, new cAMP-specific PDE7 and PDE8 inhibitors emerged as effective and safe drugs for severe unmet diseases.  The therapeutic potential of these inhibitors will be tested in the near future, as many of these drug candidates are ready to start clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPWFQGiKhADrVg90H21EOLACvtfcHk0liXld46bqPlOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FN&md5=f9ef95eeccba94736c36de427c1715b0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.968127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.968127%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGil%26aufirst%3DC.%26atitle%3DcAMP-specific%2520phosphodiesterase%2520inhibitors%253A%2520promising%2520drugs%2520for%2520inflammatory%2520and%2520neurological%2520diseases%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1311%26epage%3D1321%26doi%3D10.1517%2F13543776.2014.968127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Mulhall, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Droege, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panos, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafar, M. A.</span><span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1597</span><span class="NLM_x">–</span> <span class="NLM_lpage">1611</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1094054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1517%2F13543784.2015.1094054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=26419847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1597-1611&author=A.+M.+Mulhallauthor=C.+A.+Droegeauthor=N.+E.+Ernstauthor=R.+J.+Panosauthor=M.+A.+Zafar&title=Phosphodiesterase+4+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+review+of+current+and+developing+drugs&doi=10.1517%2F13543784.2015.1094054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span></div><div class="casAuthors">Mulhall, Aaron M.; Droege, Christopher A.; Ernst, Neil E.; Panos, Ralph J.; Zafar, Muhammad A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1597-1611</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells.  Roflumilast is the only approved PDE-4 inhibitor (PDE4I) for use in chronic obstructive pulmonary disease (COPD).  Its beneficial clin. effects occur preferentially in patients with chronic bronchitis and frequent COPD exacerbations.  Use of roflumilast as adjunctive or alternate therapy to other COPD medications reduces exacerbations and modestly improves lung function.  This article reviews the current role of PDE4I in COPD treatment emphasizing roflumilast's clin. efficacy and adverse effects.  This article also reviews developing PDE4Is in early clin. trials and in preclin. studies.  After decades of research in drug development, PDE4Is are a welcomed addn. to the COPD therapeutic armamentarium.  In its current clin. role, the salubrious clin. effects of PDE4I in reducing exacerbations and stabilizing the frequent exacerbator phenotype have to be cautiously balanced with numerous adverse effects.  Developing drugs may provide similar or better clin. benefits while minimizing adverse effects by changing the mode of drug delivery to inhaled formulations, combining dual PDE isoenzyme inhibitors (PDE1/4I and PDE3/4I) and by forming hybrid mols. with other bronchodilators (muscarinic receptor antagonist/PDE4I and β2-agonist/PDE4I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNEyjtRW-erVg90H21EOLACvtfcHk0liXld46bqPlOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ&md5=8d5130af94558b2950f624ae1528c86f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1094054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1094054%26sid%3Dliteratum%253Aachs%26aulast%3DMulhall%26aufirst%3DA.%2BM.%26aulast%3DDroege%26aufirst%3DC.%2BA.%26aulast%3DErnst%26aufirst%3DN.%2BE.%26aulast%3DPanos%26aufirst%3DR.%2BJ.%26aulast%3DZafar%26aufirst%3DM.%2BA.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520review%2520of%2520current%2520and%2520developing%2520drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1597%26epage%3D1611%26doi%3D10.1517%2F13543784.2015.1094054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petavy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, A. J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1186/1465-9921-11-26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1186%2F1465-9921-11-26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=20193079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=26-34&author=D.+Singhauthor=F.+Petavyauthor=A.+J.+Macdonald&title=The+inhaled+phosphodiesterase+4+inhibitor+GSK256066+reduces+allergen+challenge+responses+in+asthma&doi=10.1186%2F1465-9921-11-26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span></div><div class="casAuthors">Singh Dave; Petavy Frank; Macdonald Alex J; Lazaar Aili L; O'Connor Brian J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects.  We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.  METHODS:  In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR) and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7 days, followed by allergen challenge.  Methacholine reactivity was measured 24 h post-allergen.  Plasma pharmacokinetics were measured.  The primary endpoint was the effect on LAR.  RESULTS:  GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.  GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.  There was no effect on pre-allergen FEV1 or methacholine reactivity post allergen.  GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4 hours in the majority of subjects.  CONCLUSIONS:  GSK256066 demonstrated a protective effect on the EAR and LAR.  This is the first inhaled PDE4 inhibitor to show therapeutic potential in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6sWKb5nMe2ROk4JA3soTqfW6udTcc2eYKHylXAQcMVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D&md5=88d976c3aa2d963dc83c5fa8e32e4f62</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-26%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DPetavy%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520reduces%2520allergen%2520challenge%2520responses%2520in%2520asthma%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D26%26epage%3D34%26doi%3D10.1186%2F1465-9921-11-26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Boswell-Smith, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeds, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, C. P.</span><span> </span><span class="NLM_article-title">The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1124/jpet.105.099192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1124%2Fjpet.105.099192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=16682455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslOlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=840-848&author=V.+Boswell-Smithauthor=D.+Spinaauthor=A.+W.+Oxfordauthor=M.+B.+Comerauthor=E.+A.+Seedsauthor=C.+P.+Page&title=The+pharmacology+of+two+novel+long-acting+phosphodiesterase+3%2F4+inhibitors%2C+RPL554+%5B9%2C10-dimethoxy-2%282%2C4%2C6-trimethylphenylimino%29-3-%28N-carbamoyl-2-aminoethyl%29-3%2C4%2C6%2C7-tetrahydro-2H-pyrimido%5B6%2C1-a%5Disoquinolin-4-one%5D+and+RPL565+%5B6%2C7-dihydro-2-%282%2C6-diisopropylphenoxy%29-9%2C10-dimethoxy-4H-pyrimido%5B6%2C1-a%5Disoquinolin-4-one%5D&doi=10.1124%2Fjpet.105.099192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido [6,1-a]isoquinolin-4-one]</span></div><div class="casAuthors">Boswell-Smith, Victoria; Spina, Domenico; Oxford, Alec W.; Comer, Mike B.; Seeds, Esther A.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">840-848</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. of two novel, trequinsin-like PDE3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido-[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one], has been investigated in a no. of in vitro and in vivo assays.  Elec. field stimulation-induced contraction of guinea pig superfused isolated tracheal prepns. was significantly inhibited by RPL554 (10 μM) and RPL565 (10 μM) (percentage control; 93 ± 1.2 and 84.4 ± 2.7, resp.).  Contractile responses were suppressed for up to 12 h after termination of superfusion with RPL554 demonstrating a long duration of action.  RPL554 and RPL565 inhibited, in a concn.-dependent manner, lipopolysaccharide-induced tumor necrosis factor α release from human monocytes [IC50; 0.52 μM (0.38-0.69) and 0.25 μM (0.18-0.35), resp.] and proliferation of human mononuclear cells to phytohemagglutinin [IC50; 0.46 μM (0.24-0.9) and 2.90 μM (1.6-5.4), resp.].  The inhibitory effect of these drugs in vitro was translated into anti-inflammatory activity in vivo.  RPL554 (10 mg/kg) and RPL565 (10 mg/kg) administered orally significantly inhibited eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs.  Likewise, inhalation of dry powder contg. RPL554 by conscious guinea pigs (25% in micronized lactose) 1.5 h before antigen exposure significantly inhibited the recruitment of eosinophils to the airways.  Exposure of conscious guinea pigs to inhalation of dry powder contg. RPL554 (2.5%) and RPL565 (25%) in micronized lactose significantly inhibited histamine-induced plasma protein extravasation in the trachea and histamine-induced bronchoconstriction over a 5.5-h period.  Thus, RPL554 and RPL565 are novel, long-acting PDE 3/4 inhibitors exhibiting a broad range of both bronchoprotective and anti-inflammatory activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0xQkYCpZ4r7Vg90H21EOLACvtfcHk0liAN2QqIWQtCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslOlt7w%253D&md5=6669bf3bbd6e17e4246ff7695d16e5ce</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.099192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.099192%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell-Smith%26aufirst%3DV.%26aulast%3DSpina%26aufirst%3DD.%26aulast%3DOxford%26aufirst%3DA.%2BW.%26aulast%3DComer%26aufirst%3DM.%2BB.%26aulast%3DSeeds%26aufirst%3DE.%2BA.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DThe%2520pharmacology%2520of%2520two%2520novel%2520long-acting%2520phosphodiesterase%25203%252F4%2520inhibitors%252C%2520RPL554%2520%255B9%252C10-dimethoxy-2%25282%252C4%252C6-trimethylphenylimino%2529-3-%2528N-carbamoyl-2-aminoethyl%2529-3%252C4%252C6%252C7-tetrahydro-2H-pyrimido%255B6%252C1-a%255Disoquinolin-4-one%255D%2520and%2520RPL565%2520%255B6%252C7-dihydro-2-%25282%252C6-diisopropylphenoxy%2529-9%252C10-dimethoxy-4H-pyrimido%255B6%252C1-a%255Disoquinolin-4-one%255D%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26spage%3D840%26epage%3D848%26doi%3D10.1124%2Fjpet.105.099192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J.</span><span> </span><span class="NLM_article-title">A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1044</span><span class="refDoi"> DOI: 10.1183/09031936.00068908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1183%2F09031936.00068908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19213793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=1039-1044&author=J.+Vestboauthor=L.+Tanauthor=G.+Atkinsonauthor=J.+Ward&title=A+controlled+trial+of+6-weeks%E2%80%99+treatment+with+a+novel+inhaled+phosphodiesterase+type-4+inhibitor+in+COPD&doi=10.1183%2F09031936.00068908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span></div><div class="casAuthors">Vestbo, J.; Tan, L.; Atkinson, G.; Ward, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1039-1044</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an interesting class of drugs to treat inflammation in COPD.  The present authors report the findings of a phase II trial of a novel inhaled PDE4 inhibitor.  Three doses, 0.1, 0.4 and 1.0 mg b.i.d., of the compd. UK-500,001 were tested in a double-blind, placebo-controlled, 6-wk trial in 209 patients with moderate-to-severe COPD.  The primary efficacy parameter was trough forced expiratory vol. in one second after 6 wk of treatment, and secondary end-points included other lung function end-points and symptom scores assessed at 2-wk intervals.  The present study was stopped following a planned interim anal. for futility.  No effect on the primary efficacy parameter, other measures of lung function or symptom scores was obsd. at any dose of UK-500,001 after 6 wk of treatment.  However, after the first 2 wk of treatment, an improvement in a no. of outcome measures in the 1.0 mg b.i.d. dose group was obsd. compared with placebo.  The drug was well tolerated, although PDE4 inhibitor-related side-effects were obsd., esp. in the highest dose group.  The findings of the present study question the role of inhaled phosphodiesterase type-4 inhibitors in chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqfiD54uWV9bVg90H21EOLACvtfcHk0ljg0XFTkT1jXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D&md5=73ac7894ef11b2cdd9f95fcd95b52286</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1183%2F09031936.00068908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00068908%26sid%3Dliteratum%253Aachs%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DAtkinson%26aufirst%3DG.%26aulast%3DWard%26aufirst%3DJ.%26atitle%3DA%2520controlled%2520trial%2520of%25206-weeks%25E2%2580%2599%2520treatment%2520with%2520a%2520novel%2520inhaled%2520phosphodiesterase%2520type-4%2520inhibitor%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D33%26spage%3D1039%26epage%3D1044%26doi%3D10.1183%2F09031936.00068908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Xu, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocque, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span> </span><span class="NLM_article-title">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">1822</span><span class="NLM_x">–</span> <span class="NLM_lpage">1825</span><span class="refDoi"> DOI: 10.1126/science.288.5472.1822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1126%2Fscience.288.5472.1822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10846163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2000&pages=1822-1825&author=R.+X.+Xuauthor=A.+M.+Hassellauthor=D.+Vanderwallauthor=M.+H.+Lambertauthor=W.+D.+Holmesauthor=M.+A.+Lutherauthor=W.+J.+Rocqueauthor=M.+V.+Milburnauthor=Y.+Zhaoauthor=H.+Keauthor=R.+T.+Nolte&title=Atomic+structure+of+PDE4%3A+insights+into+phosphodiesterase+mechanism+and+specificity&doi=10.1126%2Fscience.288.5472.1822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span></div><div class="casAuthors">Xu, Robert X.; Hassell, Anne M.; Vanderwall, Dana; Lambert, Millard H.; Holmes, William D.; Luther, Michael A.; Rocque, Warren J.; Milburn, Michael V.; Zhao, Yingdong; Ke, Hengming; Nolte, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">5472</span>),
    <span class="NLM_cas:pages">1822-1825</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclic nucleotides are second messengers that are essential in vision, muscle contraction, neurotransmission, exocytosis, cell growth, and differentiation.  These mols. are degraded by a family of enzymes known as phosphodiesterases, which serve a crit. function by regulating the intracellular concn. of cyclic nucleotides.  We have detd. the three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resoln.  The active site has been identified and contains a cluster of two metal atoms.  The structure suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiesterase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjHOVmP5GzU7Vg90H21EOLACvtfcHk0ljg0XFTkT1jXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D&md5=4f7e42a9f7a6a0763a9dcc064ad903c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.288.5472.1822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.288.5472.1822%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BX.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DLuther%26aufirst%3DM.%2BA.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DAtomic%2520structure%2520of%2520PDE4%253A%2520insights%2520into%2520phosphodiesterase%2520mechanism%2520and%2520specificity%26jtitle%3DScience%26date%3D2000%26volume%3D288%26spage%3D1822%26epage%3D1825%26doi%3D10.1126%2Fscience.288.5472.1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Huai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colicelli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">13220</span><span class="NLM_x">–</span> <span class="NLM_lpage">13226</span><span class="refDoi"> DOI: 10.1021/bi034653e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi034653e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=13220-13226&author=Q.+Huaiauthor=J.+Colicelliauthor=H.+Ke&title=The+crystal+structure+of+AMP-bound+PDE4+suggests+a+mechanism+for+phosphodiesterase+catalysis&doi=10.1021%2Fbi034653e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fbi034653e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi034653e%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DColicelli%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520crystal%2520structure%2520of%2520AMP-bound%2520PDE4%2520suggests%2520a%2520mechanism%2520for%2520phosphodiesterase%2520catalysis%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D13220%26epage%3D13226%26doi%3D10.1021%2Fbi034653e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span><span class="refDoi"> DOI: 10.1016/j.jmb.2007.05.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.jmb.2007.05.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=17582435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=302-307&author=H.+Wangauthor=H.+Robinsonauthor=H.+Ke&title=The+molecular+basis+for+different+recognition+of+substrates+by+phosphodiesterase+families+4+and+10&doi=10.1016%2Fj.jmb.2007.05.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10</span></div><div class="casAuthors">Wang, Huanchen; Robinson, Howard; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-307</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are key enzymes that control the cellular concns. of the second messengers cAMP and cGMP.  The mechanism for selective recognition of substrates cAMP and cGMP by individual PDE families remains a puzzle.  To understand the mechanism for substrate recognition by PDE enzymes, the crystal structure of the catalytic domain of an inactive D201N mutant of PDE4D2 in complex with substrate cAMP has been detd. at 1.56 Å resoln.  The structure shows that Gln369 forms only one hydrogen bond with the adenine of cAMP.  This finding provides exptl. evidence against the hypothesis of two hydrogen bonds between the invariant glutamine and the substrate cAMP in PDE4, and thus suggests that the widely circulated "glutamine switch" model is unlikely to be the mechanism for substrate recognition by PDEs.  A structure comparison between PDE4D2-cAMP and PDE10A2-cAMP reveals an anti configuration of cAMP in PDE4D2 but syn in PDE10A2, in addn. to different contact patterns of cAMP in these two structures.  These observations imply that individual PDE families have their characteristic mechanisms for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8WN9h4LiP7Vg90H21EOLACvtfcHk0lijtnRm33r3VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D&md5=2f7f20be9aba1cae9a4d90e349581583</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.05.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520molecular%2520basis%2520for%2520different%2520recognition%2520of%2520substrates%2520by%2520phosphodiesterase%2520families%25204%2520and%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D371%26spage%3D302%26epage%3D307%26doi%3D10.1016%2Fj.jmb.2007.05.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Huai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspiotis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Enantiomer discrimination illustrated by the high resolution crystal structure of Type 4 phosphodiesterase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1867</span><span class="NLM_x">–</span> <span class="NLM_lpage">1873</span><span class="refDoi"> DOI: 10.1021/jm051273d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051273d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1867-1873&author=Q.+Huaiauthor=Y.+Sunauthor=H.+Wangauthor=D.+Macdonaldauthor=R.+Aspiotisauthor=H.+Robinsonauthor=Z.+Huangauthor=H.+Ke&title=Enantiomer+discrimination+illustrated+by+the+high+resolution+crystal+structure+of+Type+4+phosphodiesterase&doi=10.1021%2Fjm051273d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm051273d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051273d%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DEnantiomer%2520discrimination%2520illustrated%2520by%2520the%2520high%2520resolution%2520crystal%2520structure%2520of%2520Type%25204%2520phosphodiesterase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1867%26epage%3D1873%26doi%3D10.1021%2Fjm051273d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hamblin, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angell, T. D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantine, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delves, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J. O.</span><span> </span><span class="NLM_article-title">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4237</span><span class="NLM_x">–</span> <span class="NLM_lpage">4241</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2008.05.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=18539455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4237-4241&author=J.+N.+Hamblinauthor=T.+D.+R.+Angellauthor=S.+P.+Ballantineauthor=C.+M.+Cookauthor=A.+W.+J.+Cooperauthor=J.+Dawsonauthor=C.+J.+Delvesauthor=P.+S.+Jonesauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=C.+J.+Mitchellauthor=M.+Y.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=J.+O.+Wiseman&title=Pyrazolopyridines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2008.05.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span></div><div class="casAuthors">Hamblin, J. Nicole; Angell, Tony D. R.; Ballantine, Stuart P.; Cook, Caroline M.; Cooper, Anthony W. J.; Dawson, John; Delves, Christopher J.; Jones, Paul S.; Lindvall, Mika; Lucas, Fiona S.; Mitchell, Charlotte J.; Neu, Margarete Y.; Ranshaw, Lisa E.; Solanke, Yemisi E.; Somers, Don O.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4237-4241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Optimization of a high-throughput screening hit resulted in the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective inhibitors of Phosphodiesterase 4 (PDE4).  Herein, we describe early SAR studies around this novel template highlighting preferred substituents and rationalization of SAR through X-ray crystal structures of analogs bound to the PDE4 active site.  Pyrazolopyridine 20a (I) was found to be a potent and selective PDE4 inhibitor which also inhibits LPS induced TNF-α prodn. from isolated human peripheral blood mononuclear cells and has an encouraging rat PK profile suitable for oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj75z9PAk27Vg90H21EOLACvtfcHk0lijtnRm33r3VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D&md5=3b425c80dc0258bab9f2c68297260903</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.052%26sid%3Dliteratum%253Aachs%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DAngell%26aufirst%3DT.%2BD.%2BR.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DCook%26aufirst%3DC.%2BM.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DNeu%26aufirst%3DM.%2BY.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DPyrazolopyridines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4237%26epage%3D4241%26doi%3D10.1016%2Fj.bmcl.2008.05.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lunniss, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eldred, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kranz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, A. G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redgrave, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J. O.</span><span> </span><span class="NLM_article-title">Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimization for oral administration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2009.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=19195882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1380-1385&author=C.+J.+Lunnissauthor=A.+W.+J.+Cooperauthor=C.+D.+Eldredauthor=M.+Kranzauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=M.+Neuauthor=A.+G.+S.+Prestonauthor=L.+E.+Ranshawauthor=A.+J.+Redgraveauthor=J.+E.+Robinsonauthor=T.+J.+Shipleyauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=J.+O.+Wiseman&title=Quinolines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors.+Optimization+for+oral+administration&doi=10.1016%2Fj.bmcl.2009.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Optimisation for oral administration</span></div><div class="casAuthors">Lunniss, Christopher J.; Cooper, Anthony W. J.; Eldred, Colin D.; Kranz, Michael; Lindvall, Mika; Lucas, Fiona S.; Neu, Margarete; Preston, Alex G. S.; Ranshaw, Lisa E.; Redgrave, Alison J.; Robinson, J. Ed; Shipley, Tracy J.; Solanke, Yemisi E.; Somers, Don O.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1380-1385</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Crystallog.-driven optimization of a lead derived from similarity searching of the GSK compd. collection resulted in the discovery of a series of quinoline derivs. that were highly potent and selective inhibitors of PDE4 with a good pharmacokinetic profile in the rat.  Quinolines 43 and 48 have potential as oral medicines for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6HHpObSkx27Vg90H21EOLACvtfcHk0lj6lZA7Aq54QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WmsL8%253D&md5=691ca6b69fe02ee29097eac2ee6ff5b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DEldred%26aufirst%3DC.%2BD.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DPreston%26aufirst%3DA.%2BG.%2BS.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DRedgrave%26aufirst%3DA.%2BJ.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DShipley%26aufirst%3DT.%2BJ.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DQuinolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors.%2520Optimization%2520for%2520oral%2520administration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1380%26epage%3D1385%26doi%3D10.1016%2Fj.bmcl.2009.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Woodrow, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantine, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delves, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kranz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvaal, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J. O.</span><span> </span><span class="NLM_article-title">Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimization for inhaled administration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5261</span><span class="NLM_x">–</span> <span class="NLM_lpage">5265</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2009.04.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5261-5265&author=M.+D.+Woodrowauthor=S.+P.+Ballantineauthor=M.+D.+Barkerauthor=B.+J.+Clarkeauthor=J.+Dawsonauthor=T.+W.+Deanauthor=C.+J.+Delvesauthor=B.+Evansauthor=S.+L.+Goughauthor=S.+B.+Guntripauthor=S.+Holmanauthor=D.+S.+Holmesauthor=M.+Kranzauthor=M.+K.+Lindvaalauthor=F.+S.+Lucasauthor=M.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=P.+Wardauthor=J.+O.+Wiseman&title=Quinolines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors.+Optimization+for+inhaled+administration&doi=10.1016%2Fj.bmcl.2009.04.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWoodrow%26aufirst%3DM.%2BD.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DClarke%26aufirst%3DB.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDean%26aufirst%3DT.%2BW.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DEvans%26aufirst%3DB.%26aulast%3DGough%26aufirst%3DS.%2BL.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHolman%26aufirst%3DS.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvaal%26aufirst%3DM.%2BK.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DQuinolines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors.%2520Optimization%2520for%2520inhaled%2520administration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5261%26epage%3D5265%26doi%3D10.1016%2Fj.bmcl.2009.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Govek, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzola, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauregard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamache, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellberg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsien, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerch, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malecha, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staszewski, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiau, A. K.</span><span> </span><span class="NLM_article-title">Water-soluble PDE4 inhibitors for the treatment of dry eye</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2928</span><span class="NLM_x">–</span> <span class="NLM_lpage">2932</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2010.03.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2928-2932&author=S.+P.+Govekauthor=G.+Oshiroauthor=J.+V.+Anzolaauthor=C.+Beauregardauthor=J.+Chenauthor=A.+R.+Coyleauthor=D.+A.+Gamacheauthor=M.+R.+Hellbergauthor=J.+N.+Hsienauthor=J.+M.+Lerchauthor=J.+C.+Liaoauthor=J.+W.+Malechaauthor=L.+M.+Staszewskiauthor=D.+J.+Thomasauthor=J.+M.+Yanniauthor=S.+A.+Nobleauthor=A.+K.+Shiau&title=Water-soluble+PDE4+inhibitors+for+the+treatment+of+dry+eye&doi=10.1016%2Fj.bmcl.2010.03.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DOshiro%26aufirst%3DG.%26aulast%3DAnzola%26aufirst%3DJ.%2BV.%26aulast%3DBeauregard%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCoyle%26aufirst%3DA.%2BR.%26aulast%3DGamache%26aufirst%3DD.%2BA.%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DHsien%26aufirst%3DJ.%2BN.%26aulast%3DLerch%26aufirst%3DJ.%2BM.%26aulast%3DLiao%26aufirst%3DJ.%2BC.%26aulast%3DMalecha%26aufirst%3DJ.%2BW.%26aulast%3DStaszewski%26aufirst%3DL.%2BM.%26aulast%3DThomas%26aufirst%3DD.%2BJ.%26aulast%3DYanni%26aufirst%3DJ.%2BM.%26aulast%3DNoble%26aufirst%3DS.%2BA.%26aulast%3DShiau%26aufirst%3DA.%2BK.%26atitle%3DWater-soluble%2520PDE4%2520inhibitors%2520for%2520the%2520treatment%2520of%2520dry%2520eye%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2928%26epage%3D2932%26doi%3D10.1016%2Fj.bmcl.2010.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Nankervis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feil, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holien, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazzetto, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manallack, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M. W.</span><span> </span><span class="NLM_article-title">Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">7089</span><span class="NLM_x">–</span> <span class="NLM_lpage">7093</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.bmcl.2011.09.109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7089-7093&author=J.+L.+Nankervisauthor=S.+C.+Feilauthor=N.+C.+Hancockauthor=Z.+Zhengauthor=H.-L.+Ngauthor=C.+J.+Mortonauthor=J.+K.+Holienauthor=P.+W.+M.+Hoauthor=M.+M.+Frazzettoauthor=I.+G.+Jenningsauthor=D.+T.+Manallackauthor=T.+J.+Martinauthor=P.+E.+Thompsonauthor=M.+W.+Parker&title=Thiophene+inhibitors+of+PDE4%3A+crystal+structures+show+a+second+binding+mode+at+the+catalytic+domain+of+PDE4D2&doi=10.1016%2Fj.bmcl.2011.09.109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.109%26sid%3Dliteratum%253Aachs%26aulast%3DNankervis%26aufirst%3DJ.%2BL.%26aulast%3DFeil%26aufirst%3DS.%2BC.%26aulast%3DHancock%26aufirst%3DN.%2BC.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DNg%26aufirst%3DH.-L.%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DHolien%26aufirst%3DJ.%2BK.%26aulast%3DHo%26aufirst%3DP.%2BW.%2BM.%26aulast%3DFrazzetto%26aufirst%3DM.%2BM.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DManallack%26aufirst%3DD.%2BT.%26aulast%3DMartin%26aufirst%3DT.%2BJ.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DThiophene%2520inhibitors%2520of%2520PDE4%253A%2520crystal%2520structures%2520show%2520a%2520second%2520binding%2520mode%2520at%2520the%2520catalytic%2520domain%2520of%2520PDE4D2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D7089%26epage%3D7093%26doi%3D10.1016%2Fj.bmcl.2011.09.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Dal Piaz, V.; Giovannoni, M. P.; Vergelli, C.; Aguilar Izquierdo, N.</span><span> </span><span class="NLM_article-title">Pyridazin-3(2H)-one derivatives as PDE4 inhibitors</span>. PCT Int. Appl. WO 2003097613, November 27,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=V.+Dal+Piaz&author=M.+P.+Giovannoni&author=C.+Vergelli&author=N.+Aguilar+Izquierdo&title=Pyridazin-3%282H%29-one+derivatives+as+PDE4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDal%2BPiaz%26aufirst%3DV.%26atitle%3DPyridazin-3%25282H%2529-one%2520derivatives%2520as%2520PDE4%2520inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=15260978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=279-286&author=K.+Y.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+glutamine+switch+mechanism+for+nucleotide+selectivity+by+phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span></div><div class="casAuthors">Zhang, Kam Y. J.; Card, Graeme L.; Suzuki, Yoshihisa; Artis, D. Richard; Fong, Daniel; Gillette, Sam; Hsieh, Davin; Neiman, Joshua; West, Brian L.; Zhang, Chao; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-286</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that modulate the immune response, inflammation, and memory, among many other functions.  There are three types of PDEs: cAMP-specific, cGMP-specific, and dual-specific.  Here we describe the mechanism of nucleotide selectivity on the basis of high-resoln. co-crystal structures of the cAMP-specific PDE4B and PDE4D with AMP, the cGMP-specific PDE5A with GMP, and the apo-structure of the dual-specific PDE1B.  These structures show that an invariant glutamine functions as the key specificity determinant by a "glutamine switch" mechanism for recognizing the purine moiety in cAMP or cGMP.  The surrounding residues anchor the glutamine residue in different orientations for cAMP and for cGMP.  The PDE1B structure shows that in dual-specific PDEs a key histidine residue may enable the invariant glutamine to toggle between cAMP and cGMP.  The structural understanding of nucleotide binding enables the design of new PDE inhibitors that may treat diseases in which cyclic nucleotides play a crit. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRXGTDdAa1bVg90H21EOLACvtfcHk0litv_7bxazHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D&md5=32fab6a75031a67290ec5eda2c3e080b</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520glutamine%2520switch%2520mechanism%2520for%2520nucleotide%2520selectivity%2520by%2520phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30a1"><span>Erratum inMol. Cell<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span>. 10.1016/j.molcel.2004.08.015</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Erratum+inMol.+Cell+2004%2C+15%2C+659.+10.1016%2Fj.molcel.2004.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Burgin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, O. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsteinsdottir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrafnsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-72&author=A.+B.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0litv_7bxazHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D72%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Renzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Piaz, V.</span><span> </span><span class="NLM_article-title">4,5-Disubstituted 3-carbethoxyisoxazoles I</span> <span class="citation_source-journal">Gazz. Chim. Ital</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1965</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1478</span><span class="NLM_x">–</span> <span class="NLM_lpage">1491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1965&pages=1478-1491&author=G.+Renziauthor=V.+Dal+Piaz&title=4%2C5-Disubstituted+3-carbethoxyisoxazoles+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenzi%26aufirst%3DG.%26aulast%3DDal%2BPiaz%26aufirst%3DV.%26atitle%3D4%252C5-Disubstituted%25203-carbethoxyisoxazoles%2520I%26jtitle%3DGazz.%2520Chim.%2520Ital%26date%3D1965%26volume%3D95%26spage%3D1478%26epage%3D1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Chen, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eltzschig, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">Adenosine receptors as drug targets - what are the challenges?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1038/nrd3955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1038%2Fnrd3955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=23535933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=265-286&author=J.-F.+Chenauthor=H.+K.+Eltzschigauthor=B.+B.+Fredholm&title=Adenosine+receptors+as+drug+targets+-+what+are+the+challenges%3F&doi=10.1038%2Fnrd3955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as drug targets - what are the challenges?</span></div><div class="casAuthors">Chen, Jiang-Fan; Eltzschig, Holger K.; Fredholm, Bertil B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">265-286</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine signalling has long been a target for drug development, with adenosine itself or its derivs. being used clin. since the 1940s.  In addn., methylxanthines such as caffeine have profound biol. effects as antagonists at adenosine receptors.  Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors.  There is strong evidence that adenosine has a functional role in many diseases, and several pharmacol. compds. specifically targeting individual adenosine receptors - either directly or indirectly - have now entered the clinic.  However, only one adenosine receptor-specific agent - the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) - has so far gained approval from the US Food and Drug Administration (FDA).  Here, we focus on the biol. of adenosine signalling to identify hurdles in the development of addnl. pharmacol. compds. targeting adenosine receptors and discuss strategies to overcome these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqhEzWXi1WS7Vg90H21EOLACvtfcHk0lhakNKZchHjaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D&md5=898fee7a68273ebfbd5a1d3dca307dc5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd3955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3955%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DAdenosine%2520receptors%2520as%2520drug%2520targets%2520-%2520what%2520are%2520the%2520challenges%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D265%26epage%3D286%26doi%3D10.1038%2Fnrd3955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J. P.</span><span> </span><span class="NLM_article-title">Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">241</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1006/bbrc.1997.7542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;key=10.1006%2Fbbrc.1997.7542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1997&pages=175-180&author=M.+D.+Percivalauthor=B.+Yehauthor=J.+P.+Falgueyret&title=Zinc+dependent+activation+of+cAMP-specific+phosphodiesterase+%28PDE4A%29&doi=10.1006%2Fbbrc.1997.7542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1997.7542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1997.7542%26sid%3Dliteratum%253Aachs%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26atitle%3DZinc%2520dependent%2520activation%2520of%2520cAMP-specific%2520phosphodiesterase%2520%2528PDE4A%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1997%26volume%3D241%26spage%3D175%26epage%3D180%26doi%3D10.1006%2Fbbrc.1997.7542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K1I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K1I','PDB','5K1I'); return false;">PDB: 5K1I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ','PDB','1XOQ'); return false;">PDB: 1XOQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i75"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00829">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52550"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00829">10.1021/acs.jmedchem.6b00829</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00829/suppl_file/jm6b00829_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00829/suppl_file/jm6b00829_si_001.csv">jm6b00829_si_001.csv (18.25 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code of compound <b>6</b>: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K1I">5K1I</a> (see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-23%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00829" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00829" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996e6e9fcf3d24","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
